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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the 8th human herpesvirus 
discovered in 1994. After primary infection, KSHV establishes latency and, in the 
context of immunosuppression, has been associated with specific malignancies: 
Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD). Seroepidemiological surveys suggest that KSHV is not 
a ubiquitous virus and several transmission routes and risk factors must exist to 
explain its global distribution. The increased risk of KSHV-associated cancers in 
human immunodeficiency virus (HlV)-infected individuals, and the decrease of KS 
incidence after the introduction of highly active anti-retroviral therapy (HAART) in 
1997 suggest that cellular immunity plays an important role in controlling KSHV.
In this thesis, seroepidemiological studies were conducted in African, Middle 
Eastern, Mediterranean European and South American countries to determine the 
infection rate, and to determine risk factors and possible routes of KSHV 
transmission.
A new quantitative real-time PCR method was developed to detect KSHV in clinical 
samples. This assay has diagnostic and prognostic implications for the management 
of KSHV-associated diseases.
Anti-viral and immunological responses were measured and analysed, and cellular 
immune responses to KSHV were demonstrated in a cohort of HIV infected 
individuals undergoing HAART treatment. The interaction between KSHV and HIV 
was evaluated and the impact of HAART on KSHV immune reconstitution was 
investigated.
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Chapter 1 
Introduction
1.1 KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS 
(KSHV)
Moritz Kaposi was an Austro-Hungarian dermatologist, first to report five cases of 
Kaposi’s sarcoma (KS) on the skin, 130 years ago (Kaposi, 1872). The causative 
agent of KS was identified nine years ago and shown to be the 8th herpesvirus in the 
human herpesviridae family and the second identified human oncogenic herpesvirus 
following Epstein-Barr virus (Chang et al., 1994).
1.1.1 Kaposi’s sarcoma (KS)
1.1.1.1 Clinical features
For almost a century, KS was thought to be a disease predominantly occurring in 
elderly male patients of Mediterranean, East European or Jewish heritage. This form 
of KS is now called classic KS (CKS) and appears as red/blue or purple macules, 
plaques or nodules on the extremities (Franceschi and Geddes, 1995). The second 
form of KS, the iatrogenic or post-transplant-associated KS affects patients receiving 
immunosuppressive therapy like renal transplant recipients (Harwood et al., 1979). 
Iatrogenic KS develops more commonly in patients of Mediterranean, Jewish or 
Arab ancestry (Qunibi et al., 1988). It resembles CKS clinically, and regresses if 
immunosuppression is removed. A more aggressive form than CKS existed for many 
decades in some equatorial countries of Africa, even prior to the human 
immunodeficiency virus type 1 (HIV-1) pandemic (D'Oliveira and Torres, 1972). 
This form is referred to as endemic KS and is found in adults and children (Olweny 
et al., 1976; Ziegler and Katongole Mbidde, 1996). The most aggressive clinical 
form of KS is AIDS-KS and this is the most common neoplasm occurring in patients 
with acquired immunodeficiency syndrome (AIDS) (Beral et al., 1990; Rabkin et al.,
1995). It was first identified in 1981 among the young homosexual population from 
Los Angeles and New York City (CDC, 1981) and is now considered to be the most 
common form of KS. KS has spread to large populations in Africa where HIV-1
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infection has the highest incidence (Newton et al., 1996; W abinga et al., 2000; 
Ziegler et al., 1997). AIDS-KS starts as a few lesions on the skin and then, without 
treatment, can disseminate to various organs leading to a poor prognosis.
1.1.1.2 Histology of KS lesion
Kaposi’s sarcoma is a skin disease found in the dermis. Pathologically, KS is seen in 
three forms: patch, plaque and nodular. All share the same histological features: 
Infiltrating lymphocytes and plasma cells among the flat endothelial cells, which are 
surrounded by normal blood vessels (Figure 1.1.). During lesion progression, 
proliferation of abnormal blood vessels occurs and inflammatory cells are dispersed 
throughout the lesion. In the advanced nodular form spindle cells are the 
predominant type of cells that undergo mitosis and form slit-like, vascular channels 
containing erythrocytes. These spindle cells are endothelial cells with lymphatic 
markers (D upin  et al., 1999) and the majority express endothelial markers 
including Factor VIII and CD34 (Dupin et al., 1999; Nickoloff and Griffiths, 1989; 
Sturzl et al., 1992).
1.1.1.3 Angiogenesis and KS
During the proliferation and differentiation of the endothelial cells, various cytokines 
are expressed in the early stages of the disease required for the development of the 
tumour. In particular, basic fibroblast growth factor (bFGF) is a prominent cytokine
J \  Figure 1.1.
5 Histological picture of KS 
(magnification lOx) next to 
K  a KS lesion.
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produced by KS cells that promotes growth of these cells in an autocrine fashion 
(Ensoli et al., 1992; Ensoli et al., 1994a; Ensoli et al., 1994b). The severity of the 
disease in patients with AIDS prompted studies on the possible contribution of HIV- 
1 itself in KS development (Barillari et al., 1992; Ensoli et al., 1993). Indeed, the 
HIV-1 Tat protein can induce lesions phenotypically similar to KS in Tat-transgenic 
mice and HIV-1 Tat promotes angiogenesis in vitro and in vivo (Ensoli et al., 1994a). 
Tat has also been shown to directly act as an angiogenic factor and interacts with the 
vascular endothelial growth factor receptor (VEGF-R), Flk-l/KDR (Albini et al., 
1995; Albini et al., 1997). Simultaneous injection of bFGF and Tat in transgenic 
mice increased the incidence of macroscopic KS-like lesions. VEGF and interleukin 
6 (IL-6) are also expressed by KS cells and promote KS-cell growth (thus paracrine 
and autocrine) (Miles et al., 1990).
1.1.1.4 Infectious agent
Several studies supported the hypothesis that a possible infectious agent may induce 
the production of these cytokines to cause KS. The concept that an infectious agent 
may be associated with the aetiology of KS has been proposed based on the 
geographic distribution of KS in Africa and Europe. The high proportion of AIDS- 
KS in homosexual and bisexual men but not in haemophiliacs with AIDS suggested 
a sexually transmissible agent (Beral, 1991). Several candidates, including 
cytomegalovirus (CMV), BK polyoma virus, human papillomavirus (HPV) and 
mycoplasma were suggested to be the infectious cause of KS (Giraldo et al., 1972; 
Giraldo et al., 1975; Huang et al., 1992; Monini et al., 1996b; Wang et al., 1993). 
However, none of them can satisfactorily explain the epidemiology of this disease. 
Kaposi’s sarcoma-associated-herpes virus (KSHV), also called human herpesvirus 8 
(HHV-8), was identified in AIDS-KS biopsies in 1994 (Chang et al., 1994).
1.1.2 Kaposi’s sarcoma-associated herpesvirus (KSHV)
1.1.2.1 Taxonomy, morphology and genome organisation
KSHV was the third human oncogenic virus after HPV-16 (Durst et al., 1983) and 
hepatitis C virus (HCV) (Choo et al., 1989) to be identified by molecular techniques 
(Chang et al., 1994). HPV-16 DNA molecules were discovered in a sample isolated
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from a biopsy specimen of invasive cancer of cervix. HPV-11 DNA probe hybridised 
with the DNA sample only under nonstringent conditions. This DNA was further 
cloned in a lambda phage and under stringent conditions of hybridisation it cross- 
hybridised less than 0.1% with HPV types 10, 14 and 15 and showed no homology 
with other known HPV types. It was then designated as HPV-16 (Durst et al., 1983).
A random-primed cDNA library was constructed from plasma containing the 
uncharacterised non-A, non-B hepatitis (NANBH) agent and screened with serum 
from a patient diagnosed with NANBH. A cDNA clone was isolated that was shown 
to encode an antigen associated specifically with NANBH infection. This clone did 
not derive from the host genome and treatment with ribonuclease determined the 
RNA nature of the nucleic acid (Choo et al., 1989).
KSHV was the first virus to be identified by representational difference analysis 
(RDA) (Chang et al., 1994). DNA was isolated from KS tissue obtained from a 
patient with AIDS-KS. Using normal skin DNA from an area adjacent to the KS 
lesion from the same individual, repeated cycles of polymerase chain reaction (PCR) 
and hybridisation enriched for unique DNA sequences that were found only in the 
KS tissue (Chang et al., 1994). KSHV is classified as a y2-herpesvirus (genus 
Rhadinovirus) with sequence similarity to other oncogenic gammaherpesviruses 
including Epstein-Barr virus (EBV), herpesvirus saimiri (HVS) and murine 
herpesvirus 68 (MHV-68) (Table 1.1.).
KSHV exhibits typical herpesvirus morphology with a lipid envelope and a central 
core (Renne et al., 1996). The capsid is icosahedral, between the capsid and the 
envelope is the tegument, and the core consists of DNA and protein. The genome is a 
single contiguous region 140 to 145kb long and contains at least 80 open reading 
frames (ORF) (Moore et al., 1996a). In latency, the viral genome appears in a 
circular conformation (episome), but during lytic cycle, it becomes linear (Renne et 
al., 1996). KSHV gene expression analysis has revealed that the viral genes can be 
clustered into latent, primary lytic, secondary lytic and tertiary lytic depending on the 
relative time when expression was first detected, from earliest to latest (Jenner et al.,
2001).
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Table 1.1. Related oncogenic gammaherpesviruses
Gamma herpesvirus
Genus
VIRUS HOST ASSOCIATED TUMOURS
Lymphocryptovirus
Burkitt's lymphoma 
Nasopharyngeal carcinoma
or
gamma-1 herpesvirus
EBV8 Human Post-transplantation 
lymphoproliferation 
Hodgkin’s disease 
Smooth muscle sarcoma
HVSb New world T-cell lymphoma
Rhadinovirus
or
gamma-2 herpesvirus
Primates Lymphosarcoma
MHV-68C Mouse Lymphoproliferation
RFHVd Old world 
primates
Retroperitoneal
fibromatosis
8 Epstein-Barr virus
b Herpesvirus saimiri 
c Murine Herpesvirus-68
d Retroperitoneal fibromatosis-associated herpesvirus of rhesus macaques {Macaca 
mulatto:, RFHVMm and Macaca nemestrina; RFHVMn)
1.1.2.2 KSHV strain variation
Herpesviruses display nucleotide sequence variation and this variability results in 
viral clustering or subtyping, e.g. herpes simplex viruses could belong to type 1 or 2, 
human herpes virus 6 has two variants A and B and EBV also has two types, A and 
B (Ablashi et al., 2002; Hayward, 1999). Open reading frame (ORF)-Kl is used to 
subtype KSHV (McGeoch and Davison, 1999; Nicholas et al., 1998). Molecular 
epidemiological studies have phylogenetically classified KSHV into strains A, B, C 
and D. These subtypes create distribution patterns depending on geographical and 
ethnic origin of the infected individuals (Cook et al., 1999; Hayward, 1999; Lacoste 
et al., 2000; Meng et al., 1999; Poole et al., 1999; Zong et al., 1999). The variability 
among the subtypes ranges from 15 to 30% at the amino acid level. Subtype A is 
particularly associated with Western Europe and North America, subtype B is found 
primarily in patients originating from Africa, subtype C in transplant patients from 
the Middle East and elderly individuals from the Mediterranean countries and
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subtype D has been found in individuals from the Pacific Islands, South Asia and 
Australia. Another subtype, recently identified, is E and associated with Amerindian 
populations (Biggar et al., 2000). However, subtype E is phylogenetically close to D, 
and not yet clear whether it represents a separate strain (Zong et al., 2002). 
Phylogenetic analysis of the three main strains (A, B and C) has revealed that 
subtypes A and C are more similar to each other than to subtype B (McGeoch, 2001; 
Stebbing et al., 2003). Although, no correlation has yet been identified between any 
strain and disease susceptibility or progression, involvement of K1 in immune 
evasion and adaptation mechanisms has been suggested (Stebbing et al., 2003).
1.1.2.3 KSHV-associated diseases
1.1.2.3.1 Kaposi's Sarcoma (KS)
The first confirmation that KSHV is indeed involved in KS pathogenesis was the
detection of KSHV DNA by polymerase chain reaction (PCR) in all forms of the
disease and in all the fresh biopsy specimens tested (and in the vast majority of
archival paraffin embedded material) (Boshoff et al., 1995b). The virus is rarely
detectable in non-KS tissues (except blood) from the same individual, indicating that
the viral load is highest in KS lesions (Boshoff, 1998; Moore and Chang, 1995).
Many studies have shown that this virus is seldom detectable in other vascular
tumours like angiomas and skin tumours of immunosuppressed patients (Adams et
al., 1995; Boshoff et al., 1995a; Boshoff et al., 1996; Lin et al., 1996; Uthman et al.,
1996). The detection of KSHV DNA by PCR in peripheral blood of HIV-1 positive
individuals predicts who will subsequentlv develop KS (Moore et al., 1996c; Whitby
| higher
et al., 1995), indicating those at risk have‘ a detectable viral load than those not at 
risk. KSHV DNA is present in nearly all spindle cells in KS lesions as an episomal 
form (latent) and only a small but real percentage of cells undergo spontaneous lytic 
replication (Boshoff etal., 1995a; M.A Davis et al., 1997; Li et al., 1996; Rainbow 
et al., 1997; Staskus et al., 1997; Sturzl et al., 1997). Since the vast majority of the 
cells are latently infected, this infers that KSHV, like other oncogenic viruses, is 
directly involved in driving or maintaining the proliferation of the tumour cells 
(Boshoff, 1998).
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1.1.2.3.2 Primary Effusion Lymphoma (PEL)
KSHV was specifically associated with, and may have a direct role in, causing PEL 
(Cesarman et al., 1995a; Pagano, 2002). PEL presents predominantly as a malignant 
effusion in the pleural, pericardial or peritoneal cavities usually without significant 
tumour mass or lymphadenopathy (Ansari et al., 1996; Boshoff, 1998). These 
lymphomas are rare but occur predominantly in HIV-1 infected individuals with 
advanced stage of immunosuppression (Komanduri et al., 1996). The tendency of 
these lymphomas is to remain confined to body cavities without further 
dissemination. The majority of, but not all, PELs are co-infected with EBV, 
suggesting that the two viruses may cooperate in this neoplastic transformation 
(Cesarman et al., 1995a; Otsuki et al., 1996). Both (Southern blot analysis and 
quantitative real-time PCR of PEL cells have shown the presence of KSHV 
sequences in high copy numbers (50-150 viral episomes/cell), compared to those 
seen in KS (Boshoff, 1998; Lallemand et al., 2000; White and Campbell, 2000). 
Many cell lines from PEL have been established, and the BCP-1 cell-line described 
by Boshoff and colleagues from the peripheral blood of a patient with PEL, is 
KSHV+ and EBV- and is therefore useful for serological assays, i.e. the detection of 
antibodies to latent or lytic (when chemically induced) KSHV antigens (Boshoff et 
al., 1998).
1.1.2.3.3 Multicentric Castleman ’s Disease (MCD)
Castleman’s disease (CD) is a rare and usually polyclonal lymphoproliferative 
disorder (Castleman et al., 1956). Two distinct histopathological variants with 
different clinical characteristics have been described: the hyaline vascular type and 
the plasma cell type. Soulier and colleagues were the first to report the presence of 
KSHV in multicentric CD (MCD) biopsy specimens (Soulier et al., 1995). Various 
other investigators have since confirmed the presence of KSHV in some cases of 
MCD (Barozzi et al., 1996; Dupin et al., 1995a; Gessain et al., 1996). KSHV is 
nearly universally present in HIV-1 positive individuals with MCD. Among MCD 
cases in immunocompetent hosts the presence of KSHV is restricted to about 40% of 
cases (Ablashi et al., 2002). In MCD, KSHV is present in plasmablasts in the mantle 
zone (Dupin et al., 1999; Dupin et al., 2000)
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1.1.2.3.4 Association with multiple myeloma
KSHV has been considered ubiquitous by some investigators and studies have 
implicated the virus in cases of multiple myeloma (MM) (Rettig et al., 1997; Said et 
al., 1998). Most researchers, employing molecular and serological techniques, have 
not been able to reproduce the finding that KSHV is associated with multiple 
myeloma (Ablashi et al., 2000; Cull et al., 1998; MacKenzie et al., 1997; Marcelin et 
al., 1997; Masood etal., 1997; Parravicini et al., 1997a; Tarte et al., 1998; Tarte et 
al., 1999; Whitby et al., 1997). In the meantime, we must conclude that the original 
findings showing that KSHV is present in MM was most likely due to PCR 
contamination.
1.1.2.4 KSHV gene homologues and viral pathogenesis
Herpesviruses, and poxviruses, have incorporated many host genes into their own 
viral genome during the course of co-evolution (Moore et al., 1996b). KSHV 
encodes homologues of many cellular genes; more than 15% of viral genes are 
pirated from eukaryotic cellular DNA, that are involved in the cell cycle, signalling, 
differentiation and oncogenesis (Moore et al., 1996b). This piracy was achieved 
during evolution and helps the virus to maintain infectivity, replication, pathogenesis 
and survival (Boshoff and Chang, 2001).
■ vCyclin: Cellular cyclins are critical components of the cell cycle (Ganem,
1997): cyclins inactivate (by phosphorylation) various checkpoints throughout 
the cell cycle, allowing cells to enter DNA synthesis (S phase) or mitosis (M 
phase) (Boshoff and Chang, 2001). Cyclins associate with their partners (the 
cyclin dependant kinases, CDKs) to be fully active. The KSHV cyclin 
homologue has highest sequence similarity with cellular D type cyclins. Its 
association with CDK6 creates a complex that can phosphorylate, and therefore 
inactivate the retinoblastoma protein, pRb, a checkpoint protein that inhibits 
entry into S-phase (Chang et al., 1996; Godden-Kent et al., 1997; Li et al., 1997). 
This complex is also resistant to inhibition by the CDK inhibitors p i6, p21 and 
p27 (Ellis et al., 1999; Mann et al., 1999; Swanton et al., 1997) unlike cellular 
cyclin D-CD complexes. The expression of the viral cyclin in latently infected 
spindle and PEL cells indicates a possible role in inducing the proliferation or the
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arrest of differentiation of these cells and therefore tumour formation (Boshoff, 
2003; Cannell and Mittnacht, 1999; Cesarman et a l ,  1996; M.A. Davis et a l ,  
1997; Reed etal., 1998).
■ Vbcl2: KSHV encodes a gene (ORF-16) with sequence similarity to bcl2, 
similarly to EBV and HVS (Cheng et a l ,  1997; Sarid et a l ,  1997). KSHV bcl2 
can overcome bax-mediated apoptosis, and appears to be expressed during lytic 
infection (Sarid et a l ,  1998), suggesting that expression of this viral protein 
prolongs cell survival during lytic infection, until complete virions are released 
from the cell.
■ vF lip: Recently a new family of apoptosis inhibitors (vFLIP: FLICE inhibitory 
proteins) has been identified that interferes with apoptosis signalled through 
death receptors (Thome et al., 1997). Like cellular FLIP, the vFLIP encoded by 
KSHV might block one of the principal pathways by which immune mechanisms 
cause cell death -  that is, induction of apoptosis by the tumour necrosis factor 
(TNF) family of receptors (Boshoff, 1998). It has been shown that vFLIP can 
protect cells from Fas-mediated apoptosis and permits clonal growth in the 
presence of death stimuli in vitro. KSHV-FLIP can act as a tumour progression 
factor by promoting tumour establishment and growth in vivo (Djerbi et a l ,  
1999).
■ vIL-6: The viral cytokine IL-6 encoded by ORF K2 is functional in preventing 
apoptosis of IL-6 dependent mouse and human myeloma cell lines in vitro 
(Moore et al., 1996b; Neipel et a l ,  1997; Nicholas et a l ,  1997), indicating that it 
could play a part in maintaining the proliferation of PEL cells in vivo. It is 
expressed during lytic viral cycle (Sun et a l ,  1999) and highly expressed in 
KSHV associated lymphomas (Aoki et al., 1999; Cannon et a l ,  1999; Drexler et 
a l ,  1999; Staskus et a l ,  1999). The vIL-6 has also been shown to facilitate 
immune surveillance evasion by blocking interferon signalling (Chatterjee et al.,
2002).
■ vMIPs: (c/iemoattractant cytokines). The chemokines encoded by KSHV, viral 
macrophage inflammatory proteins I, II and III are known to bind to CC and 
CXC receptors on cells (Kledal et al., 1997; Nicholas et al., 1997). vMIP-I is 
similar to human cellular MIP chemokines in its ability to strongly inhibit 
replication of HIV-1 strains that depend on the CC chemokine receptor 3 (CCR3) 
and CCR5 (Boshoff et a l ,  1997; Nicholas et a l ,  1997). vMIP-I is a specific
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agonist for CCR8 that is preferentially expressed on Th2 T cells (Endres et al., 
1999). vMIP-II has an immunomodulatory role in directing inflammatory cell 
recruitment away from a Thl-type towards a Th2-type response and thereby 
facilitating evasion from cytotoxic reactions (Sozzani et al., 1998; Weber et al., 
2001). KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates 
angiogenesis, and selectively chemoattracts Th2 cells (Stine et al., 2000). 
Overall, the vMIPs could shift the KSHV microenvironment from a Thl to a 
more favourable Th2 niche, therefore facilitating viral immune evasion 
processes.
vGPCR: Another KSHV chemokine-associated protein involved in cellular 
proliferation is the viral encoded G protein coupled receptor (vGPCR), most 
homologous to the human receptors for interleukin 8 (IL-8) (CXCR-1 and 
CXCR-2) (Cesarman et al., 1996). This viral protein is able to trigger signalling 
cascades (Arvanitakis et al., 1997), leading to activation of transcription factors 
involved in cell survival and proliferation (Karin et al., 1997; Montaner et al.,
2001) and in activation of inflammatory and angiogenic factors (Kolch et al., 
1995; Montaner et al., 2003). It was also recently shown that expression of 
transfected vGPCR in umbilical vein endothelial cells (HUVEC) leads to 
immortalisation with constitutive vascular endothelial growth factor (VEGF) 
receptor-2/KDR expression and activation (Bais et al., 2003).
VIRF: Interferons (IFNs) are a family of cytokines with antiviral activity. The 
interferon regulated factor (IRF) family of transcription factors regulates IFN 
stimulated responses (Moore et al., 1996b). The vIRF of KSHV transforms 
NIH3T3 cells, however it is still unclear whether it is actually expressed during 
latency (Gao et al., 1997). The vIRF might be involved in evasion of immune 
responses of lytic infected cells by repressing IFN-mediated signal transduction 
(Boshoff, 1998). Indeed, vIRF-1 represses the interferon antiviral response (Li et 
al., 2000; Lin et al., 2001; Zhu et al., 2002) and is also able to suppress p53- 
dependent transcription, therefore regulating apoptosis (Seo et al., 2001; Seo et 
al., 2002).
Survivin-AEx3: Survivin-AEx3 is a recently identified spliced variant of human 
survivin, a protein that protects cells from apoptosis and is expressed in cancer 
cells (Mahotka et al., 1999). The viral glycoprotein K7 is a latent gene,
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structurally and functionally related to survivin-AEx3, that inhibits apoptosis by 
way of binding cellular bcl-2 and activate caspase-3 (H.W. Wang et al., 2002).
1.1.2.5 Viral tropism and propagation
In KS, the tumour cells infected by KSHV are the so-called spindle cells. These cells 
belong to the endothelial lineage and probably represent endothelial progenitor cells 
(Dupin et al., 1999). KSHV has also tropism for B cells, like EBV, which leads to 
clonal primary effusion lymphoma (PEL) in immunosuppressed individuals 
(Gaidano and Carbone, 2001; Nador et al., 1996; Said et al., 1996). The lymphomas 
are often, but not always, coinfected with EBV. Multicentric Castleman’s Disease 
(MCD) results from a polyclonal hyperplasia and the infected cells are plasmablastic 
B cells (Du et al., 2001; Dupin et al., 2000; Staskus et al., 1999). In vivo, KSHV has 
also been detected in monocytes and epithelial cells (Monini et al., 1999). In vitro, 
KSHV has been shown to infect B cells (Mesri et al., 1996; Moore et al., 1996a), 
macrophages, endothelial (Blackboum et al., 2000; Panyutich et al., 1998; Renne et 
al., 1998) and epithelial 293 cells (Foreman et al., 1997). However, none of these 
infections are highly efficient. Bone marrow endothelial cells seem to be more 
susceptible to KSHV, survive longer and are able to grow in soft agar after infection 
(Flore et al., 1998).
1.1.2.6 Methods used for the detection of KSHV infection
1.1.2.6.1 PCR-based methods
The discovery of KSHV was reported in 1994 using representational difference 
analysis (Chang et al., 1994). This was confirmed by PCR detection of KSHV DNA 
in 25/27 AIDS-KS biopsies (Chang et al., 1994). Since then, KSHV DNA has been 
detected in almost 95% of all epidemiological forms of KS (Ambroziak et al., 1995; 
Boshoff et al., 1995b; Buonaguro et al., 1996; Cathomas et al., 1996; Chuck et al., 
1996; Corbellino et al., 1996; Dupin et al., 1995b; Gaidano et al., 1996; Jin et al., 
1996; Luppi et al., 1996; O'Neill et al., 1996; Schalling et al., 1995), but not in most 
control tissues tested and not in non-KS tissue from the same patients (IARC, 1995). 
Nested-PCR has been used to detect KSHV in paraffin-embedded tissues from KS 
and MCD biopsies, lymphoid tissues from PEL patients, semen, vaginal secretions,
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urine, plasma, peripheral blood mononuclear cells (PBMCs) and saliva (Calabro et 
al., 1999; Cattani et al, 1999; Corbellino et al., 1996; Howard et al., 1997; Koelle et 
al., 1997; Lin et al., 1995; Moore et al., 1996c; Tasaka et al., 1997). KSHV can be 
detected in PBMCs in approximately 50% of AIDS-KS patients by nested PCR 
assays (Huang et al., 1997; Moore et a l, 1996c; Whitby et al., 1995). Detection of 
KSHV in PBMCs from HIV-seropositive individuals predicts the development of KS 
(Whitby et al., 1995). Studies have reported detection of KSHV in semen from HIV- 
infected individuals with, or at risk, of developing KS but not in the semen of HIV- 
uninfected donors (Howard et al., 1997; Tasaka et al., 1996). It was, although, earlier 
suggested that KSHV was detectable in the semen and prostate tissue from the 
majority of healthy men particularly those originating from areas with classic or 
endemic KS (Monini et al., 1996a; Viviano et al., 1997). Also, KSHV is frequently 
detected in oral secretions from KS patients and men who have sex with men but not 
in non-at-risk healthy individuals (Pauk et al., 2000). Recently, real-time quantitative 
PCR-based detection methods have been developed for the detection of KSHV 
infection in blood from AIDS patients with KS, PEL, MCD, transplant recipients and 
blood donors (Boivin et al., 2002; de Sanjose et al., 2002; Enbom et al., 2002; Gill et 
al., 2002; Lallemand et al., 2000; Pellet et a l, 2001; Quinlivan et al., 2002; Tedeschi 
et al., 2001; White and Campbell, 2000).
1.1.2.6.2 In situ hybridisation
In situ hybridisation was used to identify the specific cells that harbour KSHV in KS 
tissues (Boshoff et al., 1995a). It was shown that KSHV is localised in endothelial 
and spindle cells in KS lesions and this was also confirmed by others (Cesarman et 
al., 1995b; Huang et al., 1996; Li et a l, 1996; Reed et al., 1998; Staskus et al., 1997; 
Sturzl et al., 1999). This method is not any longer used for the in situ detection of 
KSHV because, since the generation of specific anti-KSHV antibodies, 
immunohistochemistry has effectively replaced it as an easier diagnostic procedure.
1.1.2.6.3 Immunohistochemistry
Available monoclonal or polyclonal antibodies to several latent and lytic KSHV 
antigens have promoted the easy detection of KSHV in formalin-fixed and paraffin- 
embedded tissues. Thus, KSHV has been detected in the spindle cells and some 
epithelial cells of KS lesions, in PEL and in plasmablasts within the mantle zone of
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MCD. This method has also suggested that specific KSHV antigens are expressed in 
specific KSHV-associated tumours. For example, the monoclonal antibody against 
the latent nuclear antigen (LANA) was the first to be developed (Kellam et al., 
1999), and is currently routinely used in histopathology laboratories to confirm KS, 
PEL and MCD (Bryant-Greenwood et al., 2003). In contrast, KSHV interleukin 6 
(vIL-6) lytic gene expression and detection is mainly associated with PEL and MCD 
and not with KS (Brousset et al., 2001; Cannon et al., 1999). vIL-6 antibody stains 
MCD lymphoid cells around lymphoid follicles, but also the follicular dendritic 
reticulum cell network (Brousset et al., 2001; Parravicini et al., 1998; Staskus et a l, 
1999).
1.1.2.6.4 Serology
Circulating plasma or serum antibodies to latent and lytic KSHV antigens have been 
detected using indirect immunofluorescence (IFA) assays, enzyme linked 
immunosorbent assays (ELISAs) and Western blots. Using serological assays, the 
prevalence of KSHV infection can be estimated and large epidemiological surveys 
conducted.
IFA was the first serological assay employed to detect KSHV IgG antibodies, against 
latent KSHV (Gao et al., 1996b; Kedes et al., 1996) and lytic proteins (Andreoni et 
al., 1999; Chatlynne et al., 1998; Lennette et al., 1996; Simpson et al., 1996). PEL 
cell lines (BCP-1, KS-1, BC-3 and BCBL-1) are commonly used as substrate cells 
for the detection of IgG antibodies against latent and lytic KSHV antigens. The cells 
are fixed and permeabilised so that the tested sera can react with the expressed 
antigens. The most characterised latent antigen is the KSHV latent nuclear antigen 
(LANA), detected by this IFA and is encoded by open reading frame 73 (ORF 73) 
(Kedes et al., 1997b; Kellam et al., 1997; Rainbow et al., 1997). LANA is one of the 
few KSHV genes expressed in latency and is also detectable up to 72 hours after 
induction of KSHV lytic replication (Jenner et al., 2001). LANA has multiple 
important functions and is associated with KSHV induced oncogenesis (Ballestas et 
al., 1999; Boshoff, 2003; Friborg et al., 1999; Radkov et al., 2000). PEL cells can be 
treated with compounds such as phorbol esters that induce lytic replication of KSHV 
and therefore expression of lytic antigens. The lytic proteins detected by lytic IFA 
have only partially been identified (Chandran et al., 1998a). The specificity of the
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lytic IFA is therefore unclear and cross-reactivity against other structural proteins, 
including Epstein'-Barr virus (EBV) antigens, has not been formally excluded 
(Whitby and Boshoff, 1998). Indeed, lytic IFA gave rise to the highest KSHV 
seroprevalence (20%) among U.S.A. blood donors thus far reported (Lennette et al., 
1996) but this result remains controversial (Chatlynne et al., 1998; Whitby and 
Boshoff, 1998) and has not been confirmed by assays based on the detection of 
antibodies against specific lytic antigens such as K8.1 (Chandran et al., 1998b), ORF 
65 (Lin et al., 1997) or whole virions (Ablashi et al., 1999; Chatlynne et al., 1998).
Immunoblot and western blot assays against latent and/or lytic viral proteins have 
also been used to detect anti-KSHV antibodies (Chandran et al., 1998b; Katano et 
al., 1999; Lang et al., 1999; Lin et al., 1997; Miller et al., 1996; Miller et al., 1997; 
Olsen et al., 1998; Raab et al., 1998; Zhu et al., 1999a). However these assays are 
impractical for large seroepidemiological studies. ELISAs have been used to detect 
KSHV antibodies against recombinant ORF 26, ORF 52, ORF 59, ORF 65, ORF 73, 
K8.1 and K12 (D.A. Davis et al., 1997; Katano et al., 1999; Lang et al., 1999; 
Oksenhendler et al., 1998; Regamey et al., 1998; Simpson et al., 1996). A whole 
virus ELISA has also been described (Chatlynne et al., 1998). This assay detects 
KSHV IgG antibodies in sera using sucrose banded whole virus lysate as antigen. 
This viral lysate contains most KSHV structural and non-structural proteins 
(Chatlynne et al., 1998). This ELISA could have a sensitivity advantage over 
peptide-based assays and single protein recombinant ELISAs since it is not restricted 
to only one viral immunogenic antigen. In contrast to lytic IFA, this assay has been 
shown to be specific for KSHV with no cross-reactivity to EBV or other known 
human herpesvirus proteins (Ablashi et al., 1999; Chatlynne et al., 1998; Chatlynne 
and Ablashi, 1999). A more recent approach, to achieve higher levels of sensitivity 
and specificity, is the development of KSHV ELISAs that combine more than one 
immunogenic epitope of KSHV in one assay (mixed antigen ELISA) or multi- 
branched antigenic peptides (Katano et al., 2000; Lam et al., 2002; Schatz et al.,
2001). Since no “gold standard” for determining positivity for KSHV antibodies is 
yet available, the assumption is that all patients with KS are infected with KSHV 
because all KS lesions are KSHV positive by PCR (Ablashi et al., 2002). Sera from 
KS individuals are therefore used to compare sensitivity of serological assays and 
will be used in this thesis.
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1.1.2.7 KSHV transmission
The modes of transmission of KSHV are still not clear unlike most human 
herpesviruses. KSHV is not ubiquitous, and the geographical pattern and scale of 
infection seem to follow that of KS.
1.1.2.7.1 In the U.S.A. and Europe (excluding classic KS areas)
Before the discovery of KSHV, epidemiological studies suggested that the aetiologic 
agent for KS was sexually transmitted (Beral et al., 1990; Beral, 1991). 
Subsequently, in the U.S.A. and other countries in northern Europe where KS is 
clustered among homosexual men with HIV-1 infection, sex between men is an 
important route of viral transmission: KSHV DNA has been detected in semen from 
HIV-1 infected men (Howard et al., 1997; Lin et al., 1995; Martin et a l, 1998) and 
in prostatic fluid, semen, saliva and peripheral blood from patients with AIDS-KS 
(Corbellino et al., 1996; Huang et al., 1997; Whitby et al., 1995). High-risk sexual 
behaviour and history of other sexually transmitted diseases (STDs) are considered 
to be important risk factors of KSHV transmission within the homosexual 
community (Martin et al., 1998; Pauk et al., 2000; Smith et al., 1999). KSHV DNA 
has also been detected in oropharyngeal cells in 30% of KSHV seropositive males 
who had sex with other men, therefore, mucosal shedding is possible and the kissing 
may be a major route of transmission (Pauk et al., 2000).
Studies have also focused on KSHV transmission via needle sharing, and an 
association of KSHV infection with intravenous drug use has been reported in the 
U.S.A. (Cannon et al., 2001). Prior to the discovery of KSHV, Beral et al. had 
already predicted the transmission of a putative infectious agent by observing the 
incidence of KS in the HIV-1 infected individuals in the U.S.A.. HIV-1 infected 
homosexual men had the highest risk of having KS compared to intravenous drug 
users or haemophiliacs who acquired HIV-1 via needle piercing or blood transfusion 
(Beral et al., 1990). KSHV DNA has also been detected in the female genital tract 
(Calabro et al., 1999; Lampinen et al., 2000; Whitby et al., 1999) however, evidence 
for heterosexual transmission in this population is inconclusive (Greenblatt et al., 
2001; Smith et al., 1999)
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In the general population, KSHV prevalence ranges from 0 to 15%, depending on the 
assay used, and serological studies have shown that a history of STDs increases the 
risk of KSHV transmission among blood donors (Gao et al., 1996b; Simpson et al., 
1996). This indicates that sexual contact is possibly the main route of KSHV 
transmission in the adult heterosexual population (Blackbourn et al., 1997; 
Chatlynne et al., 1998; Gao et al., 1996a; Gao et al., 1996b; Kedes et al., 1996). 
Transmission via saliva in the general population seems less common and difficult, 
and oral transmission may depend on the amount of KSHV shed in the saliva (Biggar 
and Goedert, 2001; Lucchini et al., 2001). In general, studies have reported limited, 
or no KSHV infection in children from the U.S.A. and U.K. (Blauvelt et al., 1997; 
Simpson et al., 1996). Overall, KSHV is considered to be a sexually transmitted 
virus but transmission is not efficient, and other co-factors might increase the risk of 
transmission in the West.
1.1.2.7.2 In populations from classic KS areas
Sexual and non-sexual routes of transmission have been suggested to occur in people 
who originate from Southern Mediterranean countries and from Israel where there is 
a relatively high incidence of KS in the elderly population and increased 
seroprevalence of KSHV in the general population (Calabro et al., 2000; Calabro et 
al . ,  2001; D av id o v ic i et al., 2001; S erra ino  et al., 2001). There is 
seroepidemiological and laboratory evidence to support the notion that KSHV is 
possibly transmitted horizontally and vertically from mother to her child, sexually 
and via oral secretions among spouses, in Israel and Italy (Ablashi et al., 2002; 
Angeloni et al., 1998; Boshoff and Weiss, 2001; Cattani et al., 1999; Davidovici et 
al., 2001; Iscovich et a l, 2000b; Pema et al., 2000; Rezza et al., 1998; Serraino et 
al., 2001; Vitale et a l, 2000; Whitby et al., 2000). However, KSHV infection in 
Spanish children is absent and KSHV prevalence in blood donors is the lowest in the 
region (Gambus et al., 2001). Thus, KSHV is able to infect the general population 
from childhood to the adult population, increasing its prevalence and transmission 
levels. Further studies are necessary to investigate which environmental and genetic 
factors predispose to KSHV infection and transmission within this population and 
KS development.
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1.1.2.7.3 In populations from endemic KS countries and rest o f Africa
In sub-Saharan Africa, KS was seen in children well before the AIDS pandemic 
(Oettle, 1962; Olweny etal., 1976). In Africa, KSHV has the highest seroprevalence 
in the world, regardless of the HIV-1 serostatus. Transmission among the adult 
population occurs and infection rates increase over time, but HIV-1 co-infection does 
not appear to increase the risk of KSHV transmission (Sitas et al., 1999a). Apart 
from sexual, other routes of KSHV transmission must occur in this population. 
Seroepidemiological studies have suggested vertical transmission (whether perinatal 
or later) of KSHV from mother to child, and the transmission risk is increased when 
the infected mother has high anti-KSHV antibody titres in South and Central Africa 
(Boshoff and Weiss, 2001; Bourboulia et al., 1998; Gessain et al., 1999; Mantina et 
al., 2001; Sitas et al., 1999b). Increasing prevalence of KSHV infection before 
puberty has also pointed out the possibility of viral transmission from child to child 
via non-sexual routes (e.g. saliva) (Andreoni et al., 1999; Plancoulaine et al., 2000; 
Plancoulaine et al., 2002). Whether there are other factors associated with KSHV 
infection, in addition to immunosuppression caused by HIV-1 and other infections, 
that contribute to an increased risk of KSHV infection and transmission in the 
African population remains elusive.
1.1.2.7.4 Blood-born transmission
Possible KSHV transmission via blood transfusion and through blood derivative 
products has also been suggested since the virus has been detected in blood and body 
fluids (Enbom et al., 2002; Goedert et al., 2003). However, this potential risk has to 
be investigated further.
1.1.2.7.5 Transmission via transplantation
There is an increased incidence of KS in transplant recipients because of drug- 
induced immunosuppression. KSHV may be present in the recipient before 
transplantation or may be transmitted in the donor tissue. Studies have shown that 
KSHV transmission from the donor of a solid organ to the transplant recipient (Luppi 
et al., 2000; Luppi et al., 2002; Parravicini et al., 1997b; Regamey et al., 1998) and 
this suggests that proper screening of both the donor and recipient would reduce the 
risk of KSHV transmission and post-transplantation associated malignancies.
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Recently it was shown that tumour cells from the organ donor can contribute to KS 
development in the recipient (Barozzi et al., 2003; Moore, 2003).
1.2 THE IMMUNE SYSTEM & KSHV 
1.2.1 An overview
The immune system is a network of lymphoid organs, cells, humoral factors and 
cytokines. The functions of the immune system are well illustrated when it 
malfunctions (allergic reactions, autoimmune diseases, immunodeficiency) (Parkin 
and Cohen, 2001) and also when vaccination is applied for protective purposes. The 
immune system is commonly divided into two major branches: the innate immunity 
characterised by its speed, and the adaptive immunity determined by its specificity. 
When applied to infection, both types of immune responses can also be subdivided 
into cytolytic and noncytolytic responses (Guidotti and Chisari, 2001; Wodarz et al.,
2002). In general, cytolytic immunity is defined as the destruction of infected cells 
whereas noncytolytic immunity is defined as the inhibition of viral replication and 
shedding by soluble mediators secreted by the immune cells.
Most viral infections in immunocompetent humans are successfully cleared, i.e. 
totally eradicated from the body by the immune system (e.g. influenza, common 
cold). Herpesviruses establish persistent infections that are never fully cleared by the 
immune mechanisms. Although the immune system is able to clear an ongoing, 
active infection (herpes simplex virus, varicella-zoster, polio, HIV), some viruses 
establish latency and persist for life. KSHV infects and persists for life like any other 
herpesvirus. Persistent infection indicates that the immune system is not able to 
successfully clear the virus after primary infection. Whether the outcome of this 
infection is disease depends on both the KSHV virulence/load and the integrity of the 
defence system.
1.2.2 Innate responses
Excluding the physical barrier, innate immunity refers to an immediate defensive 
reaction, non-specific response, taken by the host against foreign invasion (Janeway
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and Medzhitov, 2002). The role of innate immunity in the control of primary KSHV 
infection is still unknown. KSHV is not a ubiquitous virus, unlike EBV, and the 
majority of clinical studies focus on the investigation on KSHV/HIV-1 co-infected 
individuals with KS.
1.2.2.1 NK responses
Natural killer (NK) cells are lymphocytes that can be activated by viral-infected 
target cells to mediate direct lysis of these cells prior to virion assembly and 
spreading, by secretion of perforins and granzymes, leading to apoptosis of the viral- 
infected cells (Parkin and Cohen, 2001). In addition, NK cells are able to minimise 
the replication level of the virus by rapid production of cytokines (IFN-y, TNF-a and 
granulocyte-macrophage colony-stimulating factor) and chemokines (macrophage 
inflammatory protein la) (Parkin and Cohen, 2001).
A recent study demonstrated that the ability of NK cells to lyse KSHV latently 
infected cells was significantly reduced in AIDS patients with progressing KS, as 
compared to both HIV-negative patients with indolent classic KS or normal blood 
donors. The activity of NK cells was restored upon highly active antiretroviral 
therapy (HAART) (Sirianni et al., 2002). Low or no NK cell function has been 
linked with increased human sensitivity to severe disseminating herpesvirus 
infections, including those with herpes simplex, varicella zoster, EBV and CMV 
(Biron et al., 1999).
1.2.2.2 Inflammatory responses
Viral infected cells are thought to produce a number of factors, such as cytokines, 
which stimulate early innate immune responses and recruitment of cells to the site of 
the inflammation (Parkin and Cohen, 2001). Additionally, many adhesion molecules 
or cellular receptors are expressed on the surface of the migrated immune cells and 
the infected cells which helps in this cell-to-cell communication. KSHV is thought to 
primarily infect B-lymphocytes where it remains latent. In general, it is unknown 
how the innate immune system acts to minimise KSHV dissemination after primary 
infection. However, it is known that in any form of KS, KSHV is detectable in
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spindle cells, endothelial cells and monocytes in KS lesions. As described earlier, in 
early stages of KS development a variable inflammatory lymphocytic infiltrate is 
present. Progressively, eosinophils, dendritic cells, T cells, B cells and plasma cells 
are also found amongst the spindle cells. It has been suggested that inflammatory 
cytokines are upregulated during KS development and may reactivate KSHV 
infection (Monini et al., 1999). Various studies have indicated the growth promotion 
of KS due to increase expression of cytokines and growth factors such as TNF-a, IL- 
6, VEGF, transforming growth factor-p, platelet-derived growth factor, bFGF and 
oncostatin M (Cohen et al., 1996; Ensoli et al., 1989; Mesri, 1999; Miles et al., 1990; 
Miles, 1994; Nair et al., 1992; Samaniego et al., 1995). KS cells have been shown to 
respond to these stimulators because they express their corresponding receptors. 
Tumour cells escape and deregulate the immune system by the molecular mimicry of 
the human cytokine responses that a few KSHV genes have acquired, resulting) in 
immune system exploitation, evasion and occasionally tumour formation and 
angiogenesis (Murphy, 2001). Local inflammation seems to work in favour of KS 
development and progression.
1.2.3 Adaptive responses
Antigen-specific responses are the hallmark of the immune system. Adaptive 
responses occur through T and B-lymphocytes. In contrast to innate immunity, the
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adaptive response is specific and precise, however, it takes several days or weeks to 
develop after infection. Additionally, these specific responses are characterised by 
their memory; recalling the encounter with the invader and subsequent re-exposure 
to it leads to a faster and dynamic response though, still, not immediate (Parkin and 
Cohen, 2001). In general, both B and T cells express their own antigen-specific 
receptors that bind to the foreign antigens, and this leads to cell priming, activation 
and differentiation.
1.2.3.1 Antibody responses
After the encounter with an antigen, B-lymphocytes are activated to produce and 
release antibodies in the circulation. It is a major area of research, when a new virus 
is identified, to develop a specific and sensitive serologic assay that could be used to 
estimate the prevalence of the virus in the population. As already described (section
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1.1.2.6.4), levels of IgG antibodies to both latent and lytic KSHV antigens have been 
identified in the sera (or plasma) of KSHV-infected individuals by current 
immunofluorescence, ELISA and Western blot assays. The increase of antibody 
titres to both lytic and latent antigens may have a diagnostic and prognostic value in 
KSHV natural history, and particularly in KS development in HIV-1 infected 
individuals (Andreoni et al., 1999; Cannon et al., 2003; Engels et al., 2002; 
Plancoulaine et al., 2002; Sitas et al., 1999a; Sitas et al., 1999b).
1.2.3.2 T-cell mediated immunity
T-cell responses are important in the control of herpesvirus infections, and in 
particular CD8+ cytotoxic T lymphocyte responses (CTLs). CD4+ T-cell responses 
have not been investigated in KSHV infection and their importance in maintaining 
partial immunological control of KSHV is unknown. However, there is a great 
interest in CD8+ T-cell responses and this is mainly because CD8+ T cells play a 
critical role in the control of EBV replication and cell transformation in primary 
infection in healthy individuals (Callan et al., 1998), in the pathogenesis of AIDS- 
related non-Hodgkin lymphoma (van Baarle et al., 2001) and transplant recipients 
(Haque et al., 2002; Rickinson and Moss, 1997). Also, CD8+ CTLs appear to be 
critically involved in controlling cytomegalovirus (CMV) replication in healthy, 
chronically infected individuals and in the protection against CMV-related disease in 
transplant recipients (Addo and Rosenberg, 2002; Appay et al., 2002; Boeckh et al., 
2003; Ozdemir et al., 2002). Direct evidence for the importance of CD8+ CTLs is 
demonstrated by recent studies showing that adoptive transfer of in vitro expanded 
EBV or CMV-specific CD8+ CTLs can decrease viral load, prevent and protect 
against EBV- and CMV-associated post-transplantation life-threatening diseases 
(Einsele et al., 2002; Haque et al., 2002; Walter et al., 1995).
Adaptive cellular immunity to KSHV has only recently been examined. Studies have 
concentrated on KSHV cellular immunity in association with HIV-1 infection and 
AIDS-KS. That is due to the fact that KS is the most common malignancy in AIDS 
patients and HIV induced immunosuppression may contribute to loss of CTL 
responses to KSHV contributing to the development of KS (Goedert et al., 1998). 
Since 1996, HA ART has been widely used and mortality rates from AIDS have
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fallen dramatically in developed countries (Hogg et al., 1998; Palella et al., 1998). 
Also, the incidence of KS has decreased significantly and the resolution of KS 
lesions following HAART in patients with AIDS-KS has been reported (Dupont et 
al., 2000; International Collaboration on HIV and Cancer, 2000; Lebbe et al., 1998).
T cells responses to both primary and chronic KSHV infection have been 
demonstrated. In one study, none of 21 HIV-1/KSHV co-infected homosexual men, 
not on any therapy, had any T cell proliferative responses after KSHV antigen 
stimulation, however, 42% of HIV-1 negative KSHV seropositive homosexual men 
did (Strickler et al., 1999). Recently, studies have reported human leukocyte antigen 
class I (HLA class I)-restricted KSHV-specific cellular immune responses against 
latent and lytic viral proteins of KSHV. Our laboratory was the first to report strong 
HLA class I-restricted CTL responses against Kl, K8.1 and K12 whole proteins in 
KSHV-seropositive HIV-1 infected men without KS (Osman et al., 1999). 
Subsequently, we demonstrated an approximate four-fold increase of CTL responses 
in a cohort of HIV-1/KSHV co-infected individuals with KS, a year after initiation of 
HAART treatment (Wilkinson et al., 2002). KSHV specific CTLs against lytic gene 
products were also demonstrated in KSHV seropositive, HIV-1 infected and non­
infected individuals, with or without KS (Wang et al., 2000), and in HIV-uninfected 
adults with primary KSHV infection (Wang et al., 2001). In the last couple of years, 
KSHV-specific CTL epitopes were identified (Brander et al., 2001; Micheletti et al., 
2002; Stebbing et al., 2003; Q.J. Wang et al., 2002; Wilkinson et al., 2002). All these 
studies suggest that CD8+ T-cell responses to KSHV exist and may control primary 
KSHV infection and prevent development of disease.
In transplant patients, KS is known to resolve when immunosuppression is stopped 
(Jacobson et al., 1999; Weiss, 1999). KS prevalence in HIV-1 infected individuals 
has led to the investigation of the role of the immune system in the clinical setting of 
KSHV infection. The effect of adoptive KSHV specific CD8+ CTL immunotherapy 
has not been demonstrated, yet, for patients affected by KSHV associated cancers. 
Experimental immunological techniques such as enzyme-linked immunospot assay 
(ELISpot), major histocompatibility complex I (MHC class I) tetramer/peptide 
staining (Romero et al., 1998) have been developed that permit an ex vivo
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quantitative evaluation of virus-specific T cell immune responses (Altman et al., 
1996).
The identification of KSHV specific CTL immunogenic epitopes, and the knowledge 
of the frequencies of epitope-specific functional CTLs after primary and during 
chronic infection, are crucial advances for the understanding of the interaction 
between the virus and the immune system and for the eventual development of 
prophylactic and immunotherapeutic strategies against KSHV-associated 
malignancies. It is, though, astonishing that no matter how evolved the immune 
system is, herpesviruses always find ways to escape eradication and maintain life­
long persistence.
1.2.4 Exploitation of the immune system
Constant interactions between susceptible hosts and pathogens, during their co­
evolution, have been shaping the immune system. Pathogens need to survive as much 
as the host does. Therefore, a balance between them has to be maintained. Viruses, 
and in particular herpesviruses, have developed strategies to avoid the host’s immune 
defence in order to survive (French and Yokoyama, 2003; Levitsky and Masucci, 
2002; Tortorella et al., 2000). KSHV has evolved important means of partial escape 
from immune detection and this is mainly due to viral acquisition of cellular genes 
(section 1.1.2.4.). KSHV is able to evade complement or CTL recognition, and 
escape from immunological surveillance and this is important for the virus to 
establish a systemic viral infection. It is striking how many immediate early or early 
lytic cycle gene products of KSHV (Jenner et al., 2001) contribute to the evasion of 
the immune system (Table 1.2.). The interaction of viruses with the immune system 
and the viral tactics for immune evasion would provide us with further insight for 
vaccine strategies and cellular immunology.
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Table 1.2. Viral gene products that interfere with the immune system during the 
latent (light yellow), primary lytic (light turquoise), secondary lytic (light green) and 
tertiary lytic (rose) viral cycle (section 1.1.2.1.)________ _____________ ___________
GENE PRODUCT 
(Alternative name)
FUNCTION REFERENCE
INTERFERENCE WITH MHC CLASS I PATHWAY
Unknown Transporter associated with antigen processing 1 (TAP-1) 
reduced expression
(Brander et al., 2000)
K5 Inhibition of Natural Killer Cell-Mediated cytotoxicity by 
down regulation of ICAM-1 and B7-2
(Frlih et al., 2002; Ishido 
et al., 2000b; Paulson et 
al., 2001)
K3 (and K5) Downregulation and retention of major histocompatibility 
complex class I (MHC-I) from the cell surface by 
enhancing endocytosis
(Coscoy and Ganem, 
2000; Haque et al., 2001; 
Ishido et al., 2000a; 
Lorenzo et al., 2001; 
Means et al., 2002)
INTERFERENCE WITH APOPTOSIS
vFLIP (K13) (FLICE 
inhibitory protein)
vFLIP contains 2 Death Effector Domains (DEDs) and 
prevents activation of caspases by death receptors
(Thome et al., 1997)
vIAP (K7) The viral inhibitor of apoptosis protein (IAP). K7 interacts 
with effector caspases and host bd-2 and is able to inhibit 
their activity
(H.W. Wang etal., 2002)
vbcl-2 (open reading 
frame ORF16)
Regulation of programmed cell death: bcl-2 homologue (Cheng etal., 1997; 
Sarid etal., 1997)
vIRF-1 (K9) and 
vIRF-2 (K10.5)
Inhibition of interferon regulatory factor 1 (IRF-1) induced 
CD95 ligand induction and down-regulation of T cell 
receptor TCR/CD3 mediated CD95 ligand expression
(Kirchhoff et al., 2002)
K1 Downregulation of B-cell receptor surface expression (Lee et al., 2000)
INTERFERENCE WITH CYTOKINE SIGNALING
vIL-6 (K2) Viral Interleukin 6 is activated by interferon alpha (IFN- 
a), and blocks IFN-a signalling
(Chatterjee et al., 2002).
ORF45 Interacts with cellular IRF-7 and inhibits activation of type 
I interferon genes
(Zhu et al., 2002)
vGPCR (ORF74) Sequence homology with CXCR2: Constitutively active 
receptor, inhibited by stromal cell-derived factor-la 
(SDF), CXC chemokine IP-10, IFN-y and vMIP-II
(Arvanitakis et al., 1997; 
Bais et al., 1998; Geras- 
Raaka et al., 1998)
vMIP-I (K6) Viral macrophage inflammatory protein I (MIP-I) CCR8 
agonist, Th2 chemoattractant. Stimulates angiogenesis.
(Boshoff et al., 1997; 
Dairaghi etal., 1999; 
Endres et al., 1999)
vMIP-II (K4) Blocks monocyte chemotactic responses to RANTES, 
MIP-la/p, Th2 chemoattractant, chemokine receptor 
antagonist Stimulates angiogenesis.
(Boshoff et al., 1997; 
Kledal etal., 1997; 
Sozzani etal., 1998; 
Weber etal., 2001)
vIRF-1 (K9) Cellular homologue: Repression of transcriptional 
activation in response to IFN-a/p and IFN-y.
(Burysek et al., 1999a; 
Gao et al., 1997; Li et 
al., 1998)
vIRF-2 (K10.5) Cellular homologue: May modulate expression of early 
inflammatory genes
(Burysek etal., 1999b)
vMIP-III (K4.1) CCR4 agonist, stimulates angiogenesis, and selectively 
chemoattracts Th2 cells
(Stine et al., 2000)
INTERFERENCE WITH COMPLEMENT
ORF4 (KCP) KSHV complement control protein (KCP) regulates the 
classical C3-convertase pathway
(Spiller et al., 2003)
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1.2.5 Therapy for KS
KS is the most common cancer associated with KSHV infection and currently there 
is no definitive treatment. Local treatment (cryotherapy, radiation, laser/surgical, 
intralesional/topical chemotherapy) and systemic treatment (interferon a ,  
combination chemotherapy, liposomal anthracyclines, paclitaxel) have been adapted 
depending on the extent of the tumour and the systemic organs involved (Esdaile et 
al., 2002; Hengge et al., 2002; Treatment update, 2002). As previously mentioned, 
factors other than KSHV also contribute to the development of KS. Thus, other 
approaches include testing anti-angiogenic treatments such as thalidomide (Hengge 
et al., 2002; Little et al., 2000). Another approach is the use of anti-KSHV therapy, 
i.e. drugs directed against the viral DNA polymerase. Several in vitro and a few in 
vivo studies have shown that drugs such as foscamet, ganciclovir, adefovir and 
cidofovir are able to induce regression of KS in clinical trials, although not 
permanently (Fife etal., 1999; Kedes and Ganem, 1997). However, as for any other 
anti-herpesvirus remedies, these drugs inhibit KSHV DNA polymerase during lytic 
replication, and since most KS spindle cells are latently infected with KSHV, these 
drugs are not effective against advanced lesions (section 1.1.2.3.1) (Kedes and 
Ganem, 1997).
There has been a significant decline in the incidence of AIDS-KS due to the use of 
HAART in the West (Biggar, 2001; Goedert, 2000; International Collaboration on 
HIV and Cancer, 2000; Levine, 2000; Tirelli and Bemardi, 2001). It seems that the 
overall drop in the incidence of AIDS-KS is not due to a decline in the 
seroprevalence or transmission of KSHV (Osmond et al., 2002). Combination of a 
non-nucleoside-analogue reverse-transcriptase inhibitor (NNRTI) or protease 
inhibitor (PI) and two nucleoside-analogue reverse-transcriptase inhibitors (NRTIs) 
has shown through clinical trials to induce complete remission of AIDS-KS (Dupont 
et al., 2000; Gill et al., 2002; Hogg et al., 1998; Lebbe et al., 1998; Murdaca et al.,
2002). The mechanisms by which HAART induces AIDS-KS resolution are still 
debated (Boshoff and Weiss, 2002) (Table 1.3.). The treatment effect of HAART on 
AIDS-KS may result from the direct action of anti-retroviral drugs on HIV-induced 
immunosuppression and/or the antiviral effectiveness against KSHV, or HIV Tat.
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Table 1.3. How does HAART act in the resolution/prevention of AIDS-KS? 
(Adapted from Boshoff and Weiss, 2002)
ACTION MECHANISM
KSHV immune reconstitution (Blum et 
al., 1997; Brander et al., 2001; Gill et al., 
2002; Wilkinson et al., 2002)
KSHV CTLs target and kill KSHV- 
infected spindle cells
Reduction of HIV-1 Tat and other 
inflammatory cytokines levels (Ensoli et 
al., 1990; Ensoli et al., 1994a; Gallo, 
1998; Tovo, 2000)
Cytokines involved in KS angiogenesis 
(section 1.1.1.3.)
Protease inhibitor (PI) regimens have a 
direct anti-spindle cell and/or anti- 
angiogenic effect (Sgadari et al., 2002)
PI has been shown to block KS spindle­
cell growth and KS-inducted 
angiogenesis in experimental models.
Direct blocking of KSHV replication 
(Sgadari et al., 2002)
There is no evidence yet
There has been strikingly reduced morbidity and mortality among patients treated 
with chemotherapies and/or HAART combinations. Unfortunately, this success has 
not been without consequences of which the most serious are toxic side effects and 
eventual development of resistance.
1.3 REAL-TIME PCR TECHNOLOGY
The polymerase chain reaction (PCR) is a wonderfully simple idea, first conceived 
about 30 years ago (Kleppe et al., 1971) and very similar to the way that cells 
duplicate their DNA to expand their number in vivo. As a technique, it was first 
described in its initial format in 1985 (Saiki et al., 1985). In the years to follow, this 
technique rapidly became popular in most of biological sciences, including medicine.
Twenty years ago PCR was performed using several differently heated water baths. 
Since then, technology has advanced and modem thermal cyclers use heating and 
cooling elements that accurately control the temperature of the reactions. One of the
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newer and most remarkable applications in PCR technology is real-time PCR, or 
quantitative PCR (qPCR) as described by Higuchi et al. (Higuchi et al., 1993).
1.3.1 What is Real-Time PCR?
Nucleic acids detected and quantified using conventional PCR rely on endpoint 
measurements (plateau phase of PCR) that are often beyond the exponential phase of 
amplification (Figure 1.2.). In theory', during exponential phase of PCR, the number 
of DNA strands doubles during each cycle, assuming that the amplification is 100% 
efficient. If one of the components in the reaction is slightly limited the effect in the 
final amount of product is enormous. Primer-dimers consume a respectable amount 
of reagents and regardless of how high the starting amount of a template in the 
reaction is, the amount of the product could end up to be similar to a reaction where 
the initial amount of template is much less.
Theoretical Plateau
a.
4—>y3
1 Real Kineticsa
Exponential phase
Cycle number (Cp)
F igure  1.2. Theoretical versus real kinetics of PCR. During PCR, DNA 
amplification is exponential and eventually reaches a linear plateau. Real-time PCR 
monitors amplification during the exponential phase, the thermal cycler collects 
information (fluorescence emissions) and via software it translates it to plots 
amplification data throughout the PCR.
Real-time PCR allows monitoring of the PCR while the reaction is occurring, using 
fluorescence-labelled molecules. Fluorescence is measured in real-time during 
cycling, when PCR amplification is still in the exponential phase, rather than 
measuring a product accumulated after a fixed number of cycles (Figure 1.2.). The 
amount of the emitted fluorescence is proportional to the amount of the PCR product
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at any given cycle in the exponential phase of the amplification. During that phase, 
none of the reaction components is limited; therefore, values produced are highly 
reproducible in reactions starting with the same copy number. In real-time PCR, the 
amount of DNA can be calculated at any point during the exponential amplification 
and thus the initial concentration of DNA in the reaction can also be determined. The 
higher the starting amount of the nucleic acid target, the sooner the PCR cycle where 
a significant increase in fluorescence is observed (threshold cycle, Cj). After 
amplification, the PCR curve is defined as a relationship between the amounts of 
fluorescence emitted during the exponential phase of the reaction, which corresponds 
to the amount of the amplified product, at any given cycle.
1.3.2 Advantages of (quantitative) real-time PCR
Real-time PCR technology provides several advantages over other current 
quantitative PCR methods (Klein, 2002; MacKay et al., 2002):
•  Increased specificity. Fluorogenic probes provide specific amplification products, 
and detection of amplicon is only achieved when both primers and probe hybridise to 
the target.
•  The threshold cycle (CT) value used for quantification is obtained when the PCR 
is still in the exponential (log) phase. This is a more reliable method of detection and 
quantification of the starting copy number than the end-point measurements in which 
case, as discussed earlier, limitations of any PCR component have drastic effect on 
the amount of the product.
•  The development of competitive PCR was driven by a reliance on endpoint 
measurements, however, the efficiency of this reaction is not known. Determining Cp 
values by real-time PCR kinetics eliminates the need for a competitor to be co­
amplified with the target.
•  Compared to endpoint measurements, the use of Cp values also expands the 
dynamic range of quantification because data is collected for every cycle of PCR. 
There is a linear relationship between Cp and initial DNA amount. The range of 
quantification can cover 7-8 logarithmic decades reducing the need of template serial 
dilution.
•  The sensitivity of detection is very high, sometimes less than 5 copies.
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•  The initial template needed for the amplification is very small compared to other 
methods of nucleic acid detection (e.g. Southern, Inorthem blotting).
•  The obtained results are very precise and the error is minimal. Coefficient of 
variation (%CV) can be less than 2% in real-time PCR intra-assay and inter-assay 
experiments.
•  The real-time PCR method is a technically performed in a closed-tube (or 96-well 
plate) system. This eliminates any post-PCR processing of PCR products and, 
therefore, helps to avoid potential cross-contamination and carry-over.
•  Real-time PCR assay is rapid and results are generated as soon as the 
amplification in the thermal cycler is complete. Additionally, it is less time and 
labour intensive compared to conventional PCR methods, however, it is much more 
capital and reagent expensive!
• The instrumentation systems provided for real-time PCR experiments are 
constantly progressing, and currently are able to process and analyse 1 to 384 
samples simultaneously within 2 hours.
1.3.3 Applications of real-time (quantitative) PCR
PCR technology has been applied across all of the scientific and medical community. 
Need for constant improvements on PCR methodology have revolutionised 
molecular diagnostics. Real-time PCR has a great impact on monitoring infectious 
diseases. Molecular diagnostics is one field directly affected by this technology 
(Klein, 2002; MacKay et a l , 2002; Walker, 2002).
A major application is the detection and quantification of infectious agents including 
viruses, bacteria and fungi. This is achieved either by relative or absolute 
quantification. Information through relative quantification describes changes of the 
amount of target sequence compared to a pre-selected point. However, absolute 
quantification is the method of choice, when the exact number of templates present 
in a sample would provide crucial information in relation to primary, persistent or 
recurrent infection, disease prognosis and progression. It is the correlation between 
pathogen’s load and severity of disease, and response to treatment that made real­
time PCR quantification so applicable in clinical medicine. The existence of multiple 
fluorogenic probes has provided the extra tool of simultaneously detecting and
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quantifying multiple pathogens in one reaction. In the case of viral detection systems, 
multiplex real-time PCR is an elegant method applied to genotyping and monitoring 
different viral strains. Although multiplex assays have several advantages, they are 
complex and require a high degree of optimisation (MacKay et al., 2002).
Another major application of real-time PCR is in molecular medicine and, 
specifically, in clinical oncology: Identification and quantification of new, or already 
known, chromosomal mutations, in genes that are associated with inherited or 
acquired cancers and polymorphisms. In this type of experiment, the high sensitivity 
of real-time PCR is proven to be vital for the detection of minimal residual disease or 
quantification of single nucleotide polymorphisms (SNP) (Klein, 2002).
Finally, real-time reverse transcriptase-PCR (RT-PCR) has become the method of 
choice for the rapid and quantitative analysis of specific gene expression. In this type 
of experiment, cDNA or mRNA obtained from any clinical specimen (e.g. whole 
blood, tissue) is used as the template for the quantification of the gene of interest. 
This method is used on its own or as a DNA array (microarray) validation 
experiment to identify differentially expressed genes and genome transcription 
patterns. Real-time RT-PCR is very rapid, reproducible and can distinguish even 
small changes in the expression of hundreds of samples per day. One of the benefits 
of the assay is the low amounts of RNA used (nanograms) for the gene expression 
analysis, compared to traditional hybridisation assays such as I northern blotting in 
which case a minimum of 5pig of RNA is effective. The low RNA quantities needed 
make real-time RT-PCR assay applicable in the analysis of samples derived from 
laser microdissected tissue (Walker, 2002) or from any sample with a limited amount 
of RNA.
With this technology constantly evolving and new devices being designed, it will not 
be far away when the detection and quantification of nucleic acids in any clinical 
sample is routinely done, not only in academic hospitals, but also in smaller clinics 
and perhaps by all general practitioners.
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1.4 OBJECTIVES OF THIS THESIS
KSHV was identified 9 years ago. This gammaherpesvirus infects humans, persists 
for life and occasionally causes cancer. The main aim of this thesis is the 
investigation of the relationship between KSHV infection and host’s immune system.
Chapter 3 is focused on the epidemiology of KSHV using serological methods. The 
seroepidemiology, geographical distribution of KSHV and possible routes of 
transmission are explored. The objectives are to:
■ Investigate the risk of KSHV transmission from healthy mothers to their children 
in South Africa.
■ Explore the association of KSHV with different types of cancer in South Africa, 
the prevalence and age distribution of KSHV infection in patients with cancer. 
To investigate any association of KSHV infection with demographic and 
behavioural factors as well as HIV-1 infection. The distribution of KSHV 
antibody litres is also assessed in association with the development of AIDS.
■ Study the seroprevalence of KSHV among Jewish population from different 
ethnic groups in Israel and the possible association with hepatitis B virus (HBV) 
infection. Also to investigate transmission of KSHV within the Jewish family and 
the risks associated with this.
■ Identify high risk factors and population groups for KSHV infection in Spain and 
Brazil.
■ Compare the performances of three KSHV serological assays.
Chapter 4 introduces the development of a real-time quantitative PCR (qPCR) assay 
for KSHV. The objectives are to:
■ Design and optimise an assay suitable for absolute quantification of KSHV DNA 
in blood, both cell-associated and plasma/serum, and in human tissues and 
secretions.
■ Introduce an easy, rapid, reproducible and reliable quantification method of 
KSHV viral load.
50
Chapter 5 investigates the importance of HAART on KSHV immune responses and 
load. Patients with HIV-1 infection are followed-up in prospective cohort studies 
(longitudinal) and the objectives are to:
■ Investigate the KSHV immune reconstitution in HIV-1/KSHV co-infected 
patients from baseline up to 3 years following Highly active anti-retroviral 
therapy (HAART).
■ Determine the effect of (HAART) to the KSHV viraemia in HIV-1/KSHV co­
infected individuals with and without KS.
■ Correlate anti-KSHV latent and lytic antibody responses with CD8+ T cell 
responses and changes in KSHV viraemia during HAART.
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CHAPTER 2
MATERIALS AND METHODS
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Chapter 2 
Materials and Methods
2.1 GENERAL
2.1.1 Laboratory safety issues
All human-derived cell lines were cultured in a microbiological safety cabinet class 
II and in a containment level II laboratory. Laboratory coats and gloves were always 
worn. Human blood samples and its derivatives were always considered to be 
potentially infectious and were manipulated in containment level II laboratories. 
However, clinical materials derived from patients infected with human 
immunodeficiency virus-1 (HIV type I) were always manipulated in a containment 
level III laboratory in a microbiological safety cabinet class III. Disinfection was 
carried out as outlined in our local laboratory safety manual.
2.1.2 Laboratory design
Glassware and a number of media were always prepared and autoclaved in our local 
facilities. Special media were commercially purchased.
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2.1.3 Buffers and solutions
Table 2.1. The most common solutions used are:
Phosphate-buffered Saline (PBS), pH 7.4 
At 25°C (dry powder, SIGMA)
NaCl 137mM 
KC1 2.7mM
TE (Tris EDTA), pH 8.0 (QIAGEN) lOmM Tris-Cl 
ImM EDTA
Protease (20mg/ml) (QIAGEN) Lyophilised powder dissolved into nuclease- 
free H20  containing 0.04% sodium azide
Red cell lysis buffer (RCLB) 0.144M NH4C1 
ImM NaHC03
1 X TAE (SIGMA), pH 7.0 40mM Tris-acetate 
ImM EDTA
5 X TBE (SIGMA), pH 8.3 445mM Tris-borate 
lOmM EDTA
1 X DNA loading buffer 40% glycerol (v/v) in 2xTBE 
0.03% (w/v) orange G as a dye
Immunofluorescence blocking buffer 
and secondary antibody dilution buffer
3% fetal calf serum (FCS) in PBS or 
1 % non-fat dried milk powder in PBS
Wash Buffer (QIAGEN), pH 7.5 50mM MOPS-KOH 
0.75M NaCl 
15% (v/v) ethanol
Culture medium of eukariotic cell lines RPMI-1640,
10 or 20% FCS 
60/^g/ml penicillin 
100/fg/ml streptomycin
Freezing medium of eukariotic cell lines and 
PBMCs
90% FCS (Helena Biosciences)
10% DMSO (Dimethyl sulphoxide, SIGMA)
Media for E.coli
LB Medium (Luria-Bertani)/litre, pH 7.0 950mls deionised H20  
Tryptone lOg 
Yeast extract 5g 
NaCl lOg
200/d NaOH (5N) for pH adjustment 
Autoclave and store at 4°C
SOC medium (Invitrogen) 2% Tryptone 
0.5% Yeast Extract 
lOmM NaCl 
2.5mM KC1 
lOmM MgCl2 
lOmM MgS04 
20mM glucose
For agar plate preparation 15gr LB Agar (Invitrogen) was added per litre prepared 
medium and proceed to autoclave (121°C, 20mins). After cooling to 55°C, ampicillin 
was added (100//g/ml) and the medium was poured into 10cm sterile plates. When 
the medium was solidified the plates were stored at 4°C in the inverted position.
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2.2 EUKARIOTIC CELL CULTURE
2.2.1 Thawing cells
Frozen vials were removed quickly from liquid nitrogen and thawed in a 37°C H20  
bath by gentle shaking. When the cells were almost thawed they were transferred 
into a 20mls universal sterile tube and lOmls of fresh Roswell Park Memorial 
Institute (RPMI)-1640 medium (Invitrogen) supplemented with 10% heat inactivated 
Fetal Calf Serum (FCS, Helena Biosciences) were then added drop-wise to the cells. 
Cells were pelleted by centrifugation at 600g for 5mins at 22°C, resuspended into
7mls of culture medium and transferred into a 25cm tissue culture flask. The cells 
were incubated at 37°C in a humidified atmosphere containing 5% C02, checked 
daily and fed as required.
2.2.2 Cell Lines and Passaging
The cell lines used in this study are listed in Table 2.2. All cell lines were in 
suspension and grown in RPMI-1640 medium with 2mM Glutamine (Invitrogen) 
supplemented with 10% FCS, apart from BCP-1 which needed 20% FCS, and the 
antibiotics penicillin and streptomycin (Invitrogen). All cells were grown at 37°C in 
a humidified atmosphere containing 5% C02- Cell lines were split twice every 3-5 
days at a ratio of 1:5 to 1:10 depending on density and rate of growth for each cell 
line.
2.2.3 Freezing cells
Cells, almost 75% confluent in culture, were pelleted by centrifugation at | 600g
for 5mins at 4°C. Cells were counted using Neubauer (Weber) haemocytometer and 
resuspended at 5 X 106 to 1 X 107 per 1ml in cold freezing medium. One ml aliquots 
were dispensed into labelled Nunc cryovials (NalgeNunc International) and 
transferred into a freezing container, Mr Frosty (Nalgene), and put into an -80° C 
freezer. Three days later the cells were transferred into a liquid nitrogen tank.
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Table 2.2. Cell Lines used for this project
CELL LINES ORIGIN VIRUS REFERENCES
BCP-1 Human B-cell (PBMC) 
From patient with PEL1
KSHV (B oshoff et al., 1998; 
Gao et al., 1996b)
BC-3 Human B-cell (lymphoma) 
From patient with PEL
KSHV (Arvanitakis et al., 1996)
RAMOS Human B-cell (lymphoma) 
From patient with BL2 (not infected)
(Klein et al., 1975)
RAH Human B-cell (lymphoma) 
From patient with BL
EBV (Pulvertaft, 1964)
DAUDI Human B-cell | (lymphoma) 
From patient with BL
EBV (Klein et al., 1968)
1 Primary Effusion Lymphoma
2 Burkitt’s Lymphoma
2.3 SEROLOGICAL STUDIES
2.3.1 Seroepidemiological and transmission studies
2.3.1.1 Fixation and permeabilisation of cells
The primary effusion lymphoma derived B-cell line BCP-1 (provided by S. J. Gao, 
Y, Chang and P.S. Moore; Columbia University, NYC), latently infected with 
KSHV, but not EBV, was maintained under sterile conditions as described 
previously. Ramos cells were also grown and used as a KSHV negative control cell 
line. BCP-1 or Ramos cells were washed twice in PBS, fixed in 4% 
paraformaldehyde (SERVA) and permeabilised with 0.2% Triton X I00 (SIGMA). 
Cells were re-suspended in PBS, spotted on glass slides, dried and kept at -20°C until 
use.
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2.3.1.2 Indirect immunofluorescence assay (IFA)
Indirect immunofluorescence assay (IFA) was used in all studies to detect antibodies 
against the latent nuclear antigen (LANA) encoded by KSHV open reading frame 73 
(ORF73). Human plasma or serum was diluted (1:100) in PBS supplemented with 
3% FCS or 1% dried milk (MARVEL) as a blocking agent. The diluted sera (1:100) 
were applied onto the fixed BCP-1 cells and incubated for 45mins at 22°C. Slides 
were then washed in blocking buffer and fluorescein isothiocyanate (FlTC)-labelled 
rabbit anti-human IgG Ab (DAKO), diluted (1:60) in the blocking solution, was 
added. After 20mins incubation at 22°C the slides were washed in PBS and screened 
under ultraviolet microscopy. The characteristic nuclear pattern of LANA was 
observed (Figure 2.1.).
Figure 2.1.
Immunofluorescence assay 
(IFA) for KSHV LANA 
on BCP-1 cells shows the 
distinct nuclear stippling 
pattern and localisation of 
the LANA. x60
2.3.1.3 Flow cytometry
The fluorescence-activated cell sorter (FACS) can be used for the analysis of cell 
populations, detection and quantification of specific fluorescence. Fluorescence 
signal intensity of LANA antibody positive plasma samples was measured by FACS 
analysis. Ten thousand events were collected and analysed using a FACScan. Cells 
were treated as described in IFA (section 2.3.1.2.), however, were not spotted on 
slides, but were resuspended in 500/d PBS for FACS analysis.
2.3.1.4 Antibody titration
All LANA antibody positive samples were scored by indirect IFA as +, ++ or +++ 
according to fluorescence signal intensity. Most of the IFA positive sera were titrated
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(2-fold dilution) to determine antibody titre (Whitby et al., 1998) and to confirm 
whether signal intensity as measured by microscopic scoring (+ to +++) correlates 
with titre. As a negative control, the KSHV and EBV negative Ramos cells were 
used.
2.3.2 Comparative serological studies
My IFA was compared with two ELISAs for KSHV detection:
2.3.2.1 Whole virus ELISA (Enzyme-linked immunosorbent assay)
This assay is supplied by Advanced Biotechnologies (ABI) and measures antibody to 
the majority of KSHV structural proteins (Chatlynne et al., 1998). KSHV whole 
virus extract from sucrose gradient purified virus that was isolated from the KS-1
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cell line, containing >2.8 X 10 particles per ml and a protein concentration of 
>1.0mg, was coated onto ELISA plates (coated-plate supplied by ABI). Sera (or 
plasmas) at 1:100 dilution (specimen diluent was supplied 4 X concentrated) were 
allowed to react for 30mins at 37°C with the antigen-coated plate. If antibodies are 
present in the serum/plasma they will bind to the immobilised antigens on the solid 
phase microtitre wells. After three washes with supplied buffer to remove unbound 
sample components, a goat anti-human IgG(v)-horseradish peroxidase (HRP) 
conjugate was added to the wells and incubated for 30mins at 37°C. After several 
washes to remove unreacted conjugate, HRP substrate TMB (tetramethyl benzidine) 
was added for colour development; 15-30mins later, the reaction was stopped with 
IN sulphuric acid (SIGMA) and optical density (OD) measurements were read at a 
wavelength of 450 nm in a microplate reader (spectrophotometrically). The colour 
intensity of the solution is proportional to the antibody concentration in the test 
sample. The cutoff range was previously established and based on a statistical 
analysis of 107 presumed normal U.S.A. blood donors. The ranges were defined as 
follows: KSHV antibody negative was defined as the ELISA mean value of 107 
healthy uninfected donors plus 2.5 standard deviations. The positive cutoff was 
defined as the mean ELISA value of the 107 normal donors plus 3.0 standard 
deviations. The range between 2.5 and 3.0 standard deviations was designated as 
equivocal.
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2.3.2.2 KSHV K8.1 ELISA (done in Erlangen, Germany)
This ELISA detects antibodies against a polypeptide derived from K8.1 protein of 
KSHV. K8.1 is expressed during the lytic phase of the virus (Chandran et al., 1998b; 
Li et al., 1999; Raab et al., 1998). Dr. Mark-Steffen Raab from the University of 
Erlangen, Germany, kindly performed the ELISA. A polypeptide comprising amino 
acids! 27-196 of K8.1A and including an N-terminal histidine-tag 
(MRGSHHHHHHGS) was expressed in E. coli. The recombinant protein was 
purified by Ni-affinity chromatography followed by reverse-phase liquid 
chromatography (RPLC). Purified K8.1 antigen was coated on 96-well polystyrene 
microtest plates in a concentration of 1.0/*g/ml according to a standard procedure 
(Raab et al., 1998; Vomhagen et al., 1994). The concentration was measured with 
colorimetric methods. Control plates were coated with blocking buffer (phosphate 
buffered saline, 2% fetal calf serum) only. Sera were diluted 1:50 and incubated for 
60mins at 37°C with both K8.1 coated plates and control plates. After washing 4 
times with blocking buffer, goat anti-human immunoglobulin coupled to HRP was 
used as conjugate (DAKO) and incubated at 37°C for 30mins. After washing 4 times 
with blocking buffer, the enzyme reaction was performed for 30mins at 22°C using 
OPD (O-phenylenediamine) reagent (SIGMA) supplemented with 16.6y\ 30% H20 2 
per lOmls. The reaction was stopped with IN sulphuric acid after 15mins incubation 
at 37°C. Absorbency was measured at 490nm against a reference wavelength of 
650nm. For each serum, the absorbency measured on control plates was subtracted 
from the absorbency measured on plates coated with K8.1 (=K8.1 OD). To calculate 
the cutoff, K8.1 OD values were determined for 177 human sera that were found to 
be non-reactive by both lytic IFA on BCBL-1 cells (dilution 1:20), and Western blot 
using recombinant KSHV proteins K8.1, ORF73, K12, and ORF65. The mean K8.1 
OD for these 177 sera was 0.077 and the standard deviation was 0.063. Sera with an 
OD less or equal the mean plus 2 standard deviations (< 0.203) were considered 
negative; sera with an OD of more than 2 standard deviations above the mean, but 
less or equal than 2.5 standard deviation above mean were considered equivocal 
(0.203 < x <0.235). Sera with an OD of more than 0.235 (>2.5 standard deviation 
above mean) were considered KSHV positive by K8.1 ELISA.
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2.3.2.3 Statistical methods
2.3.2.3.1 KSHV infection in South Africa
Statistical analysis was done in the Epidemiology Unit at Oxford. Unconditional 
logistic regression was used to calculate the odds ratios in the relation between 
antibodies against KSHV and age, sex, education, place of birth, parity and number 
of lifetime sexual partners in the patients without KS. To examine the relation 
between anti-KSHV antibodies and type of cancer, unconditional logistic-regression 
model was used to calculate the log of the odds of KSHV seropositivity for each type 
of cancer (adjusted for age, sex, years of education and number of sexual) partners) 
Absolute risks and confidence intervals were calculated to study the relation between 
KS and fluorescent-signal intensity for anti-KSHV antibodies in HIV-1 positive and 
HIV-1 negative patients.
2.3.2.3.2 KSHV infection in Israel
Statistical analysis was performed by Batya Davidovoci. In summary, KSHV 
prevalence was analysed separately for the two groups since 88% of the former 
blood donors tested positive for HB V whereas only 1.6% of the family members did. 
Univariate analysis was used to associate various risk factors to KSHV 
seropositivity. Analysis of variance (ANOVA) was used to analyse hepatitis B virus 
(HBV) markers of infection for continuous variables whereas test was used for 
categorical variables. Multivariate models were constructed for the analyses of the 
parent-to-child and between spouse transmission. All statistical tests were two-sided 
and were considered statistically significant at p<0.05.
2.3.2.3.3 KSHV infection in Spain
The statistical analysis was performed in the Epidemiology Unit at Badalona. The yf 
test was used to assess the homogeneity of the distribution of the KSHV prevalence 
in several populations. Yate’s correction was applied when only two populations 
were compared. The t test was performed to compare the mean age according to sex, 
KSHV and HIV status. The two-way analysis of variance (ANOVA) test was used to 
study the possible effect of HIV status and transmission group on the KSHV 
antibody titre. For all the analyses, a 0.05 significance level was considered.
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2.3.23.4 KSHV infection in Brazil
Data were analysed using the SPSS software program and was performed by Regina 
Keller in Brazil. Chi-square and Fisher exact tests were performed to show 
associations between variables. Student t test for two independent samples was used 
to assess mean differences between groups. Odds ratios and confidence intervals 
were also determined. The tests were two-tails with a significance level of p<0.05.
2.3.23.5 Comparative study
Dr. Gillian Reeves from the Epidemiology Unit of the University of Oxford kindly 
carried out the statistical analysis. Pair-wise agreement between assays was 
measured using the kappa (k ) statistic for inter-rater agreement. This statistic 
measures the degree of concordance between two assays beyond that which would be 
expected by chance and is scaled to lie between 0 (poor agreement) and 1 (perfect 
agreement). P-values for each k statistic were calculated using the asymptotic normal 
distribution of k divided by its estimated standard error (Altman, 1991). Differences 
in sensitivity between the three assays were assessed using Cochran's Q statistic 
(Cochran, 1950) which is an extension of McNemar's test for differences between 
paired proportions.
2.3.23.6 HAART effects on anti-KSHV immune responses and KSHV load
The statistical analyses were kindly done by Drs. Elizabeth Allen and Andrew Copas 
from the Department of Statistical Science, UCL. To provide summary statistics over 
the study, time was grouped as baseline, 1-6, 7-12, 13-24, and >24 months. In each 
time period, with the exception of baseline, patients may have contributed more than 
one measurement. The summary statistics were calculated from all available 
measurements. At baseline, differences between patients with and without KS and 
differences between patients receiving NNRTI or PI were tested by using the Mann- 
Whitney test. To test for and estimate the magnitude of change over time, binary, 
ordinal and continuous outcomes were analysed using logistic, proportional odds and 
linear regression respectively. For each outcome the difference between baseline and 
all follow-up times was tested, and a gradual trend over time was assessed. This 
provided odds ratios (logistic and proportional odds regression) and mean outcome 
differences (linear regression) as the measures of effect. The Generalized Estimating
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Equation (GEE) methodology (Liang and Zeger, 1986) was used to account for the 
correlation between measurements from the same patient, with the exception of the 
ordinal outcomes where for computational simplicity the related survey methodology 
of STATA 7.0 (StataCorp, 2001) was used. For the GEE an exchangeable working 
correlation was selected, and the robust variance estimator was used. All analyses 
were performed in STATA 7.0.
2.4 DEVELOPMENT OF REAL-TIME QUANTITATIVE PCR 
FOR KSHV (qPCR)
2.4.1 General
Experiments involving the handling of nucleic acids were performed in accordance
with standard practice (Sambrook et al.> 1989). Sterile glassware, tubes and 
disposable pipette tips were used and latex gloves were worn at all times. All 
aqueous solutions were either autoclaved (121°C, 20mins) or filtered through a 0.2 
pim filter (Millipore Corp., Bedford, MA, USA).
2.4.2 Prevention of contamination
Precautions were taken to avoid false positives and to monitor the occurrence of
cross-contamination. Specifically the measures taken were:
Q  Separate rooms were allocated for different sections of the optimisation 
experiment:
DNA extractions 
PCR mixture preparation 
DNA sample dilutions 
DNA loading 
Plasmid DNA loading 
Gel loading
PCR run in the instrument
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Q  The inclusion of H20  control tubes in all PCR's. HzO was also used as a 
control to extract DNA from in parallel with the tested samples. Positive results 
with test samples were only accepted where all controls were negative.
Q  The inclusion of AmpErase® (Uracil TV-glycosylase) in the TaqMan® PCR 
reagent kit. This is an enzyme that has the capability to prevent carry-over of 
PCR products by degrading any template from previous PCR amplifications, 
therefore, preventing false positive results.
Q  Exposure of reaction components (H20 , buffer) and instruments (Gilson 
pipettes, filtered pipette tips, microtubes) to ultra-violet light (UV 254nm) prior 
to the addition of template DNA. This was performed using a UV cross-linker
2(Stratagene Stratalinker 2400,1 J/cm ). Primer, probes and dNTP stock solutions 
were not exposed to UV light but were diluted in UV-treated H20  or TE (Qiagen) 
and stored in aliquots at -20°C.
Q  Use of designated sets of Gilson pipettes and ‘filtered’ pipette tips for setting 
up PCRs, for DNA loading, for post-PCR analysis and for handling plasmids 
containing cloned fragments.
Q  Frequent changes of gloves and physical separation of solutions of target 
DNA and from PCR products and from plasmids.
2.4.3 Instrumentation and chemistry
The ABI PRISM® 7700 & 7000 Sequence Detection Systems (ABI PRISM, Applera 
UK, Chesire) were used in combination with TaqMan® chemistry to measure the 
fluorescence emitted by the reporter dye covalently linked to the probes (Fig. 2.2.).
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Taq pol
Forward primer 
Reverse primer
Reporter dye
Quencher dye
Figure 2.2. Principle of TaqMan® chemistry. The 5 ’-3’ nuclease activity of the 
AmpliTaqGold® DNA polymerase initiates cleavage and this leads to emission of 
the reporter fluorophore attached to the 5’-end of the probe. The fluorogenic probe 
enables the detection of specific PCR product as it accumulates during PCR 
amplification.
2.4.4 Definitions used in real-time PCR
The increase of the fluorescence of the reporter dye is a direct consequence of the 
target amplification and is measured by the thermal cycler. Each reporter signal is 
then divided by the fluorescence emitted by an internal reference dye (ROX), which 
is incorporated into the PCR AmpliTaqGold® buffer, in order to normalise for non- 
PCR related fluorescence fluctuations occurring well-to-well or over time. The 
normalised reporter signal R„+ is the Rn(normalised reporter signal) value of a 
reaction containing all components including the template. Rn- is the R„ of an 
unreacted sample. This value is obtained from the early cycles of a real-time run, 
prior to the detectable increase in fluorescence (Figure 2.3. a).
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Figure 2.3. Amplification plot and standard curve graphs, (a) Amplification plot 
explaining various real-time PCR terms. (b) Representative example of a standard 
curve showing the threshold cycle against the logarithm of the initial copy number in 
a set of standards.
ARn is the amount of the normalised reporter signal minus the amount of the reporter 
signal before initiation of amplification, i.e. ARn= (R„+) - (R„-)-
Rn+
ARn
Rn-
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Baseline is the stage during the initial cycles of PCR where little change or ARn is 
detected. An increase in fluorescence above the baseline indicates the detection of 
accumulated PCR product.
The threshold cycle or Cj is the cycle at which a statistically significant increase in 
ARn is first detected. Threshold is defined as the average standard deviation of Rn for 
the early cycles, multiplied by an adjustable factor (Figure 2.3. a).
Amplification plot is a graphic representation of ARn against the Cj.
Standard curve is a graph showing Cj values plotted against the log of the initial 
amount of nucleic acid for a set of standards and has been shown to be a straight line 
(Figure 2.3. b). In theory, the components of the PCR reaction are not limiting during 
the exponential phase of the amplification, therefore, the measurement of the 
fluorescence during this phase is proportional to the amount of PCR product 
(Higuchi et al., 1993).
2.4.5 Genes selected for qPCR
Genomic DNA sequences from the encoding regions of KSHV LANA (target viral 
gene) and the human glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH, 
endogenous control) were retrieved from the NCBI (GenBank, 
www.ncbi.nlm.nih.gov/BLAST) database and used as templates for the primers and 
probes design.
2.4.6 Oligonucleotide design
2.4.6.1 Primer Express® software
Primers (QIAGEN-OPERON, Cologne, Germany) and probes (QIAGEN-OPERON 
and ABI PRISM) were designed using Primer Express® software programme (PE 
Applied Biosystems, UK). The selection of primers and probes is based on default 
parameters and guidelines (Table 2.3.). KSHV LANA and GAPDH genomic 
sequences were imported to the programme to be analysed. Primers were designed
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first and then the probes were selected. All primers have a similar annealing 
temperature. The annealing temperature of the probes is 10°C higher that that of the 
primers. The amplicons are designed to be between 50 and 150bp in length. This 
allows the amplification to be more efficient and it can be done in universal thermal 
cycling parameters.
Table 2.3. Guidelines set in Primer Express® software for automatic selection of 
oligonucleotides (From Applied Biosystems handouts).
PRIMERS PROBE AMPLICON
*Tm = 58 -  60°C 10°C higher than primers 50 -  150bp long
**30 -  80% GC content 20 -  80% GC content 3’ end of primer as close 
to the probe as possible
9 -4 0  bases long
<2°C difference in Tm 
between the two primers
<4 contiguous G’s
Maximum of 2 out of 5 Gs 
orCs at 3’ end
No G on the 5’ end
Must not have more G’s 
than Cs
* Tm = Melting temperature 
** G or C = Guanine and cytosine
2.4.6.2 Primers and probes sequences
The forward and the reverse primers for the KSHV LANA gene amplification were 
(5 ' - T T G C C A C C C A C G C A G T C T - 3 ' )  a n d  ( 5 '  
GGACGCATAGGTGTTGAAGAGTCT- 3'), and the internal TaqMan probe was (5' 
FAM- TCTTCTCAAAGGCCACCGCTTTCAAGTC- TAMRA 3'). The primers, (5’ 
-G G  A G T C  A ACGG A T T T G G T C G T  A- 3 ’) and  ( 5 ’
GGCAACAATATCCACTTTACCAGAGT- 3') and the TaqMan probe (5'FAM - 
CGCCTGGTCACCAGGGCTGC- 3'TAMRA) were designed to quantify the human 
GAPDH gene. The amplicons were 89bp for KSHV LANA and 78bp long fragments 
for GAPDH. Primers and probes were further diluted in UV treated HzO or TE
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(QIAGEN) at the concentration of 10//M and 5//M respectively and 100/d aliquots 
were stored at -20°C.
2.4.7 Conventional PCR
Specificity of GAPDH and LANA primers was tested by a standard PCR 
amplification of template DNA derived from BC-3 cells, a KSHV positive cell line, 
using the Expand High Fidelity PCR System (Roche, Germany). For a 25/d PCR 
reaction the conditions were as follows:
FINAL CONCENTRATION
2.5/d  ( IX)
4/d (200//M)
0.5/d (5//M) each 
0.25/d (0.875Units)
2/d
14.85/d 
The reaction conditions were:
1 cycle 95°C 2mins
f  95°C 30secs
35 cycles -< 60°C 30secs
[_ 72°C 15secs
1 cycle 72°C 20secs
10 X Expand™ high fidelity buffer (15mM MgCl2) 
dNTPs mix (1.25mM)
Primers (10//M)
Taq High Fidelity 
DNA (approx. 200ng//d) 
dH20
2.4.8 Gel electrophoresis of small fragments
The GAPDH and LANA PCR products gene fragments were too small in size to be 
observed with a low percentage agarose gel. Therefore, a 4% agarose gel was 
prepared in 0.5 X TAE gel running buffer with 0.1//g/ml ethidium bromide 
(SIGMA). A 50bp DNA (GIBCO, Invitrogen) step ladder was included to estimate 
the size of the bands. Gels were captured by the Versadoc Imaging System (BioRad) 
for analysis.
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2.4.9 Purification of DNA fragments
Bands of the correct size were excised from the gel and DNA was purified using the 
QIAquick gel extraction protocol (QIAGEN). The gel slice was weighted and 3 or 6 
volumes (if the gel contained >2% agarose) of buffer QG (v/w) were added to the gel 
and incubated at 50°C till the gel was completely dissolved. One gel volume of 
isopropanol was added to the sample, mixed and applied to a QIAquick spin column. 
After lmin spin at |6,000g another 0.5ml of buffer QG was added, centrifuged and 
0.75ml of buffer PE was applied to the column to wash for another minute. The 
DNA was eluted at 30/d dH20.
2.4.10 DNA sequencing
The identity of the PCR products was verified by DNA sequencing using an 
automated application of the chain-termination method (Sanger et al., 1977). The 
PCR purified product with the primers were given to our local PCR facility and the 
analysis was done using software (Beckman, CEQ 2000) supplied by the 
manufacturer (Beckman Coulter). Fifty to hundred fmoles of DNA template and 
5pmoles//ri each of the primers were provided.
2.4.11 Quantification of DNA
DNA samples were quantified spectrophotometrically. An absorbance at 260nm of 
1.0 was taken to indicate 50/*g/ml double-stranded DNA. The ratio of absorbance at 
260 and 280nm was used to indicate nucleic acid purity.
2.4.12 Cloning procedures
2.4.12.1 E. coli growth conditions
One Shot® TOP10 chemically competent cells (Invitrogen, Life technologies, UK) 
were grown in LB (Luria-Bertani) at 37°C. Cultures with plasmid transformation and 
selection were spread on labelled LB agar plates with ampicillin to a final 
concentration of 100//g/ml.
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2.4.12.2 Cloning PCR product
The GAPDH PCR product was mixed together with the pcDNA3.l/V5-His-TOPO® 
expression vector (Invitrogen) and a salt solution (1.2M NaCl, 0.06M MgCl2). After 
5mins incubation at 22°C the reaction was transferred on ice for transformation of the 
vector to TOP 10 E. coli competent cells.
2.4.12.3 Ligation of DNA to plasmid
Ligations between vector and LANA insert was performed in 10/d reactions 
containing 1/d of T4 DNA ligase 10 X buffer (300mM Tris-HCl pH 7.8, lOOmM 
MgCh, lOOmM DTT and lOmM ATP) and lUnit of T4 DNA ligase (Promega). 
Ligations generally used a 1 to 7 molar ratio of vector to insert and were performed 
at 15°C overnight.
2.4.12.4 E. coli transformation
The transformation was performed according to manufacturer’s instructions 
(Invitrogen). Two /d of the PCR product reaction or the ligation (with appropriate 
controls) was added to One Shot®TOP10 E. coli cells on ice and mixed gently. After 
15-30mins incubation at 4°C, the bacteria were subjected to heat-shock at 42°C for 
30secs for the DNA uptake and immediately placed on ice for lmin.. Two hundred 
and fifty /d of SOC medium (at 22°C) was added to the transformations and the cells 
were incubated at 37°C for lhour, shaking at 200rpm.
2.4.12.5 Plating out and recombinant selection
LB agar plates with ampicillin were left to warm at 37°C lhour prior to plating. Fifty 
/d from each transformation was spread under sterile conditions per plate and 
incubation followed at 37°C overnight. Colonies were inoculated into 5mls LB-broth 
with ampicillin and grown at 37°C in a shaking incubator overnight.
2.4.12.6 Preparation of plasmid DNA from E.coli
Plasmid DNA was obtained from the overnight cultures using QIAprep® Miniprep
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kit (Qiagen) or the Promega Wizard Plus SV Minipreps (Promega) according to the 
kits’ handbooks. Cultures were centrifuged at] 800g i for lOmins and subjected to 
resuspension, lysis and neutralisation stages. The supernatants were transferred into 
columns and after a series of washes the plasmid DNA was eluted into 50/<l nuclease 
free H20  and stored at -20°C.
2.4.12.7 Subcloning of LANA
Almost the entire encoding region of KSHV LANA was subcloned from a lentivirus 
vector pHRCMV-LANA (construct made by Daniel Hollyman in our laboratory) to 
the pcDNA-GAPDH plasmid (pcDNA3.l/V5-His-TOPO® vector with the GAPDH 
PCR product as an insert). Double digestions were performed twice; the first for the 
pcDNA-GAPDH at 37°C for 90mins and the second for the lentivirus at 25°C for 
45mins and then at 37°C for another 45mins. Agarose 1% gel electrophoresis 
followed and the correct size LANA fragment was excised, gel purified with the 
QIAquick® gel extraction kit (QIAGEN) (section 2.4.9.) and ligated to the digested 
pcDNA-GAPDH plasmid, as previously described (section 2.4.12.3.).
2.4.12.8 Confirmation of clone identity
2.4.12.8.1 By PCR
GAPDH PCR product 78bp long insert was verified by usual PCR with the primers 
originally used to amplify the insert (section 2.4.6.2.). The PCR conditions were as 
previously described (section 2.4.7.); however, AmpliTaq DNA polymerase was 
used (Applied Biosystems) instead of the Taq high fidelity, therefore the initial cycle 
at 95°C was for lOmins. lkb DNA ladder (Invitrogen) was used to determine the size 
of the double-stranded DNA fragment.
2.4.12.8.2 By restriction enzyme digestions
The insertion of KSHV LANA fragment (3.478kb) into the pcDNA-GAPDH 
plasmid was confirmed by restriction digestions. Restriction enzymes were obtained 
from Promega and used in the supplied buffers and according to the manufacturer’s 
recommendations. Typically 10//1 digestions (single or double) were performed with 
10 units of enzyme per pig of DNA for 1-2 hours at 37°C.
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2.4.12.9 Stock of successful transformants
Once the clones were identified, culture stocks were mixed with sterile glycerol 
(15% final concentration), transferred to cryovials and stored at -80°C.
2.4.13 Standards for the qPCR
The pcDNA-GAPDH-LANA plasmid was constructed from the pcDNA 3.1/V5-His- 
TOPO vector (Invitrogen) with two cloned inserts: a 78bp GAPDH PCR product 
fragment and the subcloned LANA encoding region. The concentration was 
measured spectrophotometrically and the copy number per ji\ vector was calculated 
based on the following equation:
Copy number = 9.1 X 10" X {pig of plasmid standard/size (plasmid + insert) in kb}
Stocks of diluted standards were made and stored at -80°C. Working aliquots, 
tenfold serial dilutions in H20  (106 to 103) were prepared once for all the tests and 
were stored at -20°C. Dilutions 102 to 101 were freshly prepared for each assay.
2.4.14 qPCR consumables and parameters
2.4.14.1 Consumables
The TaqMan PCR Core Reagent kit (N8080228, Applied Biosystems) was used for 
every test. This kit contains 10 X TaqMan Buffer A, 25mM MgCl2 solution, 250 
Units AmpliTaq Gold DNA Polymerase, 100 Units AmpErase UNG; 20mM dUTP 
and lOmM each of dATP, dCTP and dGTP. The reactions were transferred to 
MicroAmp® Optical 96-well Reaction Plates with Barcode (4306737, Applied 
Biosystems) and the plates were covered with ABI PRISM optical adhesive covers 
(4311971, Applied Biosystems) before they were transferred to the thermal cycler.
2.4.14.2 Parameters
The qPCR conditions used for the amplification of each DNA sequence were 
optimised individually. Different parameters, such as primers, probes, MgCl2 and
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template concentrations were assessed separately for each gene. However, universal 
thermal cycling parameters were used for both genes and they are shown in table 
2.4.:
Table 2.4. Universal thermal cycling parameters for the qPCR for KSHV detection
TIMES AND TEMPERATURES
Initial steps Each of 45 cycles
Melting Annealing/Extension
HOLD* HOLD** CYCLE
2mins lOmins 15secs lmin
50°C 95°C 95°C 60°C
* The 2mins hold at 50°C is required for the optimal AmpErase® UNG activity 
** The lOmins hold at 95°C is required for the AmpliTaq Gold® DNA Polymerase 
activation
2.5 IMMUNOLOGICAL AND ANTI-VIRAL RESPONSES TO 
KSHV DURING ANTI-RETROVIRAL THERAPY
Human clinical samples were obtained after ethical approvals were provided from 
the University College London and the Royal Free hospitals committees, and 
patient’s own signed consent form.
2.5.1 Blood separation
Unfractionated 40mls heparinised and lOmls EDTA blood samples were obtained 
during patients’ visits. Heparinised blood was diluted 1:1 to 1:3 in PBS-2mM EDTA 
and layered onto 1/3 volume of Histopaque®-1077 Hybri-Max® gradient separation 
(SIGMA-Aldrich) in a 50mls Falcon tube within 24h after blood sampling. The 
blood was centrifuged at | 600g for 30mins at 22°C and erythrocytes settled at the 
bottom of the tube while the PBMCs formed a layer at the interphase between 
Histopaque and plasma/PBS. PBMCs were washed twice with PBS-2mM EDTA and 
counted after a small aliquot of cells was diluted 1:10 in PBS and further 1:2 in 
trypan blue (Invitrogen). PBMCs were stored at 5xl06 in freezing medium in liquid
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nitrogen till use. The EDTA samples were centrifuged at\ 800g , for lOmins and 
plasma and cell pellets from the EDTA samples were stored at -80°C until further 
processing.
2.5.2 KSHV serology for the detection of anti-latent and lytic 
antibodies against KSHV
KSHV serologic tests for the detection of antibodies against LANA were performed 
using IFA (section 2.3.1.2.). Antibody titre was expressed as the highest plasma 
dilution giving a positive result. An adapted K8.1 ELISA was used for the detection 
of anti-KSHV lytic antibodies, performed in our laboratory by Dimitrios Lagos. 
Briefly, a multiple antigenic peptide (MAP) is used as an immobilised antigen. A 
M AP o f four  cop ies  o f  the i d e n t i f i e d  ep i t ope  
(RSHLGFWQEGWSGQVYQDWLGRMNCSYENX) from the lytic KSHV 8.1 
protein (Lam et al., 2002) has been used to coat 96-well polystyrene microtest plates 
in a concentration of 5.0//g/ml in PBS. After overnight incubation at 4°C the plates 
were washed with PBS/0.1% Tween-20 and blocked with blocking buffer (PBS/0.1% 
Tween-20/5 % dried milk). The plasma samples were diluted 1:100 in blocking buffer 
and incubated on the plate for 2 hours at 37°C. After washing 4 times with blocking 
buffer, goat anti-human immunoglobulin coupled to HRP was used as conjugate 
(DAKO) at a dilution of 1:4000 and incubated at 37°C for 1 hour. HRP substrate 
TMB (tetramethyl benzidine) was added for colour development; 15-30mins later, 
the reaction was stopped with IN sulphuric acid (SIGMA) and optical density (OD) 
measurements were read at a wavelength of 450 nm in a microplate reader 
(spectrophotometrically). The colour intensity of the solution is proportional to the 
antibody concentration in the test sample. Assay sensitivity was calculated by testing 
a group of 104 KS patients as true positives and a group of 20 healthy blood donors 
as presumed negatives. The ELISA cutoff was calculated based on the mean of data 
from 20 healthy individuals plus 3 times the standard deviation, (p value = 0.997), 
assuming 100% specificity.
2.5.3 DNA extraction from clinical samples
DNA was extracted from 200/d of plasma or cell pellets using QIAamp blood Mini 
kit (Qiagen) according to manufacturers protocol. When DNA was extracted from
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plasma samples, 5/zg of sonicated salmon sperm DNA (Stratagene, Netherlands) was 
added into each sample with the lysis buffer to be extracted. In brief, 200//1 of 
sample was mixed with 400//g of Protease and 200/d lysis buffer. The samples were 
incubated at 56°C for at least lOmins, and 200//1 ethanol (100%) was added. After 
15secs vortexing, samples were briefly centrifuged and the total mixture of the 
samples was applied to the QIAamp spin column. Centrifugation at 16,000g for 
2mins followed. This allowed the DNA to be adsorbed onto the silica-gel membrane 
of the column, whereas the lysate with any protein or salt is passed through the 
column and discarded. DNA was washed further with buffers AW1 (Qiagen) and 
AW2 (Qiagen) to remove residual contaminants. Purified DNA from plasma was 
eluted in 80/d distilled H20  whereas the DNA extracted from cell pellets was eluted 
in 100/d distilled HzO and stored at -20°C until use.
2.5.4 HLA class I and II typing by PCR-SSP
To identify restriction of CTL responses against specific peptides the tissue typing of 
each individual was necessary. Patients from Royal Free and University College 
London hospitals were HLA typed as follows:
2.5.4.1 PCR plate preparation
DNA purified from the EDTA cell pellets was used for HLA class I and II typing. 
All loci are simultaneously amplified in 144 SSP (sequence specific primers) 
reactions under a single set of conditions in 96-well format PCR machines. The 
primers used for PCR-SSP are designed using the amplification of refractory 
mutation system (ARMS) principle (Krausa et al., 1993). Since amplification occurs 
at the 3’ end of the primer sequence, extension would only be allowed if the template 
and the primer are matched at the 3’ nucleotide position, in appropriate stringent 
conditions; a mismatch will cause the PCR to fail. Primer mixes (forward and 
reverse) for the HLA class I and II alleles to be amplified (and controls) were 
provided by the Oxford Transplant Centre. Five /d primer mixes (2.5/d forward and 
2.5/ri reverse) aliquots per allele were dispensed in each well (144 wells, i.e 2x 96- 
well PCR plates) using a repeating electronic dispenser (Robbins Scientific). Ten /d 
of mineral oil (SIGMA) was also dispensed on top of each primer-covered well and 
the plates (Robbins Scientific) were stored at -80°C until required.
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2.5.4.2 PCR buffers and reaction
TDMH is a PCR buffer that contains all the necessary constituents for a PCR 
reaction apart from the Taq DNA polymerase (Bioline) and the DNA that requires 
typing with the appropriate volume of H20 . TDMH was made in advance according 
to the following protocol and stored at -20°C:
Pre-mix TDMH - STOCK 13mls
X10 buffer (Bioline) 3,380/d (X10 in PCR reaction)
25mM MgCl2 (SIGMA) 2,700/d (2mM in PCR reaction)
dNTPs mix (25mM, Promega) 240/d (290nM in PCR reaction)
distilled H20  6,680/d
The two 96-well plates per DNA sample, TDMH, DNA samples and the Advance 
'QioTaq (Bioline) DNA polymerase were left to thaw out at 22°C before the PCR 
reaction. The following constituents were combined and mixed briefly by vortexing:
PCR mix
TDMH 531/d
distilled HzO 300/d
DNA (approx 0.05//g//d) 15/d
Advance BioTaq 4/d
850/d
With a multichannel pipette 8/d of PCR mix was added, on top of the aliquots I of 
primers, to all wells to give a total of 13/d PCR reaction volume. The plates were 
covered with adhesive plate sealer and centrifuged briefly at j I50g for 30secs. The 
plates were placed in two blocks in the PCR machine Tetrad™ Cycler (MJ Research,
Inc.) and the following conditions used:
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PCR parameters 
lmin denaturation 96°C
5 cycles of 25secs 96°C
45secs 70°C
30secs 72°C
21 cycles of 25secs 96°C
45secs 65°C
30secs 72°C
4 cycles of 25secs 96°C
50secs 55°C
90secs 72°C
2.5.4.3 Agarose gel electrophoresis conditions
Since running 144 DNA samples on a gel is not an easy task, Flowgen tanks that 
accomodate 12X26 well combs were used. Using these gel tanks the results from two 
plates are loaded together. DNA was fractionated according to size through Gibco 
Electrophoresis grade agarose gels (Invitrogen). Gels were made with l%w/v 
agarose in 0.5 X TBE buffer (20gr agarose in 21itres 0.5 X TBE). The mixture was 
melted in a microwave oven, mixed and ethidium bromide (0.1/ig/ml) was added and 
poured into the gel tray. The PCR products were prepared in IX DNA Orange G 
loading buffer and the gel run between 200-280volts for ~20mins. Gels were 
visualised on a UV transilluminator and photographed.
2.5.5 Synthetic peptides
2.5.5.1 HLA-A*0201 binding peptides
Previously identified A*02 restricted KSHV peptides derived from the following 
KSHV proteins were used in this study: K12 (LLNGWRWRL) (identified in our 
group) (Wilkinson et al., 2002), gH (FLNWQNLLNV) (Micheletti et al., 2002), gB 
(LMWYELSKI) (Wang et a l , 2002) and K8.1 (gp 35/37) (LVLILYLCV) which is a 
truncated 9-mer derived from two overlapping K8.1 15-mers: the 
WAVGLLLGLVLILYL and the originally identified A*02 restricted 15-mer 
LILYLCVPRCRRKKP (Wilkinson et a l, 2002). Additionally the HLA-A*0201-
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restricted HIV-1 peptide SLYNTVATL from pl7 (SL9, amino acid 77 to 85) was 
used to determine the frequency of gag—specific IFN-y-secreting cells.
2.5.5.2 Peptide synthesis
At the beginning of this study, peptides were synthesised at the Imperial College
School of Medicine in London (Advanced Biotechnology Center, Charing Cross
I wereHospital). Since more peptides needed later on, peptides were synthesised by Justin 
Stebbing and I at our local facilities using fluorenylmethoxycarbonyf (f-moc) solid- 
phase chemistry (Beck-Sickinger et al., 1991; Eichler et al., 1994).
2.5.5.2.1 Simultaneous multiple peptide synthesis -  T-bag method and f-moc 
chemistry
Due to a large number of peptides involved, a manual multiple synthesis method was 
used -  the T (tea)-bag method™ (Domer et al., 2000; Houghten, 1985). T-bags were 
prepared by containing solid phase resins within polypropylene mesh material and 
labelled with the identification number (ID) of the target peptide (prepared by Dick 
Campbell, WIBR). The peptide synthesis starts from carboxyl terminus towards the 
amino group. The carboxyl group from the first amino acid binds to resin beads. The 
side chains of each amino acid are masked with a permanent protective group so 
there is not synthesis at that direction. During peptide synthesis, every amino acid is 
temporarily protected at the a-amino terminus with f-moc protective group, so only 
one amino acid is able to bind to the previous amino acid. The f-moc protective 
group is removed when the next amino acid is coupled (deprotection). In the final 
step of the synthesis, the peptide is released and the side-chain protective groups are 
removed.
2.5.5.2.2 Peptide synthesis cycle
During the T-bag synthesis of various peptide sequences in parallel, deprotection and 
washing steps can be performed with all bags combined in a single polypropylene 
bottle, whereas when amino acids are coupled the bags are separated depending on 
the amino acid added (Fig. 2.4.).
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1 Deprotection 
Washing steps
I
Classification
Leu Pro Ala Amino acids
ciiD D iiK
1 Washing steps 
Deprotection 
Washing steps
Figure 2.4. T-bag method of manual multiple peptidle synthesis
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The buffers/solvents used are given in Table 2.5:
Table 2.5. Reagents, organic solvents, buffers and activities
Resin (Novabiochem) Solid beads Support for the amino-acids to 
bind
Piperidine
(Perseptive Biosystems)
20% in DMF Deprotects the f-moc group 
from the amino acid prior to 
coupling
NMP (SIGMA) N-methylpyrrolidinone Dissolves amino acids: 
H istidine, Proline and 
Phenylalanine
DMF (RATHBURN, 
Chemicals, LtD)
A,Af-dimethylformamide Solvent for the rest of the 
amino acids
Washes away the excess of 
amino acids and piperidine
PyBOP (Novabiochem) 
and NNM 
(RATHBURN, 
Chemicals)
A-methylmorpholine Both added in the amino acids 
solvents to activate them 
before coupling
DCM (RATHBURN 
Chemicals)
Dichloromethane Very volatile, dries the resin 
off the DMF
TFA (ALDRICH 
Chemicals)
Trifluoroacetic acid Cleaves off the permanent 
protective groups from the 
side (chains the peptide off 
the resin
TIPS (FLUKA, Chemie) Tri-isopropylsilane Added to TFA and de­
activates radicals during the 
cleavage of the protective 
groups
TBME (BDH) tert-Butylmethylether To precipitate the peptides; 
peptides are insoluble in ether
Acetic acid (MERCK) Dissolves the peptides and 
completes the deprotection
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The synthesis steps are based on the following protocol:
^  Amino acids were weighted on a digital balance (Sartorius ISO 9001) and 
dispensed in scintillation (polyethylene) vials (Qmx laboratories Ltd.) labelled with 
the ID of the peptide and the amino acid letter code.
^  Labelled T-bags with the peptide ID were added together in a polypropylene 
bottle and saturated with 20% piperidine for 20mins on a shaker.
^  Amino acids were dissolved in lOmls of NMP or DMF solvent with the 
addition of 100/d PyBOP and 50/d NMM prior to coupling.
^  The T-bags were washed 6 X with DMF, sorted and added to the labelled 
vials.
^  After 40mins shaking at 22°C the T-bags were washed 6 X per lmin each 
wash with DMF and put on the shaker for 20mins with 20% piperidine.
^  Washes followed 6 X with DMF
^  The procedure restarts from the newly weighed amino acids dissolved in their 
solvent.
^  After the peptides were synthesised the resin was dried with 3 gentle washes 
with DCM and T-bags were also dried and freeze-dried for 5-10mins at -96°C at 
zero pressure (Freeze dry machine Heto, Int).
^  Each T-bag was transferred in a scintillation vial labelled with the peptide ID 
and 2mls of 95% TFA, 2.5% TIPS and 2.5% dH20  mixture was added and left for 
3hours at 22°C on a shaker.
^  The peptides were transferred in 15mls Falcon tubes and lOmls of neat TFA 
was added for extra wash.
^  lOmls of ice cold TBME was added (5 X the volume of the peptide solution), 
5mins spin at 4,000rpm at 4°C. The solution was discarded andjthe remaining 
peptide solution was added for further centrifugation.
^  If precipitation was not obvious, peptides were stored in TBME in -80°C 
overnight and the spin was repeated the next day.
^  Speed-vacuum at maximum speed (l,800rpm) for 30mins followed. The 
peptides were dissolved in 5mls 15% acetic acid in H2Q and transferred to
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scintillation vials on a tray with dry ice and methanol. Finally, they were freeze- 
dried for 24 hours to lyophilise and stored at -80°C till use.
2.5.5.2.3 Peptide stock solution preparation
Lyophilised peptides were supplied with known molecular weight and consequently 
they were weighted (Sartorius), solubilised in 100/d DMSO and 900p\ of PBS was 
eventually added to final peptide concentration of ImM. Aliquots of 100/d were 
stored at -20°C to be used in an ELISpot assay.
2.5.6 IFN-y release ELISpot assay
Detection of single cell IFN-y release by ELISpot was performed as previously 
described (Lalvani et al., 1997) (Fig. 2.5.). Cryopreserved patient PBMCs were 
thawed, the viability assessed by trypan blue dye exclusion and the PBMC batch was 
tested in a single ELISpot assay to avoid inter-assay variation. A polyvinylidene 
difluoride (PVDF) 96-well plate (Millipore) was coated with the anti-IFN-y mAb 1- 
D1K (10/^g/ml) overnight at 4°C (Mabtech). Next day, after 6 washes with RPMI- 
1640, the plate was blocked for lhour with 10% heat-inactivated AB serum 
(SIGMA)/RPMI-1640 (RIO). Briefly, 2x10s PBMCs/well were cultured in RIO and 
stimulated with the appropriate peptides (7.5//M) or phytohaemagglutinin (PHA 
5//g/ml, SIGMA). Negative controls comprised of cells cultured with RIO alone to 
allow evaluation of background IFN-y release. Plates were incubated for 36 hours at 
37°C with 5% C 02. The plates were washed 6 X with PBS-Tween (PBS-0.05% 
Tween 20, SIGMA) and l//g/ml biotinylated anti-IFN-y mAb (7-B6-1-biotin) diluted 
in PBS was added (Mabtech). After several washes with PBS-Tween, streptavidin- 
alkaline phosphatase (Mabtech) was added (diluted 1:1000 in PBS) for 2hours 
incubation at 22°C. After 6 washes with PBS-Tween, spot-forming cells (SFC) were 
developed by adding the chromagen substrate solution (BCIP/NBT, BioRad) and 
incubating in the dark for up to 30mins. The plates were washed with tap H20  to stop 
colour development and left to dry.
The dark blue spots were inspected and counted in a dissection microscope with 40 
X magnification (Nikon). For each peptide, background values were subtracted and 
the number of spots expressed as SFC/106 PBMC. Results were considered positive
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if the number of SFCs/106 in peptide-stimulated wells was two-fold higher than that 
in control wells and there were at least 50 spots.
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Figure 2.5. Schematic representation of an ELISpot assay (Adaptation from the 
Expert Reviews in Molecular Medicine)
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2.5.7 Quantification of HIV-1 RNA and blood cell counts
Plasma HIV-1 viral loads were determined by the Bayer HIV-1 RNA 3.0 (bDNA) 
Assay (Berkshire). The lower level of detection was <50 HIV RNA copies/ml. This 
assay was performed by the Virology Departments at UCLH and RFH).
2.5.8 Quantification of KSHV in plasma and PBMCs
The amplifications were performed in a 50/d reaction mixture with a TaqMan PCR 
Core Reagent Kit (Applied Biosystems). The mixture contained 10//1 DNA solution, 
5/d of lOxTaqMan buffer, 5mM of MgCl2, 4/d of a deoxynucleotide triphosphate 
mixture (dNTPs, 2.5mM each dATP, dCTP and dGTP and 5mM dUTP), 700nM or 
each primer, 200nM of GAPDH and 150nM of KSHV LANA probe, 0.5Units of 
AmpErase uracil V-glycosylase (UNG) and 1.25Units of AmpliTaq Gold. Both 
amplifications were carried out under the same conditions. Following activation of 
the UNG (2mins, 50°C) and 1 cycle of 95°C for lOmins for AmpliTaq Gold 
activation, 45 cycles were followed (15sec at 95°C and lmin at 60°C). The absence 
of inhibitors was assessed by verifying that the copy number calculated for the pure 
DNA extract decreased linearly when the extract was diluted 1:10 in distilled H20. 
The amplification and analysis were done using the ABI PRISM® 7000 Sequence 
Detection System (Applied Biosystems).
84
CHAPTER 3
SEROEPIDEMIOLOGY OF KSHY
85
Chapter 3 
Seroepidemology of KSHV
3.1 INTRODUCTION
Soon after KSHV was identified major work was focused on answering questions 
regarding the viral epidemiology, geographical distribution and populations at risk of 
infection and transmission. Thus, serological techniques alongside epidemiological 
analyses were employed together to answer these questions.
3.1.1 Epidemiology of KS
3.1.1.1 Classic KS
Classic KS commonly occurs in elderly individuals over 65 years old of southern 
European, Middle Eastern and Jewish origin (Franceschi and Geddes, 1995). 
Therefore, classic KS is localised in Europe and particularly in Mediterranean 
countries. In individuals over 50 years old the highest incidence rates of classic KS 
are found in “high risk countries” such as Italy, Israel and, interestingly, Iceland (Dal 
Maso et al., 1999; Hjalgrim et al., 1998) (Figure 3.1.). Incidence rates are varied 
between countries and sexes (Figures 3.1. and 3.2.). In general, northern Europe has 
the lowest incidence of classic KS. Among sexes, classic KS is more common in 
men than women (ratio range from 1-20:1) (Dal Maso et al., 1999; Franceschi and 
Geddes, 1995; Hjalgrim et al., 1998) (Figure 3.2.). However, within countries, 
classic KS has a specific distribution pattern. For example in Greece, KS occurs 
more commonly in those from the Peloponnese peninsula (southern mainland 
Greece) (Boshoff and Weiss, 2001) (Dr. Hatzakis, Greece, personal communication). 
In Italy, higher incidence rates are reported in Sicily, Sardinia and southern Italy than 
in northern Italy (Bertaccini, 1959; Calabro et al., 1998; Cottoni et al., 1980; Cottoni 
et al., 1996; De Amicis, 1897; Whitby et al., 1998), except for a high prevalence in 
the Po Valley (Ascoli et al., 2001) (Figure 3.3.). In Jewish people, North African 
Jews (Sephardi) have a higher incidence of classic KS than Jews bom in Israel or in 
Europe (Iscovich et al., 1999).
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Figure 3.1. Classic KS incidence rates for individuals over 50 years of age in Europe 
and Israel between 1988-1992. Adapted from Del Maso et. a l 1999
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3.1.1.2 Endemic KS
Endemic KS in Africa affects not only elderly population but also children. The 
median age of endemic KS was 40 years (Oettle, 1962). It predominantly affects 
countries in sub-Saharan Africa, particularly Eastern than Western African equatorial 
countries (Cook-Mozaffari et al., 1998; Oettle, 1962) (Figure 3.4.). In the 1950s, the 
male to female ratio of KS incidence in adults in Africa was 10:1 and in children 3:1 
(Franceschi and Geddes, 1995). In Uganda, KS represented 10% of all malignancies 
with a male to female ratio in adults of 15:1 (Oettle, 1962). In the 1960s, this ratio
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increased to 19:1 in Uganda (Parkin et al., 1999) whereas in Zimbabwe the ratio 
between sexes was 8:1 between 1963-1972 (Chokunonga et al., 2000).
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Figure 3.4. Endemic KS in Africa before 1980, males 0-60years
3.1.1.3 Iatrogenic KS
Iatrogenic KS occurs after an organ transplant (post-transplant KS) and in other 
patients receiving immunosuppressive therapy (Harwood et al., 1979). The incidence 
of KS due to transplantation is estimated to be between 100 and 500 times that seen 
in the healthy Western general population (Moore, 2003; Penn, 1983). In countries 
where classic or endemic KS occurs (e.g. Saudi Arabia), KS is the most common 
post-transplant tumour (Qunibi et al., 1988). Patients of Mediterranean, Jewish or
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Arabian origin are also over-represented among iatrogenic immunosuppressed 
patients who develop KS in North America (Franceschi and Serraino, 1995). This 
indicates that people bom where classic KS occurs continue to be at a higher risk of 
developing KS, even after migration to “low risk” countries (Boshoff and Weiss, 
2001). The high risk could be due to genetic predisposition or continual intrafamilial 
transmission of KSHV among migrated family members.
3.1.1.4 Epidemic KS (AIDS-KS)
In 1981 the first AIDS-associated KS cases were described among young 
homosexual men in California and New York City (CDC, 1981). Epidemic KS is the 
most common neoplasm occurring in patients with HTV infection (Beral et al., 1990). 
KS was over 20,000 times more common among AIDS patients than in the general 
population and between 100-500 more common than in HIV negative organ 
transplant recipients in western countries (Beral et al., 1990). Overall, in the 1980s 
15% of AIDS patients developed KS but only 1-3% of HTV-1 infected women did 
(Kedes et al., 1997a). The highest proportion (95%) of AIDS-KS patients was seen 
in the homosexual or bisexual male community and is less common in those who 
acquired HIV through heterosexual contact or patients with haemophilia or 
intravenous drug users (Beral et al., 1990). Only 1% of HIV infected individuals 
with haemophilia developed KS compared to 21% in homosexual men at that time 
(Beral et al., 1990). The ratio between HTV positive homosexual or bisexual men and 
women has been 20:1 since the HIV epidemic started (Franceschi and Geddes, 
1995). The low incidence of KS in women (HIV infected or not) has not yet been 
explained, although, a number of studies have shown that the human chorionic 
gonadotropin (a pregnancy hormone) can inhibit growth of KS and metastasis in 
vitro and in vivo (Bisacchi et al., 2002; Lunardi-Iskandar et al., 1995; Masood et al., 
1999) and this might suggest that hormonal differences between sexes could 
influence the overall KS distribution.
Since the HIV epidemic, KS has become one of the most common tumours in parts 
of Africa (Wabinga et al., 1993). In Uganda, KS occurs in 7-10% of HIV infected 
individuals. Prior to the HIV epidemic, between 1968 and 1974, there were only 12 
cases reported in boys under the age of 15. Within 5 years (1989-1994), 63 cases in
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boys and 37 cases in girls under the age of 15 were reported, bringing the ratio in 
children to 1.7:1 compared to 3:1 prior to the epidemic (Ziegler and Katongole 
Mbidde, 1996). In Zambia, the KS male to female ratio was 10-15:1 prior to 1983, 
however, in 1996 it became 1.3:1. Among children, KS represented 0-2% of all 
cancers prior to 1983, whereas in 1996 it represented 20-25% among all cancers (He 
et al., 1998). It is not only the ratio of KS between sexes that has been altered. In 
Zimbabwe the incidence rates in adults have increased 10-25 times in both sexes 
compared to rates prior the HIV epidemic (Chokunonga et al., 1999; Chokunonga et 
al., 2000). KS accounts for 18% in Rwanda and 16% in the Democratic Republic of 
Congo (Zaire) of all HIV-AIDS cases reported (Chokunonga et al., 1999). Overall, 
the incidence and the ratio of KS between the sexes have changed significantly since 
the HIV epidemic in Africa. It is likely that the underlying immunosuppression has 
diluted out any differences that sex hormones could have played in host-viral and 
host-tumour cell equilibrium. In contrast, KS remains a rare malignancy in West 
African countries (non-KS endemic countries) such as The Gambia, Guinea, C6te 
d’Ivoire (Bah et al., 2001; Koulibaly et al., 1997). In The Gambia HTV-2 was more 
prevalent that HIV-1 infection (Bah et al., 2001), and KS is 12.4 times more 
common in those infected with HIV-1 than HIV-2 (Ariyoshi et al., 1998). Genetic 
predisposition, environmental factors and anti-viral immune mechanisms are likely 
to be involved in the moderate incidence of KS iiiWest\frica.
Overall, however, HIV does not have a dramatic effect on the incidence of KS in the 
general population in the West. In the USA between 1973-1979, KS had a low 
incidence rate in blacks and in whites, and the ratio between sexes was 2.5-3:1 
(Biggar et al., 1984; Franceschi and Geddes, 1995). In Europe between 1971-1988, 
KS incidence rates in England and Wales were low and the ratio among sexes 1-3.3:1 
(Franceschi and Geddes, 1995; Grulich et al., 1992). Reports have questioned 
whether the HIV epidemic has affected the incidence of KS in classic KS areas. In 
Greece, the incidence of KS slightly increased only in young men from 0.58 to 0.84 
(before and after 1989) (Touloumi et al., 1997). Cumulative published data from 
peer-reviewed journals, on the incidence rates and ratios between sexes of non-AIDS 
KS in different countries are shown in Table 3.1.
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Table 3.1. Reported incidence rates and ratios of non-AIDS KS. Age-standardised 
and adjusted to the local population (per 100,000). * In black, prior to the HIV 
epidemic; in red, during or after the initiation of the HIV epidemic
COUNTRY PERIOD* MALE FEMALE RATIO REFERENCE
Australia (New South Wales) 1972-1982 0.065 0.029 2.24 (Kaldor et al., 1994)
U.S. A. 1970-1979 0.29 0.1 2.90 (Biggar etal., 1984)
U.K. England & Wales 1971-1980 0.014 0.014 1.00 (Brewster et al., 1999;
1975-1988 0.010 0.003 3.33 Grulich et al., 1992)
Scotland 1976-1984 0.023 0.013 1.78
Puerto Rico 1973-1979 0.43 0.10 4.30 (Biggar et al., 1984)
Iceland 1955-1959 0 0 - (Hjalgrim etal., 1998)
1960-1964 0 0.1 -
1965-1969 0.6 0.5 1.20
1970-1974 0.6 0.5 1.20
1975-1979 0.7 0.7 1.00
Faroe Islands 1974-1984 0.8 0.9 0.89 (Hjalgrim etal., 1998)
1985-1995 0.8 0.4 2.00
1974-1995 0.8 0.6 1.33
Norway 1953-1960 0.06 0.016 3.75 (Hjalgrim etal., 1996a)
1961-1965 0.09 0.018 5.00
1965-1970 0.13 0.040 3.25
1971-1976 0.18 0.075 2.40
1977-1979 0.19 0.085 2.30
>1979 0.21 0.05 4.20
Denmark 1958-1962 0.028 0 - (Hjalgrim et al., 1996b)
1972-1976 0.021 0.017 1.24
1977-1980 0.051 0.011 4.63
1981-1984 0.068 0.039 1.74
1985-1988 0.031 0.022 1.41
1989-1991 0.030 0.025 1.20
Finland 1953-1960 0.06 0.025 2.40 (Hjalgrim et al., 1996a)
1961-1965 0.028 0 -
1965-1970 0.041 0.021 1.95
1971-1976 0.075 0.06 1.25
1977-1979 0.10 0.079 1.27
>1979 0.12 0.12 1
Sweden 1958-1962 0.27 0.06 4.50 (Calabroefa/., 1998;
1963-1967 0.26 0.10 2.60 Franceschi and Geddes, 1995;
1968-1972 0.57 0.24 2.38 Hjalgrim etal., 1996b)
1973-1977 0.52 0.17 3.06
1978-1982 0.44 0.15 2.93
<1985 0.40 0.31 1.29
Switzerland 1974-1982 0 0 - (Franceschi and Geddes, 1995)
Greece 1974-1983 0.40 0.25 1.60 (Touloumi etal., 1997)
1984-1989 0.58 0.37 1.58
>1989 0.80 0.30 2.67
Israel 1970-1989 1.93 0.73 2.64 (Iscovich etal., 1998;
Jewish immigrants from Iscovich et al., 2000a)
Central Europe/Iran 0.58 0.12 4.83
Eastern Europe 1.67 0.95 1.76
North Africa 3.09 1.36 2.27
Italy 1976-1984 1.00 0.25 4.00 (Ascoli etal., 2001; Cottoni et
North 0.87 0.26 3.35 al., 1996; Franceschi and
Po Valey (Mantua) 1989-1998 2.49 1.06 2.35 Geddes, 1995; Geddes etal.,
Centre 0.76 0 - 1995)
South (Sicily, Ragusa) 3.01 0.54 5.57
Sardinia 1987-1991 2.43 0.77 3.16
Uganda 1950-1953 2.6 Not known Not known (Franceschi and Geddes, 1995;
1960-1971 3.6 0.2 18 Parkin etal., 1999)
Zimbabwe 1963-1972 2.3 0.3 7.7 (Chokunonga et al., 2000)
Zambia 1983 Not known Not known 10-15 (He et al., 1998)
AFRICA adults 1950 Not known Not known 10.00 (Franceschi and Geddes, 1995)
children 3.00
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3.1.2 Seroepidemiology of KSHV
The seroepidemiological profile of KSHV has been generated from the data of 
various serological studies. These data confirm the general view that KSHV 
seroprevalence reflects the distribution of KS. Regardless of the serological assay 
used (immunofluorescence, ELISA, Western blots) or the KSHV antigen (latent 
and/or lytic, whole virus lysate, recombinant or mixed) used, the majority of the data 
suggest that KSHV is not a ubiquitous virus (unlike EBV), and is predominantly 
found where KS is endemic (with a few exceptions discussed below). It is also worth 
noticing the wide range of seroprevalence rates reported for every region. This is 
partly due to differences in sensitivities and specificities of the serological assays 
currently used to detect anti-KSHV antibodies.
3.1.2.1 KSHV geographical distribution in the healthy population
3.1.2.1.1 Africa
The highest seroprevalences of KSHV in healthy populations are found in sub- 
Saharan Africa. In general, KSHV infectivity rate increases steadily with age (Olsen 
et al., 1998; Rezza et al., 2000; Sitas et al., 1999a). In African countries where KS 
was relatively frequent before the spread of HIV pandemic (e.g. Uganda, Cameroon, 
Zambia, Democratic Republic of Congo, Tanzania) KSHV seroprevalence ranges 
from 14-86%, depending on the serological assay and the form of KSHV-specific 
antigen used (Dedicoat and Newton, 2002). Comparable seroprevalence rates of 
KSHV to these countries are also found in The Gambia, Ghana, Ivory Coast, 
Botswana and South Africa, where KS rarely occurred before the HIV epidemic, and 
no prevalence difference has been reported between men and women (Dedicoat and 
Newton, 2002). Studies have shown that KSHV prevalence has not changed after the 
spread of HIV in Africa; KSHV is now as prevalent as before 1980 (de Th6 et al.,
1999). KSHV is also common in African children below the age of 12 years: The 
seroprevalence rates range from 7-60% in Egypt and 12-55% in Cameroon, 
depending on the age group analysed and whether the serological assay detected 
antibodies against latent or lytic viral antigens. In South Africa the seroprevalence of 
KSHV in children is around 30%, in Tanzania 40%, whereas 37-50% of children 
below the age of 5 are KSHV seropositive in Uganda (Andreoni et al., 1999;
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Bourboulia et al., 1998; de Th6 et al., 1999; Gessain et al., 1999). These data suggest 
that non-sexual routes of KSHV transmission occur during childhood in Africa.
3.1.2.1.2 Mediterranean countries
In classic KS regions, the KSHV seroprevalence rates mirror the KS distribution 
patterns, although KS is still a rare outcome of KSHV infection. In Italy the 
prevalence of KSHV antibodies is much higher in the south (range 4-35%) and the 
geometric mean titre of anti-KSHV antibodies is also higher than in the north Italian 
blood donors (Figure 3.5.) (Calabro et al., 1998; Cattani et al., 1999; Rezza et al., 
1998; Whitby et al., 1998). Detection of KSHV antibodies in Italian children also 
supports the view of intrafamilial transmission of KSHV (Calabro et al., 2001; 
Whitby et al., 2000). In Israel, the seroprevalence of KSHV is around 10% in the 
general population, depending on the serological method used, (range 5-16%) with 
those originating from North Africa or the Middle East having the highest 
seroprevalence (Davidovici etal., 2001; Iscovich et al., 2000b). In Spain, where 
classic KS is relatively uncommon, 6.5% of the general population tested positive for 
anti-KSHV antibodies, and both sexes had a similar seroprevalence rate (Gambus et 
al., 2001).
3.1.2.1.3 Americas and rest o f Europe
In the West, the KSHV seroprevalence in the general healthy population is low 
compared to Africa and areas where classic KS occurs. In the U.S.A., a variety of 
serological assays have been used in numerous studies. As a result, the KSHV 
seroprevalence was shown to vary enormously (range, 0-30%), although the majority 
of the data support a rate of <5% in the general population (Ablashi et al., 1999; 
Baillargeon et al., 2002; Chandran et al., 1998a; Chatlynne et al., 1998; Gao et al., 
1996b; Kedes et al., 1996; Rabkin et al., 1998; Simpson et al., 1996; Zhang et al., 
1998). KSHV latent or lytic antibodies are undetectable in children in the U.S.A. 
(Chandran et al., 1998b; Lin et al., 1997; Simpson et al., 1996), however one recent 
report showed that 26% of children in south Texas were seropositive for KSHV, but 
as yet this has not been confirmed by others (Baillargeon et al., 2002). Unexpectedly, 
17% seropositivity was reported for the general population in Havana, Cuba, 
although the serostatus of HIV in the same individuals was not determined 
(Fernandez et al., 2002). In South America, studies in Brazil and French Guiana (the
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population tested were of African origin) suggested a prevalence of 6 and 12%, 
respectively (Caterino-de-Araujo et al., 1999; Plancoulaine et al., 2000; Plancoulaine 
et al., 2002; Zago et al., 2000). In the U.K. and rest of northern Europe, Southeast 
Asia, Japan and the Caribbean, the seroprevalence is between 2 to 4% (Ablashi et al., 
1999; Katano etal., 2000).
Figure 3.5. KSHV seroprevalence rates in Italian blood donors in different parts of 
Italy.
3.1.2.2 KSHV distribution in populations at-risk
The detection of anti-KSHV antibodies in groups with or at risk of having KS varies. 
Most serological assays detect antibodies in the majority of patients with classic and 
endemic KS (range, 70-100%) (Ablashi et al., 1999; Ablashi et al., 2000; Chatlynne
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et al., 1998; de The et al., 1999; Fouchard et al., 2000; Gao et al., 1996b; Marcelin ef 
a/., 1997; Newton et al., 2003; Rabkin ef a/., 1998; Simpson ef al., 1996). However, 
the picture is different in various HIV-1 risk groups. KSHV antibodies are only 
detected in 66 to 96% of AIDS-KS patients, indicating that HIV induced 
immunosuppression may contribute to a compromised humoral antibody response in 
this group of patients. In the West, KSHV antibodies are predominantly found in 
HIV positive homosexual/bisexual men, and HIV positive heterosexuals, patients 
with haemophilia or intravenous drug users have prevalence rather similar to the 
general population (Gao et al., 1996b; Simpson et al., 1996). KSHV antibodies have 
been detected in the West (including U.S.A. and the U.K.) in 20-75% of 
homosexual/bisexual men with HIV-1 infection and without KS, with the majority of 
the studies detecting 40-70% (Chandran etal., 1998a; Chandran etal., 1998b; Kedes 
et al., 1996; Lang et al., 1999; Lin et al., 1997; Martin et al., 1998; Osmond et al., 
2002; Rabkin et al., 1998; Smith et al., 1999). In the same group in Africa, the 
detection or anti-KSHV antibodies reached 80% (Ablashi et al., 1999; Gao et al., 
1996b; Simpson et al., 1996). However, among HIV-1 positive heterosexuals in 
Africa, the antibody detection is high ranging from 30 to 70% (Gao et al., 1996b; 
Simpson et al., 1996; Sitas et al., 1999a), and this is similar to the general HIV 
negative healthy population in Africa.
The seroepidemiological studies I conducted were to explore KSHV seroprevalence 
and transmission routes in different geographical regions world-wide, and in various 
population groups at risk of having HIV infection or already infected. An indirect 
immunofluorescence assay (IFA) against the latent nuclear antigen (LANA) of 
KSHV is used in all the studies described.
3.2 RESULTS
3.2.1 Comparison of three KSHV serological assays
This study was conducted in collaboration with Dr. F. Neipel in Germany and Dr. D. 
Ablashi in the U.S.A.. The aim was to compare the sensitivities and deduce the 
agreement of the assays involved in detecting antibodies (Abs) against KSHV. The
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assays compared in this study were the latent IFA (ORF 73), the whole virus ELISA 
(ABI ELISA) and K8.1 ELISA (Chapter 2, section 2.3.2.). Latent IFA (ORF 73) and 
ABI ELISA (whole virus) are both being used for KSHV seroepidemiological studies 
(Ablashi et al., 1999; Bourboulia et al., 1998; Chatlynne etal., 1998; Davidovici et 
al., 2001; Kedes et al., 1996; Luppi et al., 1998; Manns et al., 1998; Martin et al., 
1998; Sitas et al., 1999a; Sitas et al., 1999b; Whitby et al., 1997; Whitby et al., 
1998). K8.1 ELISA is a serological assay to detect anti-KSHV Abs against the lytic 
K8.1 protein (Birkmann et al., 2001; Chandran et al., 1998b; Lang et al., 1999; Li et 
al., 1999;Raabetal., 1998;Zhuetal., 1999a;Zhu etal., 1999b).
3.2.1.1 Samples
Two hundred and thirty (230) sera were independently collected and blinded, prior to 
aliquoting and testing by three different assays. IFA was performed in London 
(myself), K8.1 ELISA in Erlangen (Dr. Frank Neipel) and ABI ELISA in Maryland 
(Dr. Dharam Ablashi). Investigators testing the sera did not know the clinical status 
of the patients. The sera were obtained from patients with classic KS (n=26), AIDS- 
KS (n=50), HIV positive gay men without KS (n=8), HIV negative gay men (n=ll), 
HIV positive patients with haemophilia (n=26), U.K. and U.S.A. patients with 
multiple myeloma (n=72) and U.K. and U.S.A. blood donors (n=37). The 50 sera 
from AIDS-KS patients included 20 sera that were previously found by an 
independent investigator to be negative for KSHV by a latent IFA. These patients 
represent a special group because they either had no or low detectable anti-KSHV 
latent Abs. These sere were included in this study, but blindly retested by all 3 assays 
to evaluate whether the 2 ELISAs (lytic assays) detect lytic Abs in these patients.
3.2.1.2 Results
The sensitivity of the assays was analysed. All 3 assays detected anti-KSHV Abs in 
the vast majority of classic KS sera (Figure 3.6.). My latent IFA appeared to be the 
most sensitive, detecting a positive result in 88% of sera compared to 84.6% with 
ABI and 84.6% with K8.1, but these differences were not statistically significant. 
K8.1 was more sensitive overall than the other 2 assays for the AIDS-KS sera, but 
again there were no significant differences in sensitivity between these 3 assays. In
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the 20 AIDS-KS sera samples previously shown by another investigator (Dr. D. 
Whitby, unpublished) to be negative by IFA, latent IFA detected Abs in 5/20 (25%), 
ABI ELISA in 8/20 (40%) and K8.1 in 10/20 (50%). In the randomly selected 30 
sera from AIDS-KS patients, latent IFA detected Abs in 29/30 (96.7%), ABI ELISA 
in 23/30 (76.7%) and K8.1 ELISA in 27/30 (90%) (p value=0.03).
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Figure 3.6. Comparison of BCP-1 IFA with two ELISAs for KSHV antibody 
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The agreement among these assays was compared. Table 3.2. summarises the results 
of pairwise comparisons of the assays both in the overall data and within various 
subgroups of the data. The ELISAs against lytic proteins showed the best overall 
agreement (k = 0 .87 , p<0.0001) with only 12/230 (5.2%) discordant results. 
Comparison of latent IFA with ABI ELISA and K8.1 ELISA gave rise to a slightly 
higher proportion of discordant results, 30/230 (13%) and 28/230 (12.2%), 
respectively. However, the agreement between IFA and both of these assays was still 
relatively good (k =0.67, p<0.0001; k =0 .71, p<0.0001 respectively). In classic KS 
and AIDS-KS the ABI and K 8.1 ELISAs showed 100% and 84% concordance,
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respectively (Table 3.2.). In sera from subjects considered at "low risk" to be KSHV 
positive, that is blood donors and patients with haemophilia or multiple myeloma 
(MM), the 3 assays also correlated very well. Of the pairwise comparisons made, the 
lytic ELISAs again showed the best agreement (k=0.49, p<0.0001).
Table 3.2. Comparison of the 3 different serological assays for the detection of anti- 
KSHV antibodies (IgG) in all 230 serum samples and in various subgroups of the 
data
No. of samples
Concordant Discordant
+/+ -/- +/- -/+ k (p-value)
All sera (n=230)
IFA / ABI 47 153 22 8 0.67 (<0.001)
IFA / K8.1 53 149 16 12 0.71 (<0.001)
ABI / K8.1 54 164 1 11 0.87 (<0.001)
Classic KS (n=26)
IFA / ABI 21 2 2 1 0.51 (0.0044)
IFA / K8.1 21 2 2 1 0.51 (0.0044)
ABI / K8.1 22 4 0 0 1.00 (<0.001)
AIDS KS (n=50)
IFA / ABI 24 9 10 7 0.26 (0.03)
IFA / K8.1 29 8 5 8 0.37 (0.004)
ABI / K8.1 30 12 1 7 0.64 (<0.001)
Low risk patients* (n=135)
IFA / ABI 2 126 7 0 0.35 (<0.001)
IFA / K8.1 3 123 6 3 0.37 (<0.001)
ABI / K8.1 2 129 0 4 0.49 (<0.001)
myeloma (MM)
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Next, we analysed discordant results of the “low-risk” groups (Table 3.3.). These are 
the results where only one assay was positive, and results of sera from "low risk" 
groups. Of the IFA positive samples from patients with multiple myeloma (MM) and 
blood donors the vast majority of the IFA antibody titres were well above the 1:100 
cut-off level, inferring that these are “true” positives.
Table 3.3. Discordant results where only one assay was positive, and positive results 
from “low-risk” sera. * O.D. = optical density; +, low fluorescent signal intensity; 
++ medium fluorescent signal intensity and +++ high fluorescent signal intensity
CLINICAL
STATUS
IFA/LANA 
RESULT ANTIBODY 
TITRE
ABI ELISA 
whole virus 
RESULT O.D.*
K8.1 ELISA 
RESULT O.D.
HIV+ KS- + 1:1,600 - 0.033 - 0.084
HIV- KS- + 1:400 - 0.032 - 0.055
homosexual men + 1:100 - 0.018 - -0.007
UK HIV+ patients 
with hemophilia
0.016 + 0.238
Patients with MM - - - 0.019 + 0.256
+ 1:1,600 - 0.108 + ' 0.335
++ 1:1,600 - 0.109 - -0.046
++ 1:400 + 0.521 + 0.588
+ 1:400 - 0.070 - 0.066
+++ 1:409,600 + 0.892 + 1.583
- - - 0.034 + 0.547
U.K. and U.S.A. + 1:800 ■ - 0.015 - 0.098
blood donors + 1:3,200 - 0.011 - 0.031
+ 1:200 - 0.010 - -0.004
+ 1:6,400 - 0.009 - -0.021
Overall, these data showed that the IFA is a reasonably sensitive and specific assay 
with which to conduct large epidemiological surveys.
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3.2.2 Serological evidence for mother-to-child transmission of 
KSHV
This study was conducted in collaboration with Dr. Freddy Sitas from the South 
African Institute of Medical Research in Johannesburg, and Prof. Valerie Beral and 
Dr. Robert Newton from the Imperial Cancer Research Fund Cancer Epidemiology 
Unit in Oxford. KSHV is transmitted during sex among gay men in the West, 
whereas in endemic regions of Africa there is a high incidence of KS in children. 
Therefore other routes of transmission also must occur in this population. The aim of 
this study was to investigate any serological evidence of possible KSHV 
transmission from mother-to-child in South Africa.
3.2.2.1 Samples
Serum samples from 107 healthy mothers with median age of 29 years (range, 16-42 
years) and 111 of their children with median age of 6 years (range, 6 months to 14 
years) (61 female, 50 male) were tested using the IFA to detect IgG antibodies 
against the KSHV LANA. To investigate a possible effect of maternal KSHV 
antibody titre to the rate of the KSHV seropositive children, the KSHV seropositive 
samples from the mothers were retested in a blinded fashion at doubling dilutions 
starting from 1:200.
3.2.2.2 Results
Seventeen out of 107 mothers (16%) tested positive for anti-KSHV antibodies 
(Bourboulia et al., 1998). Of the 19 children with KSHV seropositive mothers, 42% 
(8/19) were also tested positive, whereas only 1% (1/93) of children with KSHV 
seronegative mothers were seropositive (p value <0.001). In 14 children aged less 
than 10 years at the time they were tested, 29% (4/14) was KSHV seropositive if 
their mother was seropositive, but none of the children of KSHV seronegative 
mothers were seropositive (Table 3.4.).
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Table 3.4. Percentage of children testing positive for KSHV, in relation to their 
mothers’ KSHV serostatus (Adapted from Bourboulia et al., 1998)
Age of children, y
MOTHER STATUS 0-4* 5-9 10-14 All children
KSHV seropositive 29% 29% 80% 42%
KSHV seronegative 0% 0% 13% 1%
* In children under 18 months of age it is possible that the serological assay for 
KSHV would detect circulating maternal antibodies even though the children had not 
themselves been infected: of the 4 children under 18 months old with seropositive 
mothers, one (25%) was seropositive for KSHV.
Seropositive samples from the mothers were titrated and the relation of KSHV 
antibody titre with the proportion of seropositive children was investigated (Table 
3.5.) (Sitas et al., 1999b). The proportion of children who were seropositive for 
KSHV increased in relation to their mothers’ KSHV antibody titre: From 1% if the 
mother was negative to 50% if the mother’s titre was equal or greater than 1:25,600 
(p for trend <0.001).
Table 3.5. Relation between the titre of antibody against KSHV in mothers and the 
proportion of their children who are seropositive for KSHV (Adapted from Sitas et 
al., 1999b)
Mother’s KSHV antibody titre Children who are seropositive in %
Negative (<1:100) 1
1:200 to 1:1,600 33
1:3,200 to 1:12,800 43
1:25,000 or greater 50
3.2.3 KSHV in black South African patients with different types 
of cancer
This study was conducted in collaboration with Dr. Freddy Sitas from the South 
African Institute of Medical Research in Johannesburg and Prof. Valerie Beral and 
Dr. Robert Newton from the Imperial Cancer Research Fund Cancer Epidemiology
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Unit in Oxford. South Africa has one of the highest proportion of HIV-1 infected 
individuals in the world (UNAIDS/WHO, 2002). The aim of this study was to 
investigate the prevalence of KSHV in a group of 3344 black patients with cancer, 
with or without HIV-1 infection. Association of KSHV and other cancers was 
examined and interaction with HIV-1 was investigated. The influence of anti-KSHV 
antibody titres on the risk of having KS was also tested.
3.2.3.1 Samples
Blood from 3344 cancer patients was collected and tested for antibodies against 
KSHV (myself) and HIV-1. Antibodies against KSHV LANA were detected with 
our latent IFA (Chapter 2, section 2.3.1.2). Socio-demographic data and behavioural 
characteristics, including age, sex, birthplace, residence, years of education and 
reproductive and lifetime sexual history were collected.
3000
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A rbitrary  Log scale of Fluorescent signal intensity
Figure 3.7. Fluorescent signal intensity and distribution of anti-KSHV antibody 
titres. These are the results of a FACS analysis of six patients. The intensity of the 
fluorescent signal, as determined by IFA, was low in two patients, medium in two, 
and high in two. (Adapted from Sitas et al., 1999a)
3.2.3.2 Results
To evaluate the IFA scoring system, i.e. +, ++ and +++, in association with antibody 
titres, six subjects, two of whose samples had been scored as low +, two as medium 
++, and two as high +++ in terms of the fluorescent-signal intensity were analysed by
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FACS (Sitas et al., 1999a). The scoring of the tested samples by IFA correlated well 
with the intensity of fluorescence as measured by FACS analysis (Figure 3.7.). To 
study the relation between the intensity of fluorescence and the titre of antibodies to 
KSHV, 141 serum samples were examined blindly at doubling dilutions, starting at 
1:100 for antibodies against KSHV. The score for the fluorescent-signal intensity 
was strongly related to antibody titre -  the median anti-KSHV antibody titres were 
1:200 for low signal intensity, 1:51,200 for medium and 1:204,800 for high signal 
intensity (p<0.001) (Figure 3.8.).
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Figure 3.8. Distribution of titres of anti-KSHV antibodies among those with low-
intensity signals, those with medium-intensity signals, and those with high-intensity
signals (those with no signals were excluded). The median titre in each group is
indicated by a horizontal line. BCP-1 is a PEL cell line (KSHV positive and EBV
negative) (Adapted from Sitas et al., 1999a). *Samples tested negative at 1:100 were
retested at 1:50 dilution.
The age and sex-standardised KSHV seroprevalence was 32% among patients who 
did not have KS, regardless the HIV status, and this did not differ significantly from 
the standardised seroprevalence among black blood donors in this region (Sitas et al., 
1999a). Among patients with KS the standardised seroprevalence of antibodies was 
83%. Analysis of KSHV seropositivity with socio-demographic and behavioural
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characteristics in patients without KS showed that the risk of testing KSHV positive 
increases with the number of sexual partners (p=0.05) and decreases with increasing 
years of education (p=0.007) regardless of the HIV-1 serostatus (Sitas et al., 1999a).
We then studied the seroprevalence of anti-KSHV antibodies among 3293 patients 
who did not have KS. Antibodies against KSHV LANA were detectable in 1196 
patients. The seroprevalence of antibodies increased with age, from 24% for those 
15-24 years of age to 49% for those 65 or more years of age (pcO.OOl) (Figure 3.9.)
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Figure 3.9. Age-specific seroprevalence of antibodies against KSHV and HIV-1 in 
patients without KS in South Africa (Adapted from Sitas et al., 1999a).
We next investigated KSHV seropositivity in 17 types of cancer (KS included) and 
in the normal black population. Antibodies to KSHV were significantly prevalent 
only in patients with KS, and high-intensity signal (i.e. high antibody titre to KSHV) 
was only significantly associated with KS patients (Figure 3.10.).
105
Typa or Site of Cancer 
(no. of patients)
Oral cavity (86)
Esophagus (306)
Stomach (51)
Colon or rectum (103)
Liver (88)
Lung (117)
Kaposi's sarcoma (51)
Breast (415)
Cervix (711)
Ovary (64)
Prostate (202)
Other genital (132)
Hodgkin's disease (121) 
Non-Hodgkin's lymphoma (122) 
Multiple myeloma (108) 
Leukemia (280)
Other cancers (387)
Blood donors (85)
Presence of Any Positive Signal Presence of High-lntensity Signal
20 40 60 80
Standardized Prevalence (%)
100 60o 20 40 80 10
Standardized Prevalence (%)
F igure 3.10. Standardised prevalence of anti-KSHV antibodies at two levels of 
fluorescent-signal intensity among 3344 black patients with cancer and 85 blood 
donors. Horizontal lines denote 95% confidence interval. Seroprevalence rates have 
been adjusted for age, sex, years of education, and number of lifetime sexual partners 
(Adapted from Sitas et al., 1999a).
We further examined HIV-1 serostatus and KSHV antibody titres in the presence of 
KS in the same samples. In Table 3.6. the risk of having KS if testing both HIV-1 
and KSHV negative was standardised to 1. If testing HIV-1 negative and having a 
high antibody titre against KSHV (1:204800), the risk of having KS increased to 12 
times. If testing HIV-1 potitive and having a high antibody titre to KSHV the risk of 
having KS was enormous (1683 times). Regardless HIV-1 serostatus, KS was more 
common in those patients with high score of fluorescent signal intensity of KSHV 
antibodies (pcO.001) (Table 3.6.).
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Table 3.5. Risk of having KS according to HIV-1 serostatus and anti-KSHV 
antibody titre in patients with cancer in South Africa. The risk has been adjusted to 
age, sex, years of education and number of sexual partners. The absolute risks for KS 
have been adjusted for age, sex, years of education, and number of lifetime sexual 
partners. For HTV-1 negative patients p<0.001; for HTV-1 positive p<0.001 (Adapted 
from Sitas et al., 1999a).
HTV-1 status and 
anti-KSHV antibody titre
Absolute risk of having KS
HIV-1 negative
KSHV -ve 1.0
KSHV+ve/Titre: 1:200 1.5
1:51,200 6.2
1:204,800 12.0
HIV-1 positive
KSHV -ve 10.8
KSHV+ve/Titre: 1:200 48.1
1:51,200 62.2
1:204,800 1683.0
3.2.4 Kaposi’s sarcoma associated herpesvirus in Israel
This study was conducted in collaboration with Dr. Batya Davidovici and Prof. Batia 
Sarov from the Epidemiology Department at Israel and Dr. Gary Hayward from the 
Department of Pharmacology and Molecular Sciences at The Johns Hopkins School 
of Medicine at the U.S.A. Classic KS incidence rate in Israel is one of the highest in 
the developed world (Dal Maso et al., 1999). Little is known about the means of 
transmission of KSHV in Middle East and Mediterranean countries including Israel. 
In this study we investigated the prevalence of KSHV in the Jewish population of 
Israel, the association between KSHV prevalence and population characteristics as 
well as hepatitis B virus (HBV) serostatus, possible intrafamilial transmission of 
KSHV and the KSHV strains that are present in the Jewish patients with KS.
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3.2.4.1 Samples
This study was approved by the local and national ethics committees, and the 
subjects gave written consent. There were in total 4051 subjects that formed two 
groups. The former blood donor group comprised of 1648 healthy blood donors 
determined to be positive for hepatitis B virus surface antigen (HBsAg) between 
1971-1975 during their army service. During 1992-1995 the same group was 
contacted and retested for HBV markers. The family members group, of the 1648 
HBsAg-positive former blood donors, consisted of 2403 people (807 spouses and 
1596 children). During 1992 -1995, the family members were also invited to this 
study. The family members group formed 831 families. Seventy of them were single­
parent families and were excluded only from the intrafamilial transmission analysis, 
559 couples had at least one child and 202 couples had no children. All serum 
samples taken from the two groups were tested for anti-KSHV antibodies and titres 
(myself).
1:409,600 
1:204,800 
1:102,400 
1:51,200 
1:25,600 
1:12,800 ♦
1:6,400 
1:3,200 
1:1,600 ♦♦
1:800 ♦♦♦♦♦♦
1:400 ♦♦♦♦♦♦♦
1:200 VAV«V#V«
1:1001 ♦♦♦♦
+ [n = 50] ++ [n = 50] +++ [n = 50]
Fluorescent signal intensity
Figure 3.11. Distribution of titres of anti-KSHV antibodies among those with low- 
intensity signals (n=50, +), those with medium-intensity signals (n=50, ++) and those 
with high-intensity signals (n=50, +++). The median titre in each group is indicated 
by a horizontal line.
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♦ ♦ ♦ ♦
♦ ♦ ♦
♦ ♦ ♦ ♦ ♦
♦ ♦
♦ ♦
108
3.2.4.2 Results
To study the relation between the intensity of fluorescence and the titre of antibodies 
to KSHV, 150 serum samples were selected based on the IFA scoring system, i.e. 
50+, 50++ and 50+++. The samples were examined blindly at doubling dilutions, 
starting at 1:100 for antibodies against KSHV. The score for the fluorescent-signal 
intensity was strongly related to antibody titre- the median anti-KSHV antibody titres 
were 1:200 for low signal intensity, 1:3,200 for medium and 1:12,800 for high signal 
intensity (p<0.001) (Figure 3.11.)
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Figure 3.12. KSHV antibody prevalence in the Jewish population (A) in different 
age groups and (B) in different origins of birth
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Among the family members, the seroprevalence of antibodies against KSHV was 
9.9% whereas in the historic blood donors who had tested positive for hepatitis B, it 
was 22% (Davidovici et al., 2001). KSHV seroprevalence increased significantly 
with age in the family members group (p=0.011) (Figure 3.12.A) and significantly 
varied with country of birth for both groups (p=0.005 and p<0.0001, respectively for 
the two groups) (Figure 3.12.B).
When the historic blood donor group was re-tested for HBV antibodies, 88% were 
still HBV positive and their KSHV seroprevalence was significantly higher (22.7%) 
compared to the KSHV seroprevalence (14.1%) in the HBV seronegative group 
(p=0.008). The HBV chronic carriers were also most likely to have high KSHV 
antibody titres (+++) (p=0.002) (Figure 3.13.).
Percentage
KSHV
positive
■ HBV Negative
■ Anti-HBV positive* 
□ HBsAg positive**
low (+) medium (++) high (+++)
KSHV antibody titre
Figure 3.13. Distribution of anti-KSHV antibody titre on the basis of the HBV 
serostatus. (* Anti-HBs and anti-HBcAg positive; ** HBV chronic carriers)
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Table 3.7. Association between parental and children KSHV serostatus in the Jewish 
families
INTRAFAMILIAL TRANSMISSION OF KSHV 
IN 559* JEWISH FAMILIES IN ISRAEL
SEROPOSITIVE CHILDREN
(%)
FAMILY STATUS BY KSHV
Male+ / Female + 
Male- / Female + 
Male + / Female - 
Male- / Female-
13.9
15.7
9.5
7.5
* A family includes a mother a father and at least one child
To investigate possible intrafamilial transmission of KSHV, KSHV seropositivity 
was measured within the family members. Table 3.7. shows that the highest risk for a 
child to test KSHV seropositive was when the mother tested anti-KSHV antibody 
positive (p=0.004). Also, the highest risk for a husband or wife to test positive was 
when their spouse tested positive (p<0.0001) and depended on their place of birth.
3.2.5 KSHV infection in Spain
This study was conducted in collaboration with Dr. Gambus and Prof. Casabona 
from the Centre for Epidemiological Studies on HIV/AIDS in Badalona, Spain. Since 
1998, Spain has the second highest AIDS incidence rates among the European 
countries after Portugal (European Centre for the Epidemiological Monitoring of 
AIDS, 2002). The aim of this cross-sectional seroprevalence study was to determine 
the seroprevalence of KSHV in several Spanish subpopulations with different risk 
levels of acquiring HTV-1 infection and from different geographical regions.
3.2.5.1 Samples
A total of 1699 serum samples from blood donors (n=613), children under the age of 
12 years (n=100), injecting drug users (IDU, n=382), heterosexuals attending a
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sexually transmitted disease (STD) clinic (n=273) and homosexual men attending a 
STD clinic or a HIV-based hospital unit (n=331) were analysed for anti-KSHV 
antibodies.
3.2.5.2 Results
The KSHV prevalence was 0% among children, 6.5% among blood donors, 11.5% 
among IDU, 17.2% among heterosexual STD clinic attendees and 60.1% among 
homosexual STD/HIV clinic attendees (p<0.001) (Gambus et al., 2001). When the 
analysis was adjusted by sex or HIV infection, the homosexual STD/HIV clinic 
attendees group is the only subgroup significantly different on the KSHV 
seroprevalence (Figure 3.14.). In fact, KSHV seroprevalence was 86.7% in HIV- 
positive homosexual men compared to 28% in HIV-negative homosexual men
(p<0.001).
Homosexual men* with KS 
Homosexual men* without KS 
Heterosexuals** 
IDU*** 
Homosexual men* 
Heterosexuals** 
IDU*** 
Blood donors 
Children
Percentage positive
HIV+
HIV-
Figure 3.14. Seroprevalence of KSHV antibodies in different population groups in 
Spain (Adapted from Gambus et al., 2001)
* Attendees of STD/HIV clinic; ** Attendees of STD clinic; ***Injecting drug users
□
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There was no prevalence difference found between male (5.8%) and female blood 
donors (6.9%) (p=0.69). When the KSHV seroprevalence was compared between'the 
north and south of Spain the results were similar: In the Basque country (north) the 
KSHV prevalence was 4.5% whereas in two Mediterranean areas (Andalusia and 
Catalonia) it was 7% and 8%, respectively (p=0.34).
mean
The geometric KSHV antibody titre was compared among the KSHV seropositive 
groups to assess any possible association between anti-KSHV antibody titre and risk 
of KS (Figure 3.15.). The HIV infected homosexual men with KS had significantly
high KSHV antibody titre compared to the rest of the homosexual individuals1
(p=0.006).
Homosexual men* with KS 
Homosexual men* without KS 
Heterosexuals** 
IDU*** 
Homosexual men* 
Heterosexuals** 
IDU*** 
Blood donors
■  HIV+
□  HIV-
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Figure 3.15. Geometric mean titres of KSHV antibodies (Adapted from Gambus et 
a l, 2001)
* Attendees of STD/HIV clinic; ** Attendees of STD clinic; ***Injecting drug users
Examining the distribution of KSHV antibody titres according to both HIV infection 
status and transmission risk group showed that, the HIV-negative heterosexual 
STD/HIV clinic attendees had the lowest titre and the HIV-positive homosexual 
STD/HIV clinic attendees the highest, compared to the rest of the groups (p<0.05) 
(Figure 3.16.).
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Figure 3.16. Box plot analysis showing the distribution of KSHV antibody titres in 
different transmission groups and by HIV status (Adapted from Gambus et al., 2001)
3.2.6 KSHV infection in Brazil
This study was conducted in collaboration with Adriana Zago and Regina Keller, 
from the University of Spirito Santo in Vitoria, Brazil. Little is known about the 
seroprevalence of KSHV in South America (Biggar et al., 2000). The aim of this 
study was to investigate the seroepidemiology of KSHV infection among different 
populations in Brazil.
3.2.6.1 Samples
This was a cross-sectional study conducted in Vitoria and Sao Paolo. A total of 1044 
serum samples were analysed (747 blood donors, 73 patients presenting to casualty 
departments and 224 patients attending sexually transmitted disease/AIDS clinics). 
The 224 patients attending the STD clinics comprised of 136 patients without HIV 
infection, and 88 patients with HIV infection of whom 40 had KS and 48 without 
KS. The sera were screened by my IFA and antibody titres were again determined.
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3.2.6.2 Results
The prevalence of anti-KSHV antibodies in the population tested is shown in Figure 
3.17 (Keller et al., 2001; Zago et al., 2000). KSHV was mostly associated with KS 
within the group of HIV infected patients (odds ratio O.R 23.4) (Figure 3.17.).
All HIV positive (n=88) 
without KS (48)
1
with KS (n=40)
a
|  HIV negative without KS (n=136)
O
Blood donors (n=747)
Casualty department (n=73)
0 10 20 30 40 50 60 70 80 90 100
□  STD/AIDS clinics (n=224) Percentage positive
Figure 3.17. KSHV seroprevalence in various groups in Brazil
The overall KSHV positivity was associated with hepatitis B virus (HBV) infection, 
but not with any of the other STDs tested (gonorrhea, genital herpes, condyloma, 
syphilis) (odds ratio 3.6).
3.2.7 Other serological studies
In addition to the sera tested in the above studies, I tested sera from various other 
countries: From Uganda, in collaboration with John Ziegler and Robert Newton at 
Oxford, I tested 2091 sera from individuals with malignancies other than KS, 
examining the epidemiology of conjunctival squamous cell carcinoma in association 
with KSHV and other viral infections (Newton et al., 2002). In the same population, 
the seroepidemiology of KSHV in adults with cancer and the risk factors for KS in
the HIV seronegative people were investigated (Newton et al., 2003; Ziegler et al.,
2003). From Kenya, in collaboration with Rana Chakraborty, I tested 71 sera from 
HIV infected orphan children to assess the seroprevalence rates of KSHV
1 1 1
□
■
— 1
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(Chakraborty et al., 2003). From the U.K., in collaboration with Nicola Smith and 
Jennifer Best at St. Thomas’ Hospital, I tested 2718 sera from STD clinic attendees 
to investigate KSHV transmission routes (Smith et al., 1999). From the U.K., in 
collaboration with Robert Newton at Oxford and with Antonia Kwan at Wohl Virion 
Centre, I tested 901 sera from HIV-1 infected patients who entered into MRC studies 
including Concorde, Alpha and Delta, studying the rate of KSHV seroconversion and 
risk factors associated with KSHV infection. From the U.S.A., in collaboration with 
Dharam Ablashi and James Whitman, I tested 362 sera from patients with MGUS 
(monoclonal gammopathy of undetermined significance) and 110 sera from patients 
with MM (multiple myeloma) to investigate the controversial association between 
KSHV and these diseases (Ablashi et al., 2000).
Looking at the general population at various countries, blood donor sera were also 
tested. From Greenland in collaboration with Mads Melbye, Anders Koch and 
Henrik Hjalgrim, I tested 300 sera from blood donors to estimate the KSHV 
prevalence in the population. From Hungary in collaboration with Karoly Nagy, 
Budapest, I tested 384 sera from blood donors. From Sierra Leone and China in 
collaboration with David Brown of PHLS Colindale, I tested 100 and 96 sera from 
blood donors, respectively.
I was involved in the evaluationjpZ. the performance ( k  a novel KSHV serological 
assay (ELISA ORF73) in collaboration with Dharam Ablashi from Advanced 
Biotechnologies, Maryland, by testing sera from various populations at risk or blood 
donors. Finally, and more recently, I contributed in the development of our new 
ELISA, in collaboration with Dimitrios Lagos in our laboratory. This ELISA uses a 
multiple antigenic peptide (MAP) as an immobilised antigen. We incorporated two 
copies of an ORF73 epitope (latent antigen) with 2 copies of the K8.1 peptide (lytic 
antigen) in a branched peptide tetramer. Therefore, with this ELISA we can increase 
the sensitivity of anti-KSHV antibody detection without affecting the overall 
specificity.
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3.3 DISCUSSION
3.3.1 Assessment of serological assays
The various serological assays currently used for the detection of KSHV antibodies 
have been previously introduced (Chapter 1, section 1.1.2.6.4.). Here, three major 
serological assays to detect anti-KSHV Abs were compared. The 
immunofluorescence assay (IFA) detects antibodies against the latent nuclear antigen 
(LANA) encoded by the open reading frame ORF73 of KSHV (Kedes et al., 1997b; 
Kellam et al., 1997; Rainbow et al., 1997). This assay has been used in many 
seroepidemiological studies, some of which have been stated in this chapter 
(Ariyoshi et al., 1998; Davidovici et al., 2001; Gambus et al., 2001; Newton et al., 
2003; Simpson et al., 1996; Sitas et al., 1999a; Whitby et al., 1998; Zago et al.,
2000). The ABI ELISA assay has also been used in various studies and is 
commercially available (Ablashi et al., 1999; Chatlynne et al., 1998; Gessain et al., 
1999; Osmond et al., 2002). K8.1 ELISA had not been previously evaluated, 
although K8.1 was considered to be a highly immunogenic protein (Raab et al., 
1998).
Although first generation antibody assays have been useful in confirming the 
association between KSHV and KS, agreement among assays has been limited 
(Rabkin et al., 1998). In order to assess differences in sensitivity of each assay we 
first considered the proportion of positive samples detected by each assay within 
different categories of KS patients, the assumption being that all patients with KS 
should test positive for KSHV (Ablashi et al., 2002). Figure 3.6. summarises overall 
results of the 230 sera tested by the 3 assays. The 3 assays were comparable in 
sensitivity and there was good agreement among them (Figure 3.6. and Table 3.2.). 
In the randomly selected AIDS-KS sera there was a significant difference in 
detection between the assays, and this is largely due to the lower sensitivity of the 
ABI ELISA assay (Figure 3.6. and Table 3.2.).
Studies had initially suggested a causative link between KSHV and multiple 
myeloma; KSHV was detected by PCR in clinical specimens derived from patients 
with multiple myeloma (Rettig et al., 1997; Said et al., 1998). However, the vast
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majority of molecular and serological studies support a lack of an association 
between KSHV infection and multiple myeloma (MM) (Cesarman and Knowles, 
1999; Corbellino et al., 1999; Sitas et al., 1999a; Tarte et al., 1999; Whitby et al., 
1997). In the low risk groups (MM and blood donors), only 2 cases (both with MM) 
are positive by all 3 assays and can therefore be considered truly positive (Table
3.3.). Four sera from MM patients are only positive by one assay. The titres and O.D. 
levels of these cases are well above the cutoff levels for positivity. Four blood donors 
were only positive by the latent IFA and all 4 cases had antibody titres well above 
the cutoff level suggesting that this assay might be better in detecting anti-KSHV 
antibodies in healthy individuals (Figure 3.3.). The fact that 12 cases were found 
positive by only one assay indicates that the choice of assay may affect results in low 
risk groups. The disagreement among the assays in this group could be partly due to 
the different immunogens used to target KSHV antibodies or the variations in assay 
calibration. As a result, assay sensitivity and specificity is also expected to vary.
By combining latent IFA with either ABI ELISA or K8.1 ELISA sensitivity will be 
increased. Together, latent IFA and ABI ELISA detect 85.5% of KS sera, compared 
to 75% and 69.8%, respectively, for IFA and ABI ELISA individually. Combining 
latent IFA with K8.1 ELISA detect 86.8% of KS sera, compared to 75% and 77.6%, 
respectively, for IFA and K8.1 ELISA individually. By contrast, little benefit would 
be obtained by adding ABI ELISA to K8.1 ELISA: together they detect 79% KS 
sera, whereas K8.1 ELISA on its own detects 77.6%. In the group of “low-risk” sera 
(n=135), the combination of latent IFA with K8.1 ELISA would increase the 
detection rate from 6.7% to 8.9% (Table 3.3.). To determine an individual’s KSHV 
status, particularly when “low-risk”, a positive result with any one assay should be 
confirmed by at least one other assay. Using one assay and confirming with a second 
is an approach recently adopted and adapted in various KSHV epidemiological 
studies (Cannon et al., 2001; Iscovich et al., 2000b; Renwick et al., 2002; Schatz et 
al., 2001). In addition, antigens from latent and lytic KSHV immunogenic proteins 
have been combined in one assay to increase sensitivity and specificity (Katano et 
al., 2000). The combination of a latent assay with a lytic assay does improve overall 
sensitivity, but not significantly and is therefore unlikely to alter conclusions or 
interpretations of large seroepidemiological studies (Ablashi et al., 1999; Martin et 
a l, 1998; Sitas et al., 1999a). On the other hand, improved KSHV serological assays
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or combination of assays with increased concordance, sensitivity and specificity
could be useful in the clinical management of individuals at risk of developing
KSHV associated malignancies.
3.3.2 KSHV and KS
KSHV infection is specifically associated with KS. KSHV seroprevalence is 
significantly higher among patients with KS and not any other type of cancer studied 
in South Africa (Sitas et al., 1999a). KSHV has been persistently associated with KS, 
PEL and MCD malignancies. A few studies have also associated KSHV with 
multiple myeloma (MM) and prostate cancer (Chauhan et al., 1999; Raje et al., 1999; 
Rettig et al., 1997; Staskus et al., 1997). However, the findings presented here from 
the tested sera in South Africa and the three serological assays compared do not 
support an association between KSHV and MM or prostate cancer, in agreement with 
numerous reports from others (Ablashi et al., 2000; Corbellino et al., 1999; Cull et 
al., 1998; Parravicini et al., 1997a; Tarte et al., 1998; Whitby et al., 1997).
3.3.3 KSHV and seroprevalence
In South Africa, 32% of black patients with cancer other than KS have antibodies to 
KSHV, which did not differ significantly from the seroprevalence among black 
blood donors. Similar seroprevalence was observed in both HIV-1 positive and 
negative individuals (Sitas et al., 1999a). In those without KS (n=3292), KSHV 
seroprevalence increased steadily with age, from 24% for those 15 to 24 years of age 
to 49% for those 65 or more years of age, and this suggests that the virus may have 
been prevalent in this population for some time (Sitas et al., 1999a; Sitas et al., 
1999b). A similar picture has been shown for the populations in Zambia and 
Cameroon where KS is endemic (Gessain et al., 1999; Olsen et al., 1998). In Israel, 
the prevalence of KSHV in healthy blood donors is around 10%, which is higher than 
in Northern Europe and America, similar to that in other Mediterranean countries and 
lower to that in South Africa and other sub-Saharan countries (Davidovici et al.,
2001). KSHV prevalence increased with age and varied with country of birth. The 
former indicates that horizontal routes of transmission probably occur throughout life 
within the Jewish population. Similar observations have been shown for other classic 
KS regions in the Mediterranean basin such as Italy and Egypt (Andreoni et al.,
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1999; Whitby et al., 2000), In contrast no antibodies were detected in Spanish 
children, which correlates with findings of other studies from the U.K. and the 
U.S.A. (Blauvelt et al., 1997; Gambus etal., 2001; Simpson et al., 1996). The KSHV 
seroprevalence in the blood donors group is only 6.5%, similar in both sexes around 
the country. Although classic KS incidence rates are unknown, Spain is not 
considered to be one of the “risk countries”. Finally, in Brazil 4.6% of the tested 
blood donors were positive for KSHV and this is compared to other countries in the 
West.
3.3.4 KSHV and transmission
Maternal seropositivity and high anti-KSHV antibody titres increase the risk of 
KSHV transmission from mother to child in South Africa (Bourboulia et al., 1998). 
Approximately one third of KSHV seropositive mothers infect their children in that 
African region. Acquisition of KSHV before puberty in South Africa explains the 
high incidence of endemic KS in the African children (Ziegler and Katongole 
Mbidde, 1996). Other studies in Africa have also reported antibodies to KSHV in 
children in countries such as Uganda, Cameroon and Egypt (Andreoni et al., 1999; 
Andreoni et al., 2002; Gessain et al., 1999; Mayama et al., 1998). Detection of 
KSHV in saliva suggests a potential route for transmission (Andreoni et al., 2002; 
Biggar and Goedert, 2001; Cattani et al., 1999; Koelle et al., 1997; Vieira et al., 
1997; Vitale et al., 2000). Therefore, sexual transmission is clearly not the only mode 
of spreading KSHV in South Africa, as the increase of KSHV seroprevalence with 
age suggests (Sitas et al., 1999a). In Israel, it was demonstrated that KSHV is 
transmitted within the family members from spouse to spouse and parent to child 
(Davidovici et al., 2001). This is the first study to indicate that KSHV is transmitted 
between heterosexual married couples in a Mediterranean population but not as 
efficiently since the overall prevalence is low. Mother to child transmission is also 
demonstrated in this population, however sibling to sibling transmission of KSHV 
has not been determined, as was shown to be important in an African population 
living in French Guiana in South America (Plancoulaine et al., 2000; Plancoulaine et 
al., 2002). However, in Spain and Brazil, KSHV is considered to be, thus far, a 
sexually transmitted agent (Gambus et a l, 2001; Zago et al., 2000)
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3.3.5 KSHV and antibody titre
Showing that the IFA scoring method (pos +, ++ or +++) correlates with the
fluorescence signal intensity validates the serological assay used for all the studies 
and the measuring of antibody titre in the seropositive samples (Sitas et al., 1999a). 
The analysis of the anti-KSHV antibody titres of positive samples in every country 
studied shows that the median fluorescent intensity is higher in the population from 
areas with increased rates of KS. Increased antibody titre correlates with high risk of 
intrafamilial and mother to child transmission, as well as high risk of having KS, as 
shown in the seroepidemiological studies presented here (Bourboulia et al., 1998; 
Davidovici et al., 2001; Gambus et al., 2001; Sitas et al., 1999a; Sitas et al., 1999b). 
It is still unclear whether high antibody titres indicate (high) circulating levels of 
KSHV in blood and therefore increased risk of viral transmission (Bourboulia et al., 
1999; Campbell et al., 1999). The association between high antibody titre and KS is 
reminiscent to the relation between EBV in African Burkitt’s lymphoma and 
nasopharyngeal cancer, in which high EBV antibody titre correlates with the risk of 
disease (de The et al., 1978a; de The et al., 1978b).
3.3.6 KSHV and risk factors
A high KSHV antibody titre in KSHV seropositive mothers increases the risk of the
children to test KSHV positive in South Africa (Bourboulia et al., 1998) and in Israel 
(Davidovici et al., 2001). In South Africa, regardless of the HIV-1 serostatus, 
poverty and less education are risk factors associated with high KSHV 
seroprevalence and increased AIDS-KS incidence. This appears to be different in 
Uganda, where AIDS-KS is more common in those with better education (Sitas et 
al., 1999a; Ziegler et al., 1997). KSHV seropositivity increases the risk of having KS 
and the risk of having KS is highest in the HIV-1 seropositive individuals. HIV-1 
related immune dysregulation is the most obvious reason for this: 
immunosuppression leads uncontrollable dissemination of KSHV. Other factors in 
HIV-1 infection that might contribute to KS is the transactivation protein (Tat), 
together with various inflammatory cytokines and angiogenic factors that may 
stimulate KS cell growth (Ensoli et al., 1990; Ensoli et al., 1994a; Gallo, 1998; Reitz 
et al., 1999).
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In the Jewish population in Israel, the seroprevalence of KSHV was most strongly 
associated with place of birth. The highest rates of anti-KSHV antibodies were 
detected in those bom in North Africa, and the lowest rates were found in those bom 
in Europe or North America. This observation correlates with the particularly high 
incidence of KS observed among the North African Jewish immigrants in Israel 
(Iscovich et al., 1998). Years of education were not associated with an increased risk 
of KSHV seropositivity. The risk of testing KSHV positive was associated with place 
of birth (North Africa or North Europe) and their spouse’s KSHV serostatus 
(Davidovici et a l, 2001).
One previous study from Uganda suggested a higher detection of anti-KSHV 
antibodies in children with HBV infection (Mayama et al., 1998). Our findings in 
both Israel and Brazil confirm that HBV infected individuals have an increased risk 
of testing positive for KSHV (Davidovici et al., 2001; Zago et al., 2000). In Israel 
22%, and in Brazil 25.6% of HBV infected individuals have detectable anti-KSHV 
antibodies, suggesting that KSHV and HBV are transmitted via similar routes in 
these populations or that both have similar risk factors for transmission. In Brazil, the 
majority of the HBV infected individuals were HIV-1 seropositive or attended STD 
clinics, suggesting that both KSHV and HBV are predominantly transmitted during 
sex in this population. Finally, in Brazil KSHV seroprevalence was associated with 
groups at high risk of HIV-1 infection. Homosexual or bisexual males, with or 
without HIV-1 infection, were significantly more likely to test KSHV seropositive 
compared to blood donors, heterosexuals or intravenous drug users (Gambus et al., 
2001; Zago et al., 2000). Sexual orientation is, therefore, a major risk factor 
associated with KSHV infection, and this has been confirmed by other studies in the 
West (Dukers et al., 2001; Goudsmit et al., 2000; Martin et al., 1998; Pauk et al., 
2000).
3.4 CONCLUSION
Overall, I tested over 15,000 sera from different geographical areas and population 
risk groups. Combining the data from several studies, including mine, gives an 
overall picture of the geographical distribution of KSHV in the general healthy
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population. It appears that there are three patterns of KSHV infection (Figure 3.18.): 
Most countries (bars in blue), including the U.K., where the incidence of KS is low, 
show a low KSHV seroprevalence in the general population. The second pattern 
occurs where classic KS is found (bars in green) and the KSHV seroprevalence is 
also higher. Although there are no, or few, reported cases of KS in Greenland and 
Cuba, my preliminary data from Greenland and one study from Cuba (Fernandez et 
al., 2002) show that the prevalence of KSHV is relatively high (11.5% and 16.9% in 
Greenland and Cuba, respectively). These intriguing findings need to be evaluated in 
a more representative number of sera and also confirmed using another serological 
assay. The subtyping of KSHV also needs to be determined in these two countries. 
Finally, the highest KSHV seroprevalence occurs in Africa (bars in red). Regardless 
of the incidence of KS, e.g. low in West and high in East Africa, KSHV infection is 
common throughout Africa.
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Figure 3.18. Schematic representation of KSHV seroprevalence in healthy 
individuals around the world (* studies where I tested all (or part of) the samples by 
IFA and or confirmed by ELISA; n= number of individuals tested). The percentages 
per country are estimated as averages, when more than one publication was 
considered.
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Chapter 4
Development of real-time quantitative PCR (qPCR) for KSHV
4.1 INTRODUCTION
Diagnosis and predicting prognosis are two important issues for a successful clinical 
treatment of any disease. The polymerase chain reaction (PCR) for the amplification 
of specific nucleic acid sequences has revolutionised molecular medicine with an 
outstanding range of applications, one of which is the ability to detect vanishing 
amounts of viral nucleic acid in clinical samples. Recent technological 
improvements, from automated nucleic acid isolation to real-time PCR amplification, 
have contributed to improved monitoring of viral infections, especially in the 
immunocompromised individuals.
In recent years, molecular diagnostics has focused on the detection of pathogens in 
clinical material by introducing commercially standardised assays; however these are 
available for a limited number of viral targets only: Human immunodeficiency virus 
type 1 (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus 
(CMV) and human papillomavirus (HPV) can be tested by commercially available 
detection assays (Niesters, 2002). Thus, academic laboratories have developed their 
own “in house” assays for the detection and, more recently, quantification of many 
viruses including human immunodeficiency virus type 2 (HIV-2) (Schutten et al., 
2000), human T lymphotropic virus (HTLV)-I (Miley et al., 2000), CMV (Guiver et 
al., 2001), human herpesvirus type 6 (HHV-6) (Gautheret-Dejean et al., 2002), 
parvovirus B19 (Aberham et al., 2001) and EBV (Dehee et al., 2001; Lo et al., 1999; 
Righetti et al., 2002). Real-time qPCR assays have also been developed for KSHV 
(Lallemand et al., 2000; Quinlivan et al., 2002; Tedeschi et al., 2001; White and 
Campbell, 2000).
The quantification of viral nucleic acids (DNA or RNA) is primarily performed in 
whole blood, PBMCs or/and plasma (Dehee et al., 2001; Righetti et al., 2002). 
However, when the cause of the disease is known or assumed, specific clinical 
samples are collected to be analysed, e.g. biopsy specimens from nasopharyngeal
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carcinoma are tested for EBV (Lo et al., 1999), cerebrospinal fluid from bone 
marrow transplant patients is analysed for HHV-6 (Gautheret-Dejean et al., 2002) 
and KS or MCD biopsies are analysed for KSHV, especially in HIV infected 
individuals (Boivin et al., 2002).
Real-time PCR has become a valuable tool for an improved, simplified and rapid 
quantification of nucleic acid. Development of a KSHV real-time qPCR would 
contribute in the study of KSHV pathogenesis, the improvement of antiviral 
therapies, the prediction of disease outcome and most significantly the monitoring of 
patient’s progress, particularly in the present era of the AIDS pandemic and HAART.
This chapter presents results on the design and calibration of a qPCR assay for 
KSHV DNA, while the next chapter will present results of its application to clinical 
samples.
4.2 RESULTS
4.2.1 Nucleotide sequence determination
It is important that the nucleotide sequences to be amplified derive only from the 
gene of interest. To achieve this, genomic DNA sequences of human GAPDH and of 
KSHV LANA were retrieved from the GenBank database (NCBI) and imported into 
the programme Primer Express® (Chapter 2, section 2.4.6.1.). After the selection, 
the primers and probes nucleotide sequences were assessed for the possibility of 
cross-priming against each other, other viral sequences and host genes, by searching 
GenBank using the nucleotide BLAST programme for short nearly exact matches 
sequences (www.ncbi.nlm.nih.gov/BLAST>).
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4.2.1.1 Human GAPDH oligonucleotides
The encoding GAPDH DNA sequence (position 1 to 1008) was analysed and the 
selected primers and probe are shown in Figure 4.1. The forward primer is 22 
nucleotides long, the reverse is 26 and the probe is 20 nucleotides long. Based on the 
Primer Express® software both primers anneal at 60°C and the probe at 70°C. The 
amplicon is 78bp long.
5’ forward primer
5’ end l  ATGGGGAAGGTGAAGGTCGGAGTCAACGGATTTGGTCGTATTGG
6 6  T T T T A A C T C T G G T A A A G T G G A T A T T G T T G C C A T C A A T G A C C C C T T C A T T G A C C T C A A C T A C A T G G T T T  
3’ reverse primer (complementary base sequence)
1 3 4  ACAT GTT CCAATAT GATT CCACCCAT GGCAAATT CCAT GGCACCGT CAAGGCT GAGAACGGGAAGCTT GT CA
2 0 6  TCAATGGAAATCCCATCACCATCTTCCAGGAGCGAGATCCCTCCAAAATCAAGTGGGGCGATGCTGGCGCTG  
2 7 8  AGTACGTCGTGGAGTCCACTGGCGTCTTCACCACCATGGAGAAGGCTGGGGCTCATTTGCAGGGGGGAGCCA  
3 5 0  AAAGGGT CAT CAT CT CT GCCCCCT CT GCT GAT GCCCCCAT GTT CGT CAT GGGT GT GAACCAT GAGAAGTAT G 
4 2 2  ACAACAGCCTCAAGATCATCAGCAATGCCTCCTGCACCACCAACTGCTTAGCACCCCTGGCCAAGGTCATCC  
4 9 4  ATGACAACTTTGGTATCGTGGAAGGACTCATGACCACAGTCCATGCCATCACTGCCACCCAGAAGACTGTGG  
5 6 6  AT GGCCCCT CCGGGAAACT GT GGCGT GAT GGCCGCGGGGCT CT CCAGAACAT CAT CCCT GCCT CTACT GGCG 
6 3 8  CT GCCAAGGCT GT GGGCAAGGT CAT CCCT GAGCT GAACGGGAAGCT CACT GGCAT GGCCTT CCGT GT CCCCA 
7 1 0  CTGCCAACGTGTCAGTGGTGGACCTGACCTGCCGTCTAGAAAAACCTGCCAAATATGATGACATCAAGAAGG  
7 8 2  T GGT GAAGCAGGCGT CGGAGGGCCCCCT CAAGGGCAT CCT GGGCTACACT GAGCACCAGGTGGT CT CCT CT G 
8 5 4  A CTT CAACAGCGACACCCACT CCTCCACCTTT GACGCT GGGGCT GGCATT GCCCT CAACGACCACTTT GT CA 
9 2 6  AGCT CATTT CCT GGTAT GACAACGAATTT GGCTACAGCAACAGGGT GGT GGACCT CAT GGCCCACAT GGCCT 
9 9 8  CCAAGGAGTAA 3 ’ e n d
Figure 4.1. Nucleotide sequence of the encoding open reading frame (ORF, 
nucleotide 1 -  1008) of the human GAPDH gene (Accession number M33197). In 
black, the forward and reverse primers selected. The direction of the amplification is 
also shown with the arrows. The framed sequence corresponds to the GAPDH 
Taqman® probe. Nucleotide position is indicated at the left hand side.
GAPDH Probe 
C CGCCTGGTCACCAGGGCTGC
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4.2.1.2 KSHV LANA oligonucleotides
Primers and probe sequences for KSHV LANA were determined after the analysis of 
7 LANA nucleotide sequences published in GenBank. Due to the multiple repeated 
nucleotide sequences that LANA contains, the 7 encoding ORF sequences 
(approximately 3.5kb in length) were aligned with each other, from nucleotide 
position 1 to 1000, i.e. before the repeat sequences, to detect any point mutations 
among these LANA isolates (Figure 4.2.).
M a  j  orityA TG G O SC C C C C C D G A A 'JD C G C C T C A Q G T C C E G A C G Q SQ C A C C C E C G C G C C C T T A JC G A G A G C A A G rT C T A Q G A JfiC G A A A C A Q Q rC 'E C G G A /ftG A .T G T G
I I T  I I I I I
1 0  2 0  3 0  4 0  5 0  6 0  7 0  8 0  9 0  1 0 0
------------------- 1------------------- 1 ■ I - I  ■ I I_____________ I I I_____________ L
A F 1 4  8 8 0  5ATG G G 3CCC C C  CBGAA7GCGCC T  GAGGTC CEGACGCAQCAC C CECGC G C EC TT A K G A G A G G A A G TT GTAGGA2ACGAAACAGGTC 3CCG G A JA G A TG T G  1 0 0  
A F 1 9 2 7  56A T G G 03C C C C C (B G A A T G C G C C T ® G G T C aB G A C G C »G C A C C a3C G C G C E C T T A A :G A G A G C A A C T T C S 'A G G A »C G A A A aV 3G rC 'r:C G G A J»G A T G T G  1 0 0  
A F 3  0  5  6  9  4A T G G <D C C C C C < B G A A T D C aC C T aV 3aT C C E G A C G C »3C A C C a3C aC G a:C T T A A X 3A G A G C A A G T T C 3rA G G A i»C G A A A C A G G rC T :C G G A »G A T G T G  1 0 0  
A F 3 6 0 1 2  QATGGCQCCC C C CEGAA1GCGCC TCAGGTCCEGACGCAGCAC C CECGC G C C C IT  A/CGAGAGCAAGTTCTAQGAJftCGAAACAGCTrC TCCQ GAJAGA TG^E 1 0 0  
U 5 2 0 6 4  A T G G a3C C C C C < B G A A T D C G C C T ® G G rC G 5 G A C G ® G C A C C a3 C G C G a:C T T A X :G A G A G a^A l3 rT < a,A G G A iftC G A A A C A G G T C T :C G G A »G A T G T G  1 0 0  
U 7 5 6 9 8  A TG G 03CC C C C C E G A A T B C aC C T C A G C 7rcaaG A C G ® G C A C C C E C aC G C E C T T A JC G A G A G C A A G rT C T A G G A aA C G A A A aftG G T C T :C G G A »G A .T G T G  1 0 0  
U 9 3 8 7  2  ATG G CECCCCCCBG A A TD CG CCT(A G C?rCG 3G A CG ® G CA CCG 3CQ CG CECTrA A :G A G A G CA A G TTCT'A G G A JA CG A A A <3W 3G TC'ECG G A ^ftG A TG TG  1 0 0
M a j o  r  i  t  V A C C T 13G C G A T < A C C T JC A T C T  ACAACC GCGAAGGAAGCATGXTGCC G A 7TCC C E G A C G G C C G G G  A A T G TG G iC CC C A C  K C T T G C C T A T  ACCAGGAAG  I----------------1---------------- 1-----------------1---------------1 I---------------- 1-----------------1---------------1---------------- r
1 1 0  1 2 0  1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0  1 9 0  2 0 0------------1________I________ I________ I_______ I________I________ I________ I_______ I________ L
A F 1 4  8  8  0  5A C C T T 3G C G A T C A C C T JC A T C T  ACAACC GCGAAGG AAGC A T  C K G C C  G JC T C C  CEGACGGCCGGGA ATGTGG .BCCCCAC JC C T T G C C T A T  ACCAGGAAG 2 0 0  
A F 1 9  2  7  5  6A CCTT3G C G A TC A C C T JC A T C T  ACAACC GCEA A G G A A G CA TCEG CC G JC T C C  G ’EGACGGCCQGG AATGTGGJ'CCCCAC.flCCTTGCCTAT ACCAGGAAG 2 0 0  
A F 3  0  5  6  9  4A CCTT3Q CG A TCA CCTA CA TCT ACAACC GCGAAGGAAGCATG'ICGCC G JC T C C  C E G A C G G C E G G G  A JC G T G G  JC C C C A C  JC C T T G C C T A T  ACCAGGAAG 2 0 0  
A F 3 6 0  1 2 Q ACCTT3QCG A TC A CCTJC A T C T  ACAACCGOGA AGGAA GCATG^CGCCG JCTCCCEG A CG G CCG G G A A TG TG G A ^CCCA CiCCTTG CCTA TA CEA G G A A G  2 0 0  
U 5 2 0 6 4  A C C TT5G C G A TG kC C TA ^TC TA C A A C C G C G A A G G A A G C A TG TEG C C G JC TC cfl'E G A C G G C C G Q G  A JC G T G G  JC C C C A C  JC C T T G C C T A T  A CE® 3GAA G 2 0 0  
0 7 5 6 9 8  ACCTTSQ CG A TCA CCTA CA TCT A A A CCGCGAA GGAAG CA TGX^GCCG J C T C c J  ’EG A CGG aCOQGJU STGTGG JC C C C A C /C C T T G C E T A T  A C E J3G A A G  2 0 0  
U 9 3 8 7 2  A C C T T 3G C G A T C A C C T JC A T C T A C A A C C G a3A A O G M G C A T G T :Q C C G JC T C C G T :G A C G G a= G G G A A rG T G G JC C C C A C A :C T T G < E T A T A < rA G G A A G  2 0 0
2 1 0  2 2 0  2 3 0  2 4 0  2 5 0  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0
------------------- 1----------------  1---------------- 1-------------------- 1. -  —  J-------------------- 1_____________ I_____________ I_____________ I-------------------- L
A F  1 9  2  7  5  6 T C C C A O ^ G T T y V C A T C C G G G C lS C C aV G aaT T G T B IC T A O T C T A C T rT A C C C B T Q Q C T aS C A T T C rT T C A arC G C T C C E G C A A C A C C T T T A C C T C C A  3 0 0
U 7 5 6 9 8  T C C C JC A G T G T T ^A C A 'IC C G G G C T 3C C A G O V T T rG U rC T A G T ^C T A C ,n*rA CC C BTG Q C TCEC A T T C nT T C A C C C G C T C C E G C A A C R C C T T 'IA C C T C C A  3 0 0
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Figure 4.2. Nucleotide sequences alignment of 7 LANA variants between positions 
1 and 1000. Accession numbers are given at the left hand side; majority = concensus 
sequence and it is given on the top of the alignments together with the nucleotide 
measurement scale of 10. Differences are highlighted in red. The alignment was 
performed using the MegAlign programme from the DNASTAR software based on 
the Clustal method.
130
To avoid any sequence variability, the nucleotide sequence between positions 263 
and 809 was selected for analysis in Primer Express®. The primers and Taqman® 
probe are shown in Figure 4.3..The forward primer is 18 nucleotides long, the 
reverse is 24 and the probe is 28 nucleotides long. Again, both primers anneal at 
60°C and the probe anneals at 70°C. The amplicon is 89bp long.
5' end
263 CCATTCCTTCACCCGCTCCCGCAACACCTTTACCTCCACCGGCACTCTTACCCCCCGTAACCACGTC 
330 TTCCTCCCCAATCCCTCCATCCCATCCTGTGTCTCCGGGGACCACGGATACTCATTCTCCATCTCCT
LANA Probe 
TCTTCTCAAAGGCCACCGCTTTCAAGTCJTACA
5* forward primer 
397 GCATTGCCACCCACGCAGTCTCCAGA(|
3' reverse primer (complementary base sequence)
457 GGAAGGCCAGACTCTTCAACACCTATGCGTCCGCCACCCTCGCAGCAGACTACACCTCCACAC
520 TCACCCACGACTCCTCCACCCGAGCCTCCCTCCAAGTCGTCACCAGACTCTTTAGCTCCGTCTACCC 
587 TGCGTAGCCTGAGAAAAAGAAGGCTATCGTCCCCCCAAGGTCCCTCTACACTAAACCCAATATGTCA 
654 GTCGCCCCCAGTCTCTCCCCCTAGATGTGACTTCGCCAACCGTAGTGTGTACCCCCCATGGGCCACA 
721 GAGTCCCCGATCTACGTGGGATCATCCAGCGATGGCGATACTCCGCCACGCCAACCGCCTACATCTC
3' end
788 CCATCTCCATAGGATCATCATC
Figure 4.3. LANA nucleotide sequence analysed with Primer Express®. In black, 
the forward and reverse primers selected. The direction of the amplification is also 
shown with the arrows. The framed sequence corresponds to the selected LANA 
Taqman® probe. Nucleotide position is indicated at the left hand side.
4.2.1.3 Confirmation of amplicons’ identity
The primers were tested for specificity by conventional PCR (Chapter 2, section 
2.4.7.). The PCR products were the correct size and after gel purification, were 
sequenced. Since the length of the products was under 90bp, the traces received were 
not clear. However, analysis in the majority of the sequence showed that both 
GAPDH and LANA gene fragments were amplified. Again, the analysed data were 
imported into the BLAST programme to confirm the nature of the sequences.
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4.2.2 Construction of pcDNA-GAPDH-LANA plasmid as 
standard
4.2.2.1 Insertion of GAPDH PCR product
The GAPDH PCR product was cloned into the pcDNA3.1/V5-His© TOPO® 
expression vector, which is 5.523kb in size (Chapter 2, section 2.4.12.2.) and the 
insertion was confirmed by PCR performed in 6 clones (Chapter 2, section 2.4.7.) 
using the primers originally used to amplify the product (Figure 4.4.).
4.2.2.2 Cloning KSHV LANA
The complete encoding LANA sequence 3.489kb in length (Accession number: 
U52064), was originally cloned in a lentivirus vector pHRCMV-LANAl (Chapter 2, 
section 2.4.12.7.). Using Smal and Xhol restriction enzymes, LANA was cut out by 
double digest and subcloned into the TOPO® multiple cloning site (MCS) between 
EcoRV  and Xhol sites (Figure 4.4.). Both Smal and EcoKV  create blunt ends 
whereas Xhol site creates cohesive ends. Smal cut at nucleotide position between 11 
and 12 of the encoding sequence and, Xhol cut just after the termination codon of 
LANA. The pcDNA3.1/V5-His© TOPO® was digested with EcoKV and Xhol and 
the fragment was cut out (Figure 4.4.).
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Figure 4.4. pcDNA 3.1/V5-His-TOPO® vector summarised map. The contents of the 
vector and the orientation of the fragments are shown in matched colours. The junction 
marker represents the starting position on the plasmid. The magnified area contains the 
multiple cloning site (MCS) to describe the inserts and the restriction sites:
a) The magnified fragment contains the T7 promoter/priming site, the MCS, the V5 
epitope, the polyhistidine tag and the stop codon. GAPDH PCR product (78bp in 
length), with the two alanines created by the PCR amplification, was inserted 
between the two thymines in the vector. The GAPDH double stranded sequence was 
inserted in the orientation shown together with the primers and probe sequences in 
black bold (Figure 4.1.).
b) The restriction enzymes are shown on top of the magnified region. The area between 
the enzymes in font colour blue was cut out from the plasmid and the LANA 
fragment (3.5kb in length) was inserted. The enzymes used to digest the LANA 
fragments out from the lentivirus vector are also shown in font blue at each end of 
the LANA insert. The orientation of the insert is shown with the white arrow and 
one BamUl site (between 820-821) is also indicated on the LANA fragment.
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Figure 4.4.
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4.2.2.3 Confirmation of pcDNA-GAPDH-LANA plasmid creation
Once both fragments were ligated into the vector, the plasmid transformed TOPO 10 
E. coli. The 10 colonies recovered were inoculated into bacteria cultures and DNA 
extracted. Restriction digests were performed to confirm that LANA was inserted in 
the vector (Figure 4.5.). If the insertion was successful, the construct would be 9.1kb 
in length:
5,523 bp pcDNA 3. l/V5-His-TOPO® vector
+ 78 bp GAPDH insert
21 bp EcoRV-XhoI fragment (pcDNA 3.1 /V5-His-TOPO® vector)
+ 3,478 bp LANA insert
The digests were performed with two restriction enzymes, BamHl and Xhol (Figure
4.4.). If LANA was inserted, BamHl would cut once on the vector and once on 
LANA, whereas, Xhol would cut only once creating the following fragments:
BamHl on vector - BamHl on LANA 935 bp
BamHl on LANA -  Xhol on vector 2669 bp
Cut vector 5454 bp
Figure 4.5. shows that 8 out of 10 clones had LANA inserts and, therefore, any of 
them could be used as a standard in the KSHV quantitative assay. One of the 
successful clones was further digested with Xbal and H indlll and the linearised 
fragment (3.628bp in length), present between the two restriction sites (Figure 4.4.), 
was excised, purified (Chapter 2, section 2.4.9.) and used for the creation of a 
standard curve. The concentration of the fragment was determined by measuring the 
O.D. at 260nm (Chapter 2, section 2.4.11.).
4.2.2.4 Preparation of the standard curve
The copy number of the standard (linear fragment) was calculated as mentioned in 
Chapter 2, section 2.4.13.. The standard, which contained one copy of the GAPDH 
PCR product and one copy of the LANA insert, was used to make a series of 10-fold 
dilutions, in UV-treated and filtered H20 , representing 106-103 copies of DNA per
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lOpil and stored at -20°C. The dilutions lOMO1 were prepared at the time of the 
experiment.
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Figure 4.5. Restriction digests with BamHl and Xhol restriction enzymes of 10 
clones (1-10) to confirm insertion of LANA sequence. The lkb DNA ladder 
marker is shown first and the band sizes are indicated on the left hand site. 0, 
uncut DNA from clone #1 obviously contains the LANA insert and must be the 
9058bp circular pcDNA-GAPDH-LANA construct; clones #1-5, #7-8 and #10 
are the successful ones with the LANA insert. The band sizes at the right hand 
site verify the digests: 5580bp from clones #6 and #9 that do not contain the 
LANA insert and the digests were not successful. 5454bp is the cut linearised 
vector, 2669bp is the fragment created by the BamHl (LANA) - Xhol (vector) 
and 935bp is the BamHl (vector) - BamHl (LANA) created fragment.
4.2.3 Real-time qPCR assay optimisation
The optimisation of primers, probes and MgCl2 concentrations was performed using 
DNA extracted from BC-3 cells in the ABI PRISM® 7700 Sequence Detection 
System (Chapter 2, section 2.4.3 ). The Cj- value for each experiment was determined 
by the first cycle number at which fluorescence exceeded the 10 times standard 
deviation of baseline emissions.
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4.2.3.1 Optimising primer concentrations
Primer optimisation for both genes was based on varying forward and reverse primer 
concentrations (Table 4.1.) and keeping the rest of the reagents constant (probes at 
250nM and MgCl2 at 3.5mM). Every combination was ran in triplicate and with the 
PCR thermal cycle conditions described at Chapter 2 Table.
Table 4.1. Primer concentrations used in the primer optimisation matrix. Nine 
different combinations were used for each optimisation (modified from the 
Taqman® Universal PCR Master Mix protocol).
REVERSE
PRIMER
(nM)
FORWARD PRIMER (nM)
100 500 1000
100 100/100 100/500 100/1000
500 500/100 500/500 500/1000
1000 1000/100 1000/500 1000/1000
The optimal performance is achieved by selecting the primer concentrations that 
provide the lowest threshold cycle (C,-) and the highest AR„ for a fixed amount of 
template (Figure 4.6.) and this applies to both GAPDH and LANA primer 
optimisation.
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Figure 4.6. GAPDH primer optimisation results showing amplification plots of all 
nine primer combinations in the primer optimisation matrix in a linear view. Group 
A: combinations that contain at least a 500nM concentration of forward and reverse 
primer. Group B: combinations that contain a lOOnM concentration for forward or 
reverse primer. Group C: lOOnM concentrations of forward and reverse primer.
After repeating the same procedure for LANA primer optimisation, the primer 
concentration for both genes was adjusted at 700nM for the forward and for the 
reverse primers (Figure 4.1.a and b ). The primer optimisation was also repeated in 
the ABI PRISM® 7000 Sequence Detection System using the standard as template 
and the results were identical (data not shown).
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Figure 4.7. Graphic representation of various primer concentrations against the 
threshold cycle (CT) for (a) GAPDH and (b) LANA. The experiments were done in 
triplicate and the standard error of the mean is shown. F = forward and R = reverse in 
nM. The actual CT values per combination are shown on top of each bar.
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4.2.3.2 Optimising probe concentrations
Keeping the optimal primer concentrations constant, the MgCl2 at 3.5mM and the 
same amount of BC-3 DNA template, the probe concentrations varied between 25 
and 225nM (Figure 4.8. a and b). Again, the principle is the same as in the 
optimisation of the primers. The optimal concentration for both GAPDH and LANA 
probes was 200nM.
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Figure 4.8. Graphic representation of various probe concentrations against the 
threshold cycle (Cj) for (a) GAPDH and (b) LANA genes. The experiments were 
done in triplicate and the standard error of the mean is shown. The actual Cx values 
per probe concentration are shown on top of each bar
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The optimisation of probes was also repeated in the ABI PRISM® 7000 Sequence 
Detection System using the standard as template and a newly purchased LANA 
probe from a different supplier (Figure 4.9.). This result shows that the optimum 
concentration of GAPDH probe remained the same, but the optimum concentration 
for LANA probe changed to 150nM.
26.5 
26.0
25.5
25.0
C 245 
T
24.0
23.5
23.0
22.5
Probe concentration (nM)
Figure 4.9. Probe optimisation experiment performed in an ABI PRISM® 7000 
Sequence Detection System. The LANA probe was purchased from another supplier. 
The experiment was done in triplicate for both genes and the standard error of the 
mean is shown.
4.2.3.3 Optimising MgCl2 concentrations
For this experiment, the optimal primers and probes concentrations were used and 
the MgCl2 varied from 1 to 9mM (Figure 4.10. a and b). The best concentration for 
MgCl2 was determined to be 5mM for both genes.
Probe optimisation GAPDH
LANA
25 50 75 100 125 150 175 200 225
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Figure 4.10. Graphic representation of various MgCl2 concentrations against the 
threshold cycle (Cj) for (a) GAPDH and (b) LANA. The experiments were done in 
triplicate and the standard error of the mean is shown. The actual Cj  values per 
MgCl2 concentration are shown on top of each bar
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4.2.4 Assay validation
Every assay performed was considered valid only if the correlation coefficient, R2,
for the standard curves was >0.98 and the slope values for the regression line ranged 
from -3.3 to -3.9, i.e. the efficiency of the PCR reaction was at least 80% (efficiency 
= 10( l/slopc) -  1 x 100) (Klein et a l, 1999).
4.2.4.1 Linear range
To study whether there is, and what is the degree of, an association between copy
number and Cp value, the correlation coefficient was calculated. The quantitative 
standard (linear fragment, section 4.2.2.4.) enabled real-time quantitative 
measurements over a wide linear range from 10 to 106 copies per PCR reaction 
(Figure 4.11. a and b). Five replicates of each standard dilution was tested and 
quantitative test results were obtained for each dilution. The results indicate that 
there is a good correlation (Pearson’s r) between log10 of input copy number and the 
mean Cp values and that the linear range of the assay is 6 orders of magnitude. 
Within this range KSHV and GAPDH can be reliably quantified (Figure 4.11.).
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Figure 4.11. Linear range of the assay for (A) GAPDH and (B) LANA showing (a) 
amplification plots and (b) correlation graphs of a dilution series of the standard. 
Serial 10-fold dilutions with 106 to 10 copies were made in H20 .  (a) T h e  
amplification was performed for 45 cycles. Each group of plots indicates the dilution 
of the standard. The threshold was adjusted to 25 times the standard deviation of the 
baseline fluorescence, (b) Each data point represents the mean value of the 5 
replicates per dilution and the error bars indicate the 95% confidence interval of the 
mean. The correlation coefficient, r, is also shown with the p value.
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4.2A.2 Sensitivity
To determine the sensitivity of the assay for both GAPDH and LANA amplification, 
five replicate tests for each control standard dilution was carried out. The standard 
was diluted in distilled H20  from 106 to 1 copies per sample. Each sample was 
submitted to the quantitative real-time PCR five times for each dilution. The 
detection rate was 100% for each dilution >10 copies per well and was 40% for 1 
copy per well (Table 4.2.) and that was for both GAPDH and LANA.
Table 4.2. Limit of detection and intra-assay variability of KSHV real-time qPCR. 
Standard (linear fragment) was diluted in H2Oa
Copy number 
of standards
Detection rate (%) 
GAPDH & LANA
Range of CT values 
GAPDH LANA
*CV(%) 
GAPDH LANA
106 100 18.72-18.79 18.15-18.34 0.17 0.43
105 100 21.87-22.03 21.07-21.32 0.30 0.53
104 100 25.30-25.51 24.46-24.75 0.32 0.48
103 100 28.89-29.28 28.09-28.39 0.49 0.43
102 100 32.54-33.12 31.02-31.90 0.75 1.17
101 100 35.66-38.65 34.67-35.90 2.91 1.57
10° 40c 39.75-40.98 36.73-37.51 2.15 1.49
a Measurements were repeated 5 times in the same experiment 
b CV, coefficient of variation = standard deviation/average of Cj values X 100 
c Calculated for samples with Cj values of <45
4.2.4.3 Intra-assay precision
Intra-assay reproducibility, the precision under the same operating conditions over a 
short interval of time, was evaluated by testing five times in the same experiment a 
serial 10-fold dilution of the standard (Table 4.2.). The %CV of the CT values ranged 
for GAPDH from 0.17 to 2.91% and for LANA from 0.43% to 1.57% meaning that 
the PCR is highly reproducible within an experiment (Table 4.2.). Figure 4.12. shows 
a regression analysis of the standard curve plots for GAPDH and LANA from the 
quantified standard with observed correlations R2 higher than 0.99. The slopes of the 
standard curves were -3.636 for GAPDH and -3.415 for LANA. These
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measurements demonstrate that the amplification efficiency for GAPDH is ~88.35% 
and for ~96.28% LANA (Figure 4.12.).
(a)
(b)
45.00
40.00
35.00A
2  30.00
*  25.00
U 20.00 
■o
|  15.00
wi
£  io .o o  £
H 5.00 
0.00 
-5.00
10*2 10*3
S tartin g
10* 4 
Quantity
10*5 10*6
45.00
40.00
35.00
g  30.00
Z 25.00 
*
« 20.00 2
•  15.00w
£ 10.00 n
H 5.00 
0.00 
-5 .00
10*2 10*3
S tartin g
10* 4 
Q uantity
1 0*5 10*7
Unknowns
Standards
S lo p e : -3.636
Y -In tercep t: 40.235
C orrelation 0.994 
C oeff:
Unknowns
Standards
-3.415
38.462
0.997
S lope:
Y- In te r c e p t:
C orrelation
C oeff:
Figure 4.12. Standard curves (blue lines; regression lines) for (a) GAPDH and (b) 
LANA showing amplification by Taqman® KSHV qPCR of a dilution series of the 
standard 106 to 101. For each data point (black spots) five replicates were done and 
plotted against the Cj cycle. Serial 10-fold dilutions with 106 to 10 copies were made 
in H20 . The correlation coefficient R2, the slope and the y-intercept (the Q  cycle 
where the 1 copy would be detectable) values are also indicated for each case.
4.2.4.4 Inter-assay precision
Inter-assay precision expresses the variation among different experiments. To 
estimate the inter-experimental variability 10-fold dilutions from 10 to 106 of the
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same original stock of the standard was tested in three different experiments. The 
%CV of the CT values was less than 2% for each dilution for these experiments 
indicating that the assay is highly reproducible when performed independently for 
both GAPDH and LANA detection (Figure 4.13.). In addition, the R2 values were 
repeatedly higher than 0.998 and the slopes of the regression lines were greater than 
-3.7, indicating a consistently high amplification efficiency (greater than 88%) 
(Figure 4.13.).
4.2.5 Analysis of biological samples
In addition to the conditions mentioned at section 4.2.4, all DNA samples extracted 
from biological material were tested neat and diluted 1:10 to verify the absence of 
inhibitors.
4.2.5.1 Cell-associated viral load
For the quantification of intracellular KSHV copy number, the assay was accepted 
only when at least 10,000 cells were analysed and that was verified measuring the 
GAPDH copy number. The normalised value of the KSHV load was calculated as 
(KSHV average copy number/GAPDH average copy number) x 2 x 105 and 
expressed as KSHV copies per 105 PBMCs.
Various KSHV non-infected and infected cell lines were subjected to real-time 
qPCR. PCR was performed on DNA extracted from KSHV-seronegative healthy 
laboratory personnel’s PBMCs, and from Ramos (uninfected), Raji (EBV) and Daudi 
(EBV) cell lines. In all cases, there was no amplification for KSHV. However, when 
the BC-3 KSHV infected cell line was assayed in at least two different experiments 
in duplicate, the average viral load was 60 copies per cell, which is in agreement 
with previous studies (O'Donovan et al., 2001).
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Figure 4.13. Inter-experimental variability of (a) GAPDH and (b) LANA by real­
time qPCR for KSHV detection. The jc-axis indicates the Log10 input number of 
copies and the y-axis indicates the threshold cycle (Q ). The threshold of the 
fluorescence was adjusted to 25 times the standard deviation of the baseline 
fluorescence for all 3 independent experiments. A serial 10-fold dilution of the 
standard in H20  was tested five times in the three independent experiments. The 
equivalent copy number ranged from 106 to 101. Each matched coloured symbol 
corresponds to the mean Q  value (5 replicates) for one dilution in one independent 
assay. The solid line corresponds to linear regression analysis. The coefficients of 
variation CV among the three separate experiments are represented in percentage 
above the symbols for each dilution.
The performance of real-time qPCR for the quantification of cell-associated KSHV 
DNA was also evaluated by serial dilution of latently infected BC-3 cells into
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PBMCs from a KSHV-seronegative healthy donor. 5X105 BC-3 cells were mixed 
with equal number of PBMCs and 10-fold serial dilutions of BC-3 were performed in 
the PBMCs. At each dilution the total amount of cells was approximately IX106. 
DNA was extracted from six 10-fold dilutions of BC-3 cells in PBMCs, starting from 
4.5X105 up to 4.5 BC-3 cells per dilution, and real-time qPCR analysis was 
performed on duplicate samples. To verify that there were no inhibitors that could 
affect the amplification, every sample was also diluted at 1/10 in H20. Table 4.3. 
shows the KSHV copy number of input DNA from the theoretical number of BC-3 
infected cells per reaction that could be detected and quantified over a range of 
infected cell number (Table 4.3.). It is clear from the DNA dilutions that the presence 
of human DNA from the PBMCs in the DNA samples did not affect the performance 
of this amplification (Table 4.3.).
Table 4.3. Quantification of KSHV DNA in PBMCs. Latently infected BC-3 cells 
were diluted in PBMCs from a KSHV-seronegative donor. Six serial 10-fold BC-3 
dilutions in PBMCs were performed and DNA was extracted from the cell mix.
Theoretical number of 
BC-3 cells per reaction*
Experimental mean 
KSHV copy number*
Experimental mean KSHV 
copy number (DNA dil. 1/10)
45000 1642863 186264
4500 184671 16172
450 19629 1860
45 2998 290
4.5 269 30
0.45 29 10
* Deduced number of BC-3 cells from the initial count of cells
* Mean copy number determined in three independent experiments.
4.2.52  Cell-free associated viral load
DNA extracted from plasma samples from 10 healthy laboratory personnel were 
subjected to real-time qPCR. No KSHV amplification was observed in these 
samples. To address whether the DNA extraction and quantification methods are 
accurate, DNA was extracted twice from plasma samples, derived from a healthy
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blood donor, that contained from 5 to 5x10s copies serial ten-fold dilutions of the 
standard for each PCR reaction. The assay was performed in duplicate and in two 
independent experiments for each extraction, and the coefficient of variation between 
the two extractions was R2 =0.9181 (Table 4.4.).
Table 4.4. Quantification of standard serially diluted in plasma from a KSHV 
seronegative donor. Six aliquots of 400/ri plasma were prepared, 5/<g of salmon 
sperm DNA was added (as a DNA carrier) in each aliquot and 8xl06 copies of 
fragments was added in the first aliquot of plasma. Serial ten-fold dilutions were 
prepared, each of the plasma dilutions were divided into two tubes (200/ri each), 
DNA was extracted and eluted in 80/ri dH20. 10/d DNA was used per reaction
Theoretical input and 
expected copy number of 
standard per reaction*
Extraction 1 
Experimental mean 
standard copy number*
Extraction 2 
Experimental mean 
standard copy number*
500000 245312 202951
50000 19054 19223
5000 1968 1961
500 402 523
50 62 109
5 16 6
* If the output DNA amount was 100% recovered aliter the DNA extractions
* Mean copy number determined in two independent experiments
The amount of standard DNA present in the purified preparations was determined by 
quantitative real-time qPCR and compared to the expected amount if recovery was 
100% (Figure 4.14.). The figure shows comparison between the regression analyses 
of the two extractions (pink and yellow symbols) with that of the standard dilutions 
in dH20  (blue symbols). Quantification of standard copies in plasma was efficiently 
determined down to 50 copies per reaction (error bars, 90% confidence interval). 
However, only one of the extractions was good enough for efficient quantification of 
the 5 copies (yellow symbols).
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Figure 4.14. Regression analysis of the input serial ten-fold DNA dilutions of the 
standard in H20  (blue symbols, 5xl05 to 5 copies) compared to the output serial ten­
fold DNA dilution of the standard in plasma from a KSHV seronegative individual 
(average of two independent experiments). DNA was extracted from two different 
sets of standard dilutions in plasma; extraction 1 (pink symbols) and extraction 2 
(yellow symbols). The error bars in the input serial ten-fold DNA standard dilutions 
in H20  indicate a 90% confidence interval.
4.3 DISCUSSION
The aim of this chapter was to design and optimise a quantitative PCR-based assay 
suitable for absolute quantification of the KSHV viral load in PBMCs, plasma, 
ascitic fluid and other human tissues or secretions. Real-time qPCR is a technique 
that provides a rapid and accurate quantification of PCR products. Specificity, 
sensitivity and reproducibility are the most important qualitative characteristics of 
applied molecular diagnostics in clinical science. All steps, in such an assay design, 
have to be properly optimised and tested for a quality control.
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The initial step for the development of this assay was to choose the genes of interest. 
Human GAPDH was used as the endogenous reference to normalise the variations 
due to differences in PBMC number or DNA extraction techniques. KSHV LANA, 
encoded by ORF73, was chosen to be the target viral gene. It has been shown that 
ORF73 is one of the most conserved sequences in the KSHV genome and the only 
genetic variations are located in the repeat region 2 of the internal domain (Zhang et 
al., 2000). Furthermore, ORF73 has no sequence similarity to another known human 
virus or to a cellular gene.
The next step was to prepare the standard, a DNA fragment at a known copy number, 
containing one copy of GAPDH and LANA DNA sequences. Simultaneous 
quantification of a cellular and a viral gene in a real-time qPCR assay has been 
previously reported for KSHV and EBV (Dehee et al., 2001; Lallemand et al., 2000). 
The 60 KSHV DNA copies per BC-3 cell calculated was in agreement with previous 
findings (O'Donovan et al., 2001) and helped to validate the accuracy of my assay.
The optimisation of primers, probes and MgCl2 concentration in the qPCR followed. 
It is showed that the optimal probe concentration varied when prepared from a 
different supplier (Figure 4.9.). The concentration of the probes (and primers and 
MgCl2) has to be optimal for the assay to reach the maximum sensitivity of detection.
Testing several dilution series of a standard control revealed that the assay is linear 
over 6 orders of magnitude (Figure 4.11.). Within this range, the assay reliably 
quantifies samples containing human genomic and KSHV viral DNA. The lowest 
detection and quantification level was 10 copies with 100% sensitivity (Table 4.2.). 
Less than 10 copies were also detectable but not in all amplifications. The real-time 
qPCR for KSHV was found to be remarkably reproducible for the standard 
measurements, in both intra- and inter-assays, with %CV of Cp values lower than 3 
and 2% respectively (Table 4.2. and Figure 4.13.). In all amplifications the 
coefficient of variation was giving a value of >0.98, indicating a very good 
correlation between copy number and threshold cycle.
Assay specificity was also verified by analysing DNA extracted from cell lines not 
infected by KSHV, and plasma samples from KSHV-seronegative healthy blood
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donors. KSHV was not amplified in any of these cases; however, it is worth pointing 
out that when these samples were repeatedly tested by real-time qPCR, occasional 
increases of fluorescence were measured after 40 cycles of amplification. This means 
that an insignificant amount of copy number (<1 copy) was detected in the DNA 
template, which of course is outside the limit of detection and, therefore, is 
considered undetermined.
The assay reproducibility, including the DNA extraction step, was also evaluated on 
PBMCs and plasma samples. BC-3 cells were titrated in PBMCs and KSHV was 
detectable even when DNA was extracted from PBMCs that theoretically contained 
1 BC-3 cell (Table 4.3.). Since one BC-3 cell contains approximately 60 copies of 
KSHV DNA, the quantification of KSHV in the serial dilutions of BC-3 in PBMCs 
from a seronegative individual appeared accurate (Table 4.3.). Ten-fold dilutions of 
the DNA samples from the PBMCs/BC-3 mix also shows that inhibitors were not 
present in the samples, since there is a linear decrease of the detectable KSHV copy 
number in these samples. If inhibitors were present, the DNA extraction would be 
repeated.
The assay was also evaluated to determine cell-free associated KSHV viral load. 
Standard was serially 10-fold diluted in plasma from a KSHV seronegative healthy 
individual and DNA was extracted from two sets of plasma aliquots. The standard 
copy number was determined to be similar in both sets of extractions with a good 
correlation, R2=0.9787 (Table 4.4.). However, when compared to the expected 
values, if DNA recovery was 100%, then the determined copy number was almost 
2.5 times lesqthan that expected in the first 3 dilutions and almost twice as much for 
the last two dilutions (50 and 5 copies) (Table 4.4.). I conclude that I can confidently 
estimate the viral load in plasma to 50 copies within 90% confidence interval (Figure 
4.14.). Detection of 5-50 copies is possible, however further optimisation will have 
to be done for this to be accurately reproducible.
The results indicate that a real-time qPCR assay that combines quantification of 
KSHV and the human GAPDH gene is a sensitive and specific tool for measuring 
KSHV viral load. This assay allows us to quantify the KSHV copy number in KSHV 
infected cells, PBMCs, plasma and other human tissues or secretions. The sensitivity
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and linear range of the developed real-time qPCR assay is similar to those of 
previously described real-time quantitative qPCR KSHV DNA assays (Lallemand et 
al., 2000; White and Campbell, 2000) and quantitative competitive PCR assays 
(Boivin et al., 1999; Lock et al., 1997). Given that this technique allows cellular and 
viral quantification without time-consuming post-PCR analysis and possible cross­
contamination, this assay could be of use in large-scale clinical investigations. 
Clinical application of this assay is described in Chapter 5.
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CHAPTER 5
HAART EFFECTS ON 
ANTI-KSHV IMMUNE RESPONSES 
AND ON KSHV LOAD
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Chapter 5
HAART effects on anti-KSHY immune responses and 
on KSHV load 
5.1 INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is the outcome of the battle between 
human immunodeficiency virus (HIV) infection and host immune defensive 
mechanisms. AIDS is characterised by a disrupted immune system and therefore 
susceptibility to infection with opportunistic pathogens or the occurrence of 
malignancies caused by viruses other than HIV- 1[HIV). The introduction of more 
effective therapies to treat HIV infection in developed countries has led to a decline 
in the incidence of AIDS-associated neoplasms and death, while the life expectancy 
of HIV infected individuals has also been extended (Hogg et al., 1998; International 
Collaboration on HTV and Cancer, 2000; Palella et al., 1998; Pomerantz and Horn, 
2003).
5.1.1 The natural course of HIV infection
HIV primarily infects CD4+ T helper lymphocytes (CD4 cells) and macrophages, 
establishes chronic infection and is never fully cleared by the immune system 
(Stevenson, 2003; Wyatt and Sodroski, 1998). After primary infection, HIV copy 
number increases in the peripheral blood and adaptive immune responses are elicited 
leading to seroconversion (Figure 5.1.). Viral dissemination is controlled by 
activated CD8+ cytotoxic T lymphocytes (CTL), that not only inhibit viral spreading 
but also kill viral infected cells (Letvin and Walker, 2003; McMichael and Rowland- 
Jones, 2001). As HIV replicates, mutations occur that allow variants to emerge that 
can escape antibody, CTL recognition and antibody neutralisation (Klenerman et al., 
2002; Price et al., 1997; Richman et al., 2003; Wei et al., 2003). During the course 
of infection, the number of CD4+ T cells declines significantly, leading to an 
overwhelming immunosuppression, increased susceptibility to opportunistic 
infections and eventually death. Without treatment, most HTV-infected individuals 
will progress to AIDS and death within 10-15 years after primary infection.
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Figure 5.1. Relative immune responses to HIV. Env = HIV Envelope protein; CTL = 
Cytotoxic T lymphocytes; p24 = HIV protein (Adapted from Weiss, 1993)
5.1.2 Highly active antiretroviral therapy (HAART)
5.1.2.1 Types of antiretrovirals
HAART, a cocktail of 3 or more antiretroviral drugs, is widely used by HIV-infected 
individuals in North America, Europe and Australia since 1997, although 
monotherapy (zidovudine, AZT) existed since 1987. The anti-retroviral agents for 
HIV are divided into four groups (Pomerantz and Horn, 2003):
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) or “non-nucleoside” 
inhibitors. They stop HIV production by binding directly onto reverse 
transcriptase and preventing the conversion of RNA to DNA.
• Nucleoside analogues (NRTIs). They were the first effective class of anti­
retroviral drugs. They act by incorporating themselves into the DNA of the virus, 
thereby inhibiting the reverse transcription from RNA to DNA. Therefore, the 
resulting DNA is incomplete and not able to create new virus.
• Protease inhibitors (PIsT These drugs work at the last stage of HIV reproduction
cycle. They prevent the virus from being successfully assembled and released 
from the infected cell.
• Fusion/entrv inhibitors. A new class of agents that prevents HIV entry. These
drugs target the CD4 binding, the chemokine receptor (CCR5 or CXCR4)
binding and the membrane fusion stages of viral entry.
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5.1.2.2 Effectiveness of HAART
HIV-induced immune deficiency is both qualitative and quantitative and is 
characterised by a progressive decrease in circulating CD4 cells, functional 
impairment of the remaining CD4 cells and defects in the function of other 
lymphocytes. In 1997, several studies showed that combination therapies of NRTIs 
with Pis dramatically suppress HIV RNA plasma levels, lead to restoration of 
immune function by increasing the CD4 cell number, and delay progression to AIDS 
in HIV-infected individuals (Gulick et al., 1997; Hammer et al., 1997). Combination 
therapies of triple NRTIs, or two NRTIs and one NNRTI, have been introduced, and 
trials have demonstrated that they are equally effective (Staszewski et al., 1999; 
Staszewski et al., 2001).
The efficacy of these combinations is, however, limited by the poor tolerability, 
metabolic toxic effects, drug interactions and incomplete adherence (to take the 
treatment exactly as prescribed) due to the complexity of dosing regimens (Benn et 
al., 2001). As a result, drug resistant HIV strains appear which are less susceptible to 
the effects of one or more of these drugs, leading to treatment failure, HIV load 
rebound and poor prognosis (Little et al., 2002).
Suppression of HIV replication results in significant restoration of the immune 
responses therefore decreased morbidity and mortality. However, HIV infected 
individuals respond to HAART in different ways (Lederman and Valdez, 2000). At 
present, the number of circulating CD4 cells in HIV infected individuals is the most 
useful index of immunocompetence and used to predict development of opportunistic 
infections or progression to AIDS (Casari et al., 1999; Lederman and Valdez, 2000). 
There are still no straightforward guidelines on what the optimum time is for starting 
which and how long for, an antiretroviral combination therapy (Egger et al., 2002; 
Lederman and Valdez, 2000).
5.1.2.3 AIDS-associated cancers and HAART
Malignancies associated with AIDS are caused by common viruses (Table 5.1.)
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(Boshoff and Weiss, 2002). KS, high-grade B-cell NHL and invasive cervical cancer 
are the established AIDS-defining neoplasms. HIV-induced immunosuppression and 
immunological failure to control these viruses may contribute to these malignancies 
(Frisch et al., 2001; Goedert et al., 1998). During the 1980s, the incidence rates of 
|KS and NHL were increased over 100-fold among patients with AIDS in the 
USA (Goedert et al., 1998). Several epidemiological studies have demonstrated that 
since the introduction of the highly active anti-retroviral therapy (HAART), the 
incidences of KS and NHL, particularly CNS lymphomas, have decreased. However, 
the risk of NHL is still high among patients with AIDS, displaying incidence rates 
that occasionally exceed those of KS (Figure 5.2.) (International Collaboration on 
HIV and Cancer, 2000; Jacobson et al., 1999; Jones et al., 2000; Ledergerber et al., 
1999).
Table 5.1. Viruses associated with AIDS-related cancers
CANCER TYPE CAUSE OR CO-FACTOR*
Kaposi’s sarcoma (KS) KSHV
Non-Hodgkin’s lymphoma (NHL) KSHV and EBV
Hodgkin’s disease (HD)
Central nervous system (CNS) lymphoma
EBV
Oropharyngeal squamous cell carcinoma EBV and HPV
Cervical squamous carcinoma 
Anal squamous carcinoma 
Conjunctival squamous carcinoma (in 
Africa)
HPV
Liver cancer HBV, HCV
* KSHV, Kaposi’s sarcoma-associated herpesvirus; EBV, Epstein-Barr virus; HPV, 
human papilloma virus; HBV, hepatitis B virus; HCV, hepatitis C virus
However, HAART has not only contributed to the decrease in the incidences of 
AIDS-associated malignancies; most HIV infected individuals with AIDS-KS 
completely resolve their KS lesions within a year of initiation of therapy and in as 
little as 2 months (Lebbe et al., 1998). Studies have demonstrated CD8+ CTL 
responses against latent and lytic KSHV antigens and specific HLA class I-restricted
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epitopes, suggesting that KSHV CD8+ T cell responses might also play their role in 
the resolution of KS (Brander et al., 2001; Micheletti et al., 2002; Osman et al., 
1999; Stebbing et al., 2003; Stockier et al., 1999; Wang et al., 2000; Wang et al., 
2001; Wang et al., 2002; W ilkinson et al., 2002). However, there is no clear 
evidence on whether CD8+ CTLs contribute to the resolution of KS and, most 
crucially, what is the interplay between HIV and KSHV in the course of HAART 
treatment
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In this chapter, I investigate the long-term (>24 months) and short-term (within 12 
months) effects of HAART on KSHV replication in peripheral blood as well as 
plasma viraemia using the real-time qPCR described in Chapter 4. Antibody 
responses against latent (LANA) and lytic (K8.1) proteins are measured using IFA- 
LANA and ELISA K8.1. Finally, CD8+ T cell responses against well-defined 
KSHV-specific cytotoxic T cell (CTL) epitopes are determined using IFN-y release 
ELISpot assay.
5.2 RESULTS
5.2.1 Patient characteristics at baseline
Twenty-seven HIV-infected homosexual males (median age, 35; range, 27-55yrs) 
were recruited at the Bloomsbury clinic at University College London Hospital 
(UCLH) in 1999. Seventeen adhered to this study for the first 12 months, whereas 
only 8 continued until the end of the study (>24 months) (Table 5.2). Four patients 
provided only one sample (the baseline), 5 provided between two and 5 samples and 
18 provided between 6 and 10 blood samples. The median follow-up period was 23 
months (range, 0-38), and patients visited the clinic every three months from the start 
of HAART. The HAART regimen consisted of a triple-drug combination, including 
two nucleoside analogue reverse transcriptase inhibitors and one protease inhibitor or 
a further non-nucleoside reverse transcriptase inhibitor.
The baseline patients’ characteristics (prior to initiation of HAART) are shown in 
Table 5.2.. Six patients were given PI and 21 were given NNRTI after the baseline 
sample was drawn. The only statistically significant difference on the specific 
characteristics was the baseline median CD4+ T cell count between patients with 
(n=4) and without KS (n=23) (p=0.03) (Table 5.2.).
5.2.2 Anti-KSHV antibody responses and KSHV DNA detection 
at baseline
Twenty out of 27 (74.07%) individuals had detectable anti-latent (LANA) antibodies 
prior to HAART (Table 5.2.) (Bourboulia et al., 2003). In contrast, only 12/27
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Table 5.2. Baseline characteristics
ALL N=27 KS + KS- PI NNRTI
n=4 n=23 n=6 n=21
No of samples provided for KSHV analysis 1 4 (14.81) 0 4 (17.39) 1 (16.67) 3 (14.29)
n (%) 2-5 5 (18.52) 1(25) 4 (17.39) 2 (33.33) 3 (14.29)
6-10 18 (66.67) 3(75) 15 (65.22) 3(50) 15(71.43)
Age, years, median (range) 35 (27-55) 41 (2942) 34(27-55) 35 (29-55) 36(27-46)
KSHV anti-LANA antibody positive, n (%) 20 (74.07) 3(75) 17 (73.91) 4 (66.67) 16(76.19)
KSHV anti-LANA titre, median (range) 1600 (0-204800) 6450 (0-204800) 1600(0-204800) 450 (0-6400) 1600 (0-204800)
KSHV anti-K8.1 ELISA antibody positive, n (%) 12 (44.44) 3(75) 9(39.13) 2 (33.33) 10 (47.62)
KSHV anti-K8.1 ELISA O.D./cut off, median (range)* 0.86 (0.23-4.89) 1.35 (0.764.89) 0.82 (0.23-2.47) 0.84 (0.23-1.29) 0.89 (0.314.89)
KSHV DNA copies/10 ^  cells, detectable, n(%) 14 (51.85) 3(75) 11(47.83) 4 (66.67) 10 (47.62)
KSHV DNA copies/10^ cells, median (range)** 42 (154923) 17 (16-60) 57 (154923) 22 (15-181) 59(16-4923)
KSHV DNA copies/ml plasma, detectable, n(%) 7 (25.93) 1(25) 6 (26.09) 2 (33.33) 5 (23.81)
KSHV DNA copies/ml plasma, median (range)** 6143 (948-48381) 948 6686 (3924-48381) 5576 (3924-7228) 6143 (948-48381)
CD4 cell count (cell s/mm3 ), median (range) 200 (10-350) 65 (10-90) 215 (20-350) 95(10-270) 215 (20-350)
CDS cell count (cells/mm3 ), median (range) 925 (330-2840) 910 (730-1470) 925 (330-2840) 1150 (540-2840) 925 (330-2170)
CD3 cell count (cells/mm3 ), median (range) 1230 (370-3100) 985 (780-1640) 1240(370-3100) 1275 (580-3100) 1205 (370-2610)
HIV RNA copies/ml plasma, median (range) 155050 (4100-358100) 193850 (33000-231200) 124100 (4100-358100) 124700(33000-358100) 155050 (4100-308900)
* cutoff = the average O.D. from 20 blood donors plus 3 times the standard deviation
** if detectable
KS: Kaposi’s sarcoma 
PI: Protease inhibitors
NNRTI: Non-nucleoside reverse transcriptase inhibitors
(44.44%
) 
had 
detectable 
anti-lytic 
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antigens.
KSHV load was determined in both PBMCs and plasma (Table 5.2.). Before 
HAART, 14/27 (51.85%) showed detectable KSHV DNA in PBMCs, whereas only 
7/27 (25.93%) had detectable KSHV load in plasma. Patients with KS had less 
median number of KSHV copies in PBMCs (17 copies/105 cells) and plasma (948 
copies/ml, one individual) compared to those without KS (57 copies/105 cells and 
6686 copies/ml plasma, respectively), although the number of patients with KS (n=4) 
is too small to suggest a significant finding.
5.2.3 Anti-KSHV antibody responses during HAART
The effects of HAART on anti-KSHV antibody responses were determined by 
studying changes in the percentage of positive samples and in the antibody levels 
(titres and ODs) annually and over 24 months on HAART (Table 5.3.) (Bourboulia 
et al., 2003). Overall, no significant changes and specific trends were observed for 
the anti-LANA antibody responses after the initiation of HAART until the end of the 
study. However, the percentage of samples positive for anti-K8.1 antibodies 
increased with time (Table 5.3.). The levels of anti-K8.1 lytic antibodies had an 
increasing trend only during the first 12 months of HAART, but significantly 
declined after that.
5.2.4 KSHV DNA detection in PBMCs and plasma during 
HAART
To investigate whether HAART has an effect on KSHV viraemia, KSHV DNA load 
was measured in all PBMCs and plasma samples provided after baseline (Table 5.4.) 
(Bourboulia et al., 2003). When I examined the effect of HAART at all time points 
analysed versus the baseline, there was a decrease of KSHV detectability in PBMCs 
samples but this was not significant (odds ratio 0.62; 95% confidence interval Cl 
0.25-1.53). However, a significant decreasing trend of KSHV DNA in PBMCs was 
observed during the second year on HAART and thereafter, when this was compared 
with the first 12 months on therapy (odds ratio 0.40; 95% Cl 0.26-0.63) (Table 5.4.).
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Table 5.3. KSHV antibody measurements.
C.I., confidence interval; OD, optical density; OR, odds ratio
Measure Time
(months)
Distribution
Effect o f therapy, 
all times vs baseline
Effect o f  therapy,  
trend over time, 
increase o f  1 year
Anti-LANA 
antibody litres Initial 1-6 
7-12 
13 -24 
>24
<100 neg
7 (26.0) 
11 (33.3) 
6 (18.8) 
15 (30.0) 
2(14.3)
k-fold dilution , n (%) 
200-1(00 3200-25600
9 (3 3 3  ) 9(33.3) 
6(18 .2 ) 1 2 (3 6 .4 )  
9(28 .1 ) 8(25 .0) 
6(12 .0 ) 19(38.0) 
5(35.7) 5(35.7)
51200 +
2 (7.4)
4 (12.1)
9 (28.1)
10 (20. 0) 
2 (14.3)
Proportional OR* (95 %C I) 
1.48 (0.82 -  2.68)
Proportional OR * (95 % C l) 
1.16 (0.89 -  1.50)
K 8.10D Initial
1-6
7-12
13-24
>24
Positive responses, Mean log10
rln (%) K8.1 OD value (s. d.) 
12/27(44.4) -0.06 ( 0.28) 
16/31(51.61) 0.0 2 (0.30) 
17/32(53.13) 0.0 5 (0.32) 
27/48 (56.25) -0.04 ( 0 .29 ) 
9/14(64.29) 0 .04  (0.23)
Difference in 
mean log10 OD value 
(range)
0.03 (-0.04 -  0.10)
Difference in 
mean log10 OD value 
(range)
-0.04 (-0 .08--0 .01)
* Odds ratio, for each category, of being in one of the higher categories
Table 5.4. KSHV load measurements.
VL, viral load; sd, standard deviation; OR, odds ratio
Measure Time 
(months)
KSHV DNA bad  in 
PBMCs and pbsma
Effect o f  therapy, 
all times vs baseline
Effect o f  therapy, 
trend over time, 
increase o f  1 year
Detectable VL, 
rln (%)
Mean logJ0 VL 
if  detectable (sd)
Detectable vs 
undetectable 
OR (95% Cl)
Difference in 
mean b g 10 VL 
if detectable
Detectable vs 
undetectable 
OR (95% Cl)
Difference in 
mean log10 VL 
if  detectable
Copies per 105 cells 
(detectable >10 copies)
Initial
1-6
7-12
13-24
>24
14/27(51.9) 
18/33(54.6) 
17/32 (53.1) 
14/50(28.0) 
1/14 (7.1)
1.87(0.80) 
1.86(0.56) 
1.70(0.45) 
2.45 (0.93) 
1.83 -
0.62 
(0.25 -1.53)
0.10 
(-0.33 -  0.54)
0.40 
(0.26 -  0.63)
0.24 
(-0.12 -0.60)
Copies per ml plasma 
(detectable >400 copies)
Initial
1-6
7-12
13-24
>24
7/27 (25.9) 
7/33(21.2) 
4/32(12.5) 
3/50(6.0) 
0/14 (0)
3.80(0.52)
3.24(0.32)
2.92(0.19)
3.00(0.19)
0.31 
(0.12 -0.80)
-0.72 
(-1.15 -  -0.29)
0.31 
(0.12 -0.80)
-0.46 
(-0.73 -  -0.19)
KSHV DNA load in plasma was next analysed (Table 5.4.). Both the percentage of 
plasma samples with detectable KSHV load and the amount of virus detected were 
significantly reduced during HAART. Within 12 months only 12.5% of all samples 
had detectable KSHV viraemia compared to 25.9% at baseline, and this percentage 
further decreased (6%) during the second year. KSHV became undetectable in 
plasma after 24 months on HAART. The amount of virus detected in plasma also 
significantly declined, both at all time points and annually, versus baseline mean 
logjQ KSHV load (Table 5.4.).
5.2.5 KSHV-specific CD8+ T cell responses during HAART
To investigate the presence and function of KSHV-specific CD8+ T cells, 4 
previously identified KSHV specific CD8+ HLA A*02 restricted CTL epitopes (9 
amino acids long), derived from 1 latent (K12) and 3 lytic (K8.1, gB and gH 
glycoproteins) antigens, were used to stimulate patients PBMCs from 9 HLA A*02 
and 5 non-A*02 patients, at baseline and during HAART. To detect and assess the 
function of antigen-specific CD8+ T cells, the IFN-y release ELISpot assay was 
used, which shows the number of IFN-y-producing T cells after peptide stimulation. 
None of the non-A*02 patients showed any responses when their PBMCs were 
stimulated with either the K12 or the K8.1 CTL epitopes, at baseline and during 
HAART (Figure 5.3.) (Bourboulia et al., 2003).
To assess the effects of HAART on the KSHV-specific CD8+ T cell responses from 
9 HLA-A*02 patients, the trend of the responses over time was calculated from all 
available measurements (Table 5.5.). Responses to K12 and K8.1 peptides were 
significant when they were compared with those from the non-HLA A*02 patients 
(p=0.007 for K12 and p=0.013 for K8.1 peptides respectively). At baseline, none of 
the 9 HLA A*02 patients had detectable CD8+ T cell responses to the KSHV 
epitopes. In contrast, KSHV-specific CD8+ T cell responses were demonstrated after 
therapy started (Table 5.5.). There was a significantly increasing trend in the 
responses to the K12 epitope (odds ratio 6.94; 95% Cl 2.24 -  21.52), particularly 
during the second year on HAART. Responses against the K8.1 epitope appeared 
early on HAART and were maintained thereafter.
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Figure 5.3. Frequency of K12 (top graph) and K8.1 (bottom graph) peptide- 
responsive CD8+ T cells. PBMCs from 5 non-HLA-A*02 patients were incubated 
with 7.5/<M of the two peptides in ELISpot assays. Each point represents the mean 
number of spots from the 5 patients, whereas the bars represent the mean ± the 
standard error of the mean. Data from each experiment per patient represent the 
average of 2 wells. The jc-axis crosses the y-axis at the minimum number of spots (50 
spots/106 PBMCs) above which the results are considered positive (Chapter 2, 
section. 2.5.6.).
167
Table 5.5. KSHV-specific CD8+ T cell responses in 9 HLA A*02 patients
Peptide Time
(months)
Positive r/n (%) 
(>50 spots/10 6PBMC s)
O.R. (95% Cl) 
trend over time, 
increase 1 year
N = 8
K12 Initial 0/7(0) 6.94
1-6 1/8(12.5) (224 -21.52)
7-12 0/9(0)
13-24 5/16(31.25)
>24 8/9(88.9)
N = 9
K8.1 Initial 0/6(0) 1.65
1-6 2/8(250) (0.94 -292)
7-12 6/10(60.0)
13-24 5/20(25.0)
>24 4/10(40.0)
N = 9
gag Initial 3/9 (33.3) 1.23
1-6 4/11 (36.4) (0.74-2.04)
7-12 2/12 (16.7)
13-24 9/20 (45.0)
>24 3/10 (30.0)
To determine whether the recovery of CD8+ T cell responses against the KSHV 
epitopes K12 and K8.1 represents the effects of HAART on all 9 patients studied, i.e. 
the analysis is not biased towards a few patients that may have provided most of the 
analysed samples, the number of responders to these epitopes was measured at every 
time point (Figure 5.4.). This analysis confirms the previous results (Table 5.5.) that 
recovery of CD8+ T cell responses against KSHV epitopes occurs in most A*02 
patients tested (Table 5.5.). At baseline, no patients demonstrated any CD8+ T cell 
responses against the KSHV epitopes. Within 6 to 12 months, 37.50% had developed 
responses and after 24 months over 70% did. KSHV specific CTL epitopes from gB 
and gH antigens were also tested in a smaller number of patients due to a limited 
number of viable PBMCs. Responses to gB and gH epitopes were very limited and 
appeared late on therapy (Figure 5.4.).
168
ALL KSHV 
PEPTIDES TESTED
Time on HAART (months)
HLA A*02 patients: n° of responded/n° of patients tested (%)
Time follow up 
(months)
ALL KSHV 
PEPTIDES
K12 K8.1 gB gH HIV/Gag
KSHV specific Initial 0/9 (0) 0/7 (0) 0/6 (0) 0/2 (0) 0/5 (0) 3/9 (33.33)
CD8+
T cell responses 1-6 3/8 (37.50) 1/6(16.67) 2/6 (33.33) 0/2 (0) 0/5 (0) 3/8 (37.50)
7-12 3/8 (37.50) 0/6 (0) 3/7 (42.86) 0/1 (0) 0/4 (0) 2/8 (25.00)
13-24 7/9 (77.78) 5/8 (62.50) 3/9 (33.33) 1/2(50.00) 0/5(0) 6/9 (66.67)
>24-38 6/8 (75.00) 6/7 (85.71) 4/8 (50.00) 0/2 (0) 1/4 (25.00) 3/8 (37.50)
Figure 5.4. Longitudinal analysis of ex vivo antiviral CD8+ T cell responses in 9 
HLA A*02 patients before initiation and during HAART. Patients responding to 
KSHV or HIV specific antigenic stimulation are monitored at specific time points 
during therapy. n°, number.
5.2.6 Responses to HIV infection at baseline and during HAART
Prior to HAART, the median HIV RNA load in plasma from all 27 patients was 
155,050 copies/ml (range 4,100-358,100) (Table 5.2.) (Bourboulia et al., 2003). The 
median CD4+ T cell count was 200cells/mm3 (range 10-350) and the median CD8+ 
T cell count was 925cells/mm3 (range 330-2,840). Decrease in HIV RNA levels to
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below detectable level (50copies/ml), paralleled by an increase in CD4+ T cell 
counts, was observed in all patients studied and no individual failed HAART during 
this study.
CD8+ T cell responses to HIV were measured using an immunodominant HLA 
A*02 restricted CTL epitope, associated with chronic HIV infection, to stimulate 
patients PBMCs. Responses to HIV Gag SL9 epitope were demonstrated even prior 
to initiation of HAART. Thirty three per cent of patients tested showed responses to 
the epitope prior to HAART but no definite trend was demonstrated during HAART 
(Table 5.5. and Figure 5.4.).
5.3 DISCUSSION
The aim of this study was to investigate the effects of HAART on KSHV infection, 
in the presence of HIV induced immunosuppression and in association with the 
functionality of the immune system. To explore these parameters, anti-KSHV latent 
and lytic antibody responses were measured using IFA-LANA and ELISA for K8.1 
antigen. KSHV load was determined using real-time qPCR (described in Chapter 4). 
The ELISpot assay was also adapted to detect and quantify KSHV antigen-specific 
CD8+ T cells. ELISpot is sensitive and does not require prior expansion of specific T 
cells (Lalvani et al., 1997).
I first showed a high seroprevalence of KSHV, as measured by IFA-LANA in 
patients without KS (n=23), prior to HAART (Table 5.2.) (Bourboulia et al., 2003). 
Over 73% of the patients in our cohort had detectable anti-LANA antibodies prior to 
therapy and this percentage did not change significantly during treatment. We have 
previously reported a lower seroprevalence rates of KSHV in London, within HIV- 
infected individuals without KS, using the same IFA-LANA; between 1995-1996 
only 31% (12/39) of HIV infected individuals attending an STD clinic in London had 
detectable antibodies to KSHV (Smith et al., 1999), whereas between 1998-1999 the 
rate was 53% (8/15) in HIV infected patients without antiretroviral therapy (Gill et 
al., 2002). The increased KSHV seroprevalence in our study might be a cohort 
effect, since all our patients are homosexual males in central London. However,
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larger seroepidemiological studies have to be conducted to elucidate whether the rise 
of KSHV seroprevalence does not reflect an overall increase of KSHV infection rates 
in the general population in London or in the UK.
Detection of anti-LANA antibodies is primarily used as a marker of an established 
persistent latent KSHV infection. LANA is one of the few viral proteins expressed 
during latency and one of the most immunogenic KSHV antigens. HAART had little 
effect on the detection or titre of the anti-latent KSHV LANA antibodies (Table
5.3.). However, antibody levels have been shown to significantly increase for 
EBNA-1, a functional homologue of LANA, and early antigen (EA) of EBV during 
HAART (O'Sullivan et al., 2002). In particular, EBNA-1 has been correlated with 
immune reconstitution and the control of EBV replication, and decrease of anti- 
EBNA-1 IgG levels have been associated with increased immunosuppression 
(Stevens et al., 2002).
I next show that the anti-lytic KSHV K8.1 antibody responses increased during the 
first 12 months of HAART (Table 5.3.). K8.1 is the most immunogenic envelope 
glycoprotein of KSHV (Chandran et al., 1998). We have previously suggested that 
anti-lytic KSHV antibodies might be more effective in the control of KSHV 
pathogenesis than anti-latent antibodies (Gill et al., 2002). A significant increase of 
anti-lytic antibody levels has also been shown for glycoprotein B of CMV in patients 
early on HAART (Deayton et al., 1999). Although the percentage of samples with 
detectable antibodies against K8.1 increased during HAART, the levels significantly 
started to decline during the second year on therapy. Although this result is difficult 
to interpret, it may suggest a gradual reduction of antigenic stimulation due to 
decreased lytic viral replication and, therefore, decreased number of virions in the 
circulation. The increase of anti-lytic antibody responses during the first 12 months 
on HAART (Table 5.3.) correlates with the decrease in plasma viral load (Table
5.4.), and such anti-KSHV lytic responses may be important in the control of KSHV 
lytic replication.
I next investigated the effects of HAART on KSHV load in PBMCs and plasma. The 
percentage of PBMC samples with detectable virus is similar to previous reports, 
when real-time PCR was used as the detection method (Gill et al., 2002). I showed
that the percentage of PBMC samples with detectable KSHV load significantly 
reduced after 24 months on HAART (Table 5.4.). Moreover, the number of plasma 
samples with detectable KSHV load and viraemia levels significantly decreased
| during the first and second year on HAART, whereas KSHV load in plasma 
became undetectable after 24 months on HAART (Table 5.4.). It is of note that the 
majority of our patients were receiving NNRTI and not PI based triple therapy 
(Table 5.2.). This confirms previous results (Gill et al., 2002), that PI are not 
essential to clear KSHV load, as some had suggested (Blum et al., 1991; Sgadari et 
al., 2002). In addition, I monitored 8 individuals up to 38 months on HAART and 
KSHV DNA was only detected in one PBMC sample (68 copies/10s PBMCs) (Table
5.4.). This shows that HAART can suppress KSHV replication for a prolonged 
period of time, correlating with the decreased incidence of KS development on 
HAART (Beral and Newton, 1998; Jacobson et al., 1999). In contrast, EBV load in 
PBMCs in HIV-infected individuals remains stable and can occasionally increase 
during HAART (Righetti et al., 2002). This could partially explain why the 
incidence of HIV associated NHL declines to a lesser extent than KS (Eltom et al., 
2002; Grulich et al., 2001).
Finally, I studied KSHV CD8+ T cell responses against previously defined HLA 
A*02 specific CTL epitopes (Micheletti et al., 2002; Wang et al., 2002; Wilkinson et 
al., 2002). By measuring IFN-y release I was able to study whether the functionality 
of KSHV-specific CD8+ T cells was improved with HAART. The ELISpot is 
reliably used in the identification and characterisation of CD8+ T cell responses to 
HIV antigens during acute and chronic infection (Goulder et al., 2001), and to EBV 
antigens (Kostense et al., 2002; van Baarle et al., 2001). ELISpot assays are used for 
the evaluation of HAART induced immune restoration, vaccine design against HIV 
(Novitsky et al., 2001) and to EBV antigens for the monitoring of adoptive cellular 
immunotherapy (Yang et al., 2000).
I showed that prior to therapy, none of the 9 HLA A*02 individuals studied showed 
significant CD8+ T cell responses against the known KSHV peptides, whereas such 
responses increased significantly during HAART (Table 5.5 and Figure 5.4). CD8+ 
T cell responses to the lytic KSHV K8.1 epitope appeared earlier on HAART (within
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6 months) and their frequencies increased within 12 months (Table 5.5.). In contrast, 
responses to the latent K12 epitope significantly recover during the second year on 
HAART and the frequencies were significantly increased during HAART (Table 
5.5). Although the number of patients analysed was small, specific responses to gB 
and gH epitopes were almost absent during therapy (Figure 5.4.). However, studies 
on KSHV seropositive non-HIV infected individuals have shown significant 
responses to these epitopes (Micheletti et al., 2002; Wang et al., 2002). My data 
suggest the importance of the CD8+ T cell responses against K12 and K8.1 towards 
KSHV immune recovery. However, responses to one or two specific epitopes do not 
reflect the full repertoire of anti-KSHV immune responses. Therefore, future work 
has to determine whether other KSHV specific epitopes are able to elicit potent 
CD8+ T cell responses and contribute to the restoration of KSHV specific T cells.
Although, HIV A*02-SL9 CD8+ T cell responses have been associated with the 
control of HIV replication during chronic HIV infection (Goulder et al., 2001), 3 
patients had significant gag-specific CD8+ T cell responses at the beginning of 
HAART (Figures 5.4.). Patients in whom gag-specific CD8+ T cell responses were 
detectable, maintained longitudinally these responses and no HIV rebound was 
observed confirming the inverse association between HIV RNA load and these 
responses (Ogg et al., 1999).
In conclusion, I show that HAART promotes long-term KSHV immune 
reconstitution. This was demonstrated by a significant decline of KSHV load in 
PBMCs and plasma, an initial increase of anti-lytic antibodies and a significant 
increase of anti-KSHV-specific CD8+ T cell responses within 12 months on 
HAART. However, prolonged HAART (more than 12 months) is necessary for these 
anti-KSHV effects to be established and maintained.
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Chapter 6 
Discussion
6.1 Highlights of this thesis
In this thesis I have:
>  Conducted seroepidemiological surveys in various countries and showed that 
(Chapter 3):
• KSHV is associated with KS and not with any other cancer studied in South 
Africa
• HTV-1 infection increases the risk of KS
• KSHV prevalence increases with age in South Africa and in Israel
• High KSHV antibody titre increases the risk of having KS in HIV-1 positive 
and negative individuals.
• Of the countries studied, the highest KSHV seroprevalence rates in the general 
healthy population occur in South Africa (blacks, 32%), followed by Israel 
(10%), Spain (6.5%) and Brazil (4.6%)
• Mother-to-child transmission is one of the main routes of acquiring KSHV in 
South Africa and Israel; intrafam ilial transm ission between spouses 
(heterosexual) in Israel and sexual transmission in Spain and Brazil also occur.
• High maternal KSHV antibody titre increases the risk of mother-to-child 
transmission
• KSHV seroprevalence in Israel is associated with place of birth and correlates 
with the KS incidence rates in different Jewish ethnic groups
• KSHV seroprevalence is associated with HBV infection in Israel and Brazil
• Sexual behaviour is associated with KSHV infection in Spain and Brazil
>  Developed a quantitative real-time PCR detection system for KSHV that is 
(Chapter 4):
• Reproducible
• Specific
• Sensitive
• Optimised for KSHV detection in most clinical specimens
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>  Determined the effects of HAART (protease inhibitors and/or NNRTI based 
regimens), in a longitudinal prospective study, on virological and immunological 
variables, and compared the results to baseline (no therapy):
• Anti-KSHV LANA antibody detectability or titres remain unchanged
• Anti-KSHV K8.1 antibody detectability |develops and increases during 
HAART
• KSHV viral load in PBMCs remains detectable over 2 years, but is 
significantly less detectable after 2 years on therapy
• KSHV viral load in plasma is undetectable after 2 years, but is significantly 
less detectable after 1 year on therapy
• Significant recovery of CD8+ T cell responses against a KSHV latent CTL 
epitope (from K12 protein) occurs after 12 months on HAART
• Recovery of CD8+ T cell responses against a KSHV lytic epitope (from K8.1 
protein) occurs from 6 months on therapy
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Figure 6.1. Atlas of (A) KSHV and (B) KS distribution in adults. Coloured 
countries indicate current known (published or preliminary data) of KSHV 
seroprevalence or classic and endemic KS incidence rates in healthy adults. Red fond 
indicates recent data on AIDS-KS incidence rates (range, max-min) in West and East 
Africa. Age-standardised per 100,000 population.
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6.2 KSHV and KS epidemiology
Figure 6.1. reveals how limited our knowledge still is on the global seroprevalence of 
KSHV. Unlike EBV, KSHV is not widespread in the general population and reasons 
for this could include: Co-factors (e.g. environmental) or risk factors (e.g. HIV-1 
infection), genetic susceptibility (e.g. possession of the cellular receptor) and anti­
viral immune responses (e.g. immunosuppression) may all be associated with viral 
infection and pathogenesis.
The clustering of KS and the elevated prevalence of KSHV in specific geographical 
areas may be promoted by environmental co-factors that several case control studies 
have identified, including exposure to volcanic soils or high altitude (Cook- 
Mozaffari et al., 1998; Ziegler et al., 2001), drinking water from rivers (McHardy et 
al., 1984) and malaria (Geddes et al., 1995; Taylor et al., 1972). However, the 
epidemiological map of KS does not provide clear evidence and detailed studies, 
especially in endemic KS regions would elucidate the role of the environment in KS 
pathogenesis and KSHV virulence. Analogies have been sought in the prevalence of 
EBV infection. EBV-associated Burkitt’s lymphoma incidence is dramatically 
increased in areas where malaria occurs in sub-Saharan Africa (Figure 6.2.).
• BL 
M alaria belt
Figure 6.2.
Burkitt’s lymphoma (BL) in Africa
Courtesy of Chris Boshoff
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The increase incidence of KS in East Africa compared to West Africa also suggests 
the presence of co-factors that favour transmission of KSHV without promoting KS 
pathogenesis (Wabinga et al., 2000) (Figure 6.I.B.). Prior to the AIDS epidemic, KS 
was a relatively rare cancer in thejwestand centre of the continent and still remains 
relatively rare in these regions (Bah et al., 2001; Oettle, 1962). Although, this might 
have been explained as a reflection of different KSHV prevalence rates between East 
and West Africa, studies have shown that contemporary seroprevalences of KSHV 
are comparable between these regions (Ariyoshi et al., 1998; Echimane et al., 2000) 
(Figure 6.1.A.). In The Gambia, HIV-2 infection is higher (1.1%) than HIV-1 (0.6%) 
and KS is particularly associated with HIV-1 infection (Ariyoshi et al., 1998; 
O’Donovan et al., 2000). HIV-1 Tat protein, actively secreted from infected cells, 
has been implicated in promoting KS by acting as a mitogenic factor for 
angiogenesis and for KS spindle cell growth (Ensoli et al., 1990). Even though this 
may provide a reasonable explanation for the existing differences of KS distribution, 
other co-factors may also be important but remain to be determined.
Although the HIV-1 pandemic has dramatically affected the incidence of endemic 
KS, the KSHV seroprevalence is comparable between HTV-1 infected and uninfected 
individuals in South Africa (Sitas et al., 1999a) and in other African countries 
studied (He etal., 1998; Olsen etal., 1998; Simpson et al., 1996). This indicates that 
HIV-1 infection is a significant co-factor for KS development, although KSHV 
infection has already existed prior to the epidemic in Africa. The main role of HIV-1 
could be to induce immunosuppresion that leads to the reactivation of KSHV. This is 
similar to the proposed model of EBV-driven lymphomas in HIV-1 infected 
individuals (Gaidano et al., 2000). The KSHV seroprevalence in Africa, prior to the 
HIV-1 epidemic, has not yet been reported. In contrast, in developed Western 
countries KS develops more often in men who are infected by KSHV after infection 
with HIV-1 than in those already infected with KSHV who then acquire HIV-1 
(Goudsmit et al., 2000). Therefore, HIV-l-induced immunosuppression may increase 
the pathogenic effects of KSHV after primary infection.
Anti-retroviral therapy may partially promote immune reconstitution, not only for 
HIV-1, but also against KSHV infection. However, in endemic areas of KS, where 
the use of HAART is almost non-existent, HIV-1 associated immune deficiency
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would encourage viral transmission, replication and pathogenesis. Innate and cellular 
immune responses would not be able to cope with the viral infection and immune 
evasion would easily occur. This could partially explain the high KSHV 
seroprevalence in Africa in both adults and children. KSHV, like EBV, is detectable 
in | saliva and this could be one of the main routes of transmission for both agents in 
those regions. It would be of great interest to compare KSHV and EBV load in 
sputum from the same individuals.
Elevated anti-KSHV antibody titres are associated with a higher risk of intrafamilial 
and mother-to-child transmission, as well as the risk for the development of KS 
(Bourboulia et al., 1998; Davidovici et al., 2001; Sitas et al., 1999a; Sitas et al., 
1999b). In addition, both the prevalence and antibody titres are higher in healthy 
individuals from areas with increased rates of KS. The biological meaning of 
antibody titre is not clearly understood. Studies have suggested that high antibody 
titres reflect circulating virus in the blood, therefore increased antigenic stimulus, but 
this has not been verified (Bourboulia et al., 1999; Campbell et al., 1999). Increased 
antibody titres in African, compared to classic KS areas, may indicate constant re­
exposure to viral infection or viral reactivation. Uncontrollable dissemination would 
lead to higher transmission levels.
Although, it is generally accepted that KSHV infection in the general healthy 
population mirrors the incidence of KS, it is apparent from Figures 3.18. and 6.1. that 
this may not be as accurate as was thought. Medium rates of KS incidence occur in 
North European particularly in Scandinavian countries, in Iceland and Faroe islands, 
where KSHV prevalence in the general population has not been determined yet. 
Unexpectedly high KSHV infection appears in Greenland and Cuba where KS is 
either absent or insignificant. Only two cases of KS in the native Eskimos before the 
HIV-1 epidemic have been described (Mikkelsen et al., 1977) and one case of AIDS- 
KS was reported in a heterosexual man (Moi et al., 1993). Detailed studies need to 
determine how the virus was introduced to the human populations in the Arctic 
region and host genetics may provide information on possible protective factors for 
the development of KS (Foster et al., 2000; Lehmbecher et al., 2000).
At the cellular level, KSHV seems to need more than one molecule to enter the target
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cell and may involve more than one viral protein in this process (Akula et al., 2002; 
Wang et al., 2001; Wang et al., 2003). Preferential expression of these molecules in 
specific populations would make them genetically more susceptible to KSHV 
infection. It is clear that future sero- and molecular epidemiological studies need to 
explore other parts of the world where KSHV prevalence is unknown and KS 
existence is puzzling, in order to elucidate these controversies.
First generation serological assays have already elucidated the extent of KSHV 
distribution around the world. Detailed future seroepidemiological surveys will be of 
great importance in answering some of the questions already presented here and a 
more sensitive, specific and, above all, less laborious serological assay is needed to 
fulfil this task. Various groups, including ours, have reached the same conclusion 
that an ELISA detecting anti-KSHV antibodies to a lytic epitope from a highly 
immunogenic protein is necessary for large seroepidemiological studies. However, a 
latent assay should also be included in confirming the equivocal results.
6.3 KSHV and HAART
In the beginning of the AIDS pandemic, up to 25% of HIV-1 infected individuals 
developed KS. Since the introduction of HAART, this has fallen to less than 5% 
(Eltom et al., 2002). Therefore, it is of great interest to investigate KSHV 
pathogenesis during immunosuppresion and upon HAART-induced immune 
recovery.
HAART was introduced in the West in 1997; therefore, there are currently only a 
few studies addressing (only partially) the effects of HAART on HIV-1/KSHV 
coinfected individuals. In chapter 5 ,1 investigated and provided a general account on 
how an oncogenic virus behaves, and how the immune system responds in the 
context of HIV-1 infection, in the presence or absence of antiretroviral therapy. 
Recent studies on the effects of HAART on EBV infection suggest that KSHV 
behaves differently (Kostense et al., 2002): EBV load does not appear to decline, and 
occasionally increases in PBMCs during HAART (Stevens et al., 2002; van Baarle et 
al., 2001), whereas KSHV DNA becomes less detectable (Chapter 5). Anti-EBNA 
antibody titre also increases during HAART (O'Sullivan et al., 2002), whereas
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LANA antibody titre does not (Chapter 5). Since viraemia is considered as a marker 
of disease progression, this difference may partially explain why KS incidence 
declines, and KS resolution occurs, whereas EBV-associated NHL incidence does 
not decline as dramatically, on HAART (Bourboulia et al., 2003).
The role of CD8+ cytotoxic T cell responses (CTLs) in controlling lentiviral and 
herpesviral-associated infections is well established (Barouch and Letvin, 2001). 
CD8+ CTLs are able to contain HIV-1 replication by inhibiting in vitro replication in 
autologous CD4+ T cells (Walker et al., 1986). Primary infection with EBV induces 
a magnitude of EBV-specific CTL responses able to control EBV replication (Callan 
et al., 1998; Rickinson and Moss, 1997). EBV-specific CD8+ CTLs have also been 
effectively used in the prevention and treatment of post transplant 
lymphoproliferative disease (Haque et al., 1998; Haque and Crawford, 1999; Haque 
et al., 2002; Macsween and Crawford, 2003). I have shown that when KSHV 
specific CTL epitopes are used to stimulate PBMCs from HIV-1 infected individuals, 
there is a significant recovery and increase of CD8+ T cell responses during HAART 
(Chapter 5) (Bourboulia et al., 2003). This immune recovery occurs in parallel with a 
significant decline of KSHV viraemia in PBMCs and clearance in plasma. However, 
other components of the immune system may also contribute and have to be 
investigated. The increase of anti-lytic antibodies (humoral immunity) may also 
contribute in the clearance of the virus. Although there is an obvious immune 
recovery towards KSHV, particularly after 12 months on HAART, this does not 
clearly explain why KS often resolves within weeks when HAART is started. 
Recovery of the innate immune system may be more important in the rapid clinical 
response and KS to resolve. It has recently been shown that NK function was 
significantly reduced in AIDS patients, but was restored after HAART was 
introduced (Sirianni et al., 2002)
Studies have to continue evaluating the importance of the innate and adaptive 
responses in controlling KSHV replication, dissemination and tumour formation after 
KSHV infection, especially in immunocompromised cases. The interaction of KSHV 
with the immune system, and the viral tactics for immune evasion would provide us 
with additional information to develop adoptive immunotherapies and vaccine 
strategies.
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